

GenCore version 5.1.6  
Copyright (c) 1993 - 2004 Compugen Ltd.

OM protein - protein search, using sw model

Run on: November 16, 2004, 16:34:37 ; Search time 40 seconds  
(without alignments)  
1096.871 Million cell updates/sec

Title: US-09-905-589A-2

Perfect score: 2364

Sequence: 1 MRKISNHSGLRVAKVAYPLG.....ALGAIFHYDLSLNQKSPAS 456

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 283416 seqs, 96216763 residues

Total number of hits satisfying chosen parameters: 283416

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : PIR\_79:\*

1: pir1:\*

2: pir2:\*

3: pir3:\*

4: pir4:\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	590.5	25.0	479	T23508	hypothetical prote
2	508	21.5	556	T39109	probable guanosis
3	498	21.1	518	A40732	guanosine-diphosph
4	485	20.5	454	JC4616	apyrase (EC 3.6.1.
5	442.5	18.7	455	S48859	nucleoside triphos
6	372	15.7	516	G84442	probable nucleosid
7	343	14.5	485	T34147	hypothetical prote
8	339.5	14.4	483	S86276	hypothetical prote
9	329.5	13.9	630	S20463	hypothetical prote
10	307	13.0	557	T16696	hypothetical prote
11	301	12.7	405	E86276	hypothetical prote
12	285.5	12.1	510	I56242	lymphoid cell acti
13	281.5	11.9	572	T40856	probable nucleosid
14	245.5	10.4	1052	T04439	hypothetical prote
15	219	9.3	508	C86276	7A19.33 protein -
16	140.5	5.9	628	A55421	nucleoside-triphos
17	111	4.7	679	C71007	probable formate d
18	108.5	4.6	1186	T12737	tail protein - Met
19	106.5	4.5	665	E75124	formate dehydrogen
20	104.5	4.4	322	T24948	hypothetical prote
21	103.5	4.4	322	T27308	hypothetical prote
22	102.5	4.3	440	I39847	cell-division prot
23	102	4.3	475	G72274	glutamyi tRNA-Gln
24	102	4.3	623	G81346	heat shock protein
25	102	4.3	4162	T42633	connectin/titin -
26	100	4.2	1233	T37045	nitrate reductase
27	100	4.2	26926	I38344	titin, cardiac mus
28	99.5	4.2	470	S13839	dihydrolipoamide d
29	99.5	4.2	504	S17724	H+-transporting tw

30	99.5	4.2	633	2	I39585	dnak-type molecula
31	99.5	4.2	2411	2	A46299	cyrosine kinase su
32	98.5	4.2	633	2	AE2591	DNAA Protein limpo
33	98.5	4.2	633	2	E97373	dnaj protein (heat
34	97.5	4.1	415	1	C64473	adenosylhomocyste
35	97.5	4.1	548	2	S32615	triacylglycerol li
36	97	4.1	2611	2	T14591	actinomycin synthe
37	96.5	4.1	815	2	T35970	probable efflux pr
38	96	4.1	711	2	S73898	DNA topoisomerase
39	96	4.1	1217	2	T25894	hypothetical prote
40	95.5	4.0	325	2	T32940	hypothetical prote
41	95.5	4.0	325	2	D87733	protein W03D8.9 fi
42	95	4.0	527	1	S25478	heat shock transcr
43	95	4.0	549	2	S23448	triacylglycerol li
44	95	4.0	15281	2	S41309	cyclosporin synthe
45	94.5	4.0	489	2	F97119	nicotinic acid pho

ALIGNMENTS

RESULT 1

T23508

hypothetical protein K08H10.4 - Caenorhabditis elegans

C:Species: Caenorhabditis elegans

C>Date: 15-Oct-1999 #sequence\_revision 15-Oct-1999 #text\_change 09-Jul-2004

C:Accession: T23508

R:Gardner, A.

submitted to the EMBL Data Library, November 1996

A:Reference number: Z19750

A:Accession: T23508

A>Status: preliminary; translated from GB/EMBL/DDBJ

A:Molecule type: DNA

A:Residues: 1-479 <WILL>

A:Cross-references: UNIPROT:Q9XU84; EMBL:Z83113; PIDN:CAB0544.1; GSPDB:GN00023; CESP:K08

A:Experimental source: clone K08H10

C:Genetics:

A:Gene: CESP:K08H10.4

A:Map position: 5

A:introns: 36/3; 83/3; 189/1; 300/2; 412/3

C:Superfamily: nucleoside triphosphatase chromatin-associated

Query Match	25.0%;	Score 590.5;	DB 2;	Length 479;
Best Local Similarity	34.2%;	Pred No. 4.4e-40;		
Matches 134;	Conservative 78;	Mismatches 155;	Indels 25;	Gaps 9;
QY	73	YGYMFDAGSTGTRVHVVFQTRPRREP-----TLTHTFKAVKPLGLSAYADDDVKSAGQ	127	
Db	42	FFTVIVDAGSTGTRLHLKYFIHDPALASHGMPFKVEKIFQEVKPLGLSFAKSPSSAADS	101	
QY	128	IREILLVAKQDIPDFWKATPLVLKATAGLLPGEKAQKLLQKVE-VFKASPLVGGD	186	
Db	102	LEPLLQARKEVPHFPMWEKTEITLKATAGLLPGEKADDDLESVEERIFNSGFFAAPPD	161	
QY	187	CVSIMNGTDEGVSAMITINFLTGSL-----KTPGGSSVGMGLDGGSGTQAFAPRV	237	
Db	162	AVNVWPSDEGVSWFTNLILLETFLFDEPTVGHKPAHRVAAFDLGGSGTQITWENN	221	
QY	238	EGTIQASPPGYLTALRMFNRITYKLYSYSLGLGLMSARLAILGGVGGOPAKDKELVSPC	297	
Db	222	EAVF-SEHVGYERIDFFGHHIRLFTSHFLNGLIARLILQLETDNEIESTHQLITSC	280	
QY	298	LSPSPFK-GEHEAEVTVYVSQKAAASLHELCAARVSEVLQ-NRVHRTVEVKHVDVFAPS	355	
Db	281	MPEGYQYTEWYALKFWNING--SSSHSFESCYCTTKNFVSESSIMHLRELKSPVVLFS	338	
QY	356	YYVPLAAGVGLDAEKGGSLVVGDFEATAKVCTLETOPQSS----PFCMDLTIVV-SL	410	
Db	339	YFFDRALNSGLVKGNEGKTELRFQKAAEATACRREKTEIDDGSHWMPQCLDITYISL	398	
QY	411	LLQEFGRPRSKVLKLTAKIDNVETSWALGAIF	442	
Db	399	LRDGYQFEDNPLVLAKKIKGMEVSWGQGLAF	430	

## RESULT 2

T39109  
probable guanosine-diphosphatase - fission yeast (Schizosaccharomyces pombe)  
C;Species: Schizosaccharomyces pombe  
C;Date: 03-Dec-1999 #sequence\_revision 03-Dec-1999 #text\_change 09-Jul-2004  
C;Accession: T39109  
R;Barrell, B.G.; Rajandream, M.A.; Quail, M.; Seegar, K.; Harris, D.  
submitted to the EMBL Data Library, October 1999  
A;Reference number: Z21828  
A;Accession: T39109  
A;Status: preliminary; translated from GB/EMBL/DBJ  
A;Molecule type: DNA  
A;Residues: 1-556 <BAR>  
A;Cross-references: UNIPROT:Q9UT35; EMBL:AL121741; PIDN:CAB57338.1; GSPDB:GN000066; SPDB:  
A;Experimental source: strain 972h-; cosmid c824  
C;Genetics:  
A;Gene: SPDB:SPAC824.08  
A;Map position: 1

Query Match 21.5%; Score 508; DB 2; Length 556;  
Best Local Similarity 32.4%; Pred. No. 2.8e-33;  
Matches 142; Conservative 66; Mismatches 142; Indels 88; Gaps 17;  
Qy 74 YGIMFDAGSTGTRVHVFQFTRPPREPTLTHTETKAVKPGLSAYADVDVEKSAQGIREDLLD 133  
Db 134 YVLMIDAGSTGSRVHVVFQFN-CNPSPKLEEFPMIEPGLSSFAGDPEGAAASLDPLLD 192  
Qy 134 VAKQDIPDFEMKATPLVLKATAGLRLLPGEKAQKLLQKVEVFKAS-PFLVGDVCSIMN 192  
Db 193 YAMENVEEYRRCSPIAVKATAGLRLTGESEAKILKSVRQHLENDYFPPIVKGVSTLE 252  
Qy 193 GTDEGVSAWITINFLTGSLKTPGG-----SSVGMLDLGGSTQIAFLRVEGTLOASPPG- 247  
Db 253 GSGMEGIWAMITINLLGTPL--GGKATHSTVAVMDLGGASTQLVFPFPAFSGSLVDGD 309  
Qy 248 YLTALRMFNRTYKLYSYLGLGLMSAR-----LAILGGVEGQPAKDG 290  
Db 310 HKYVDVNGEQYELYQHSHLYGLKEARKLHKFVNNAAEKLELLG-----DS 361  
Qy 291 KELVSPCL-----SPSFKEGWEHAEVYTVRSVGOKAAASLHELCAARVSEVLQ----- 337  
Db 362 TSIHPCLLNASLTHPDSKS--BASEVVF-VGFSLAHLSLQ--CRGIAEKALYKDKNCP 416  
Qy 338 -----NEVHR--TEEVKHVDFAFYSYYDLAAGVGLIDAEKGSLLVVGDFEIAAKVVC 388  
Db 417 VRPCSFNGVHQPKFTETFTDSPYLLISFYDRMISLGM-----PSTFTIEDMKYLANSV 471  
Qy 389 -----RTLETQPOSSPSPSCMDLTY-VSLLQLQEFQFPFRSKVLKTRKIDN 431  
Db 472 SGPTYWQDAFSLTDALKELKEPE-----WCLLDNVMSLLSVGVBEIPNNRQLHTAKIDN 527  
Qy 432 VETSWALGAIHYIDSLN 449  
Db 528 KELGWLGLGASLSMLSEQN 545

## RESULT 3

A40732  
guanosine-diphosphatase (EC 3.6.1.42) - yeast (Saccharomyces cerevisiae)  
N;Alternate names: protein YEL042w  
C;Species: Saccharomyces cerevisiae  
C;Date: 21-Sep-1993 #sequence\_revision 18-Nov-1994 #text\_change 09-Jul-2004  
C;Accession: A40732; S40732; S30837; S50502  
R;Abelson, C.; Yanagisawa, K.; Mandon, E.C.; Hausler, A.; Moremen, K.; Hirschberg, C.B.;  
J. Cell Biol. 122, 307-323, 1993  
A;Title: Guanosine diphosphatase is required for protein and sphingolipid glycosylation  
A;Reference number: A40732; MUID:93308137; PMID:8391537  
A;Accession: A40732  
A;Molecule type: DNA  
A;Residues: 1-518 <ABE>  
A;Cross-references: UNIPROT:P32621; EMBL:L19560; NID:g349392; PIDN:AAA34656.1; PID:g3493

A;Note: sequence extracted from NCBI backbone (NCBIN:134708, NCBI:P:134711)

A;Accession: B40732

A;Molecule type: protein

A;Residues: 125-144;238-257;276-281;366-374;399-412 <AB2>

R;Mulligan, J.T.; Dietrich, F.S.; Hennessey, K.M.; Sehl, P.; Komp, C.; Wei, Y.; Taylor, I.

submitted to the EMBL Data Library, February 1993

A;Reference number: S30812

A;Accession: S30837

A;Molecule type: DNA

A;Residues: 1-518 <MUL>

A;Cross-references: GB:U18779; EMBL:L10830; NID:g603625; PIDN:AAB65000.1; PID:g603637

R;Dietrich, F.S.

submitted to the EMBL Data Library, December 1994

A;Description: The sequence of *S. cerevisiae* cosmids 8199, 8334, and 9871.

A;Reference number: S50491

A;Accession: S50502

A;Molecule type: DNA

A;Residues: 1-518 <DIE>

A;Cross-references: EMBL:U18779; NID:g603625; PIDN:AAB65000.1; PID:g603637; MIPS:YEL042w

C;Genetics:

A;Gene: SGD:GDA1

A;Cross-references: SGD:S0000768; MIPS:YEL042w

A;Map position: 5L

C;Function:

A;Description: hydrolase

C;Superfamily: nucleoside triphosphatase chromatin-associated

C;Keywords: glycoprotein; Golgi apparatus; hydrolase; transmembrane protein

F;10-24/Domain; transmembrane #status predicted <TM>

F;41,280,335/Binding site: carbohydrate (Asn) (covalent) #status predicted

Query Match 21.1%; Score 498; DB 2; Length 518;  
Best Local Similarity 33.1%; Pred. No. 1.7e-32;  
Matches 144; Conservative 60; Mismatches 153; Indels 78; Gaps 15;

Qy 65 TAADGHEVFVGIMFDAGSTGTRVHVFQF---TRPPREPTLTHTETKAVKPGLSAYADVD 121  
Db 86 TCSSEHK--YVIMIDAGSTGSRVHIYKFDVCTSP-----PTLLDEKFDLMLEGLSFDTS 139  
Qy 122 EKSAQGIREDLLDAKQDIPDFWKATPLVLKATAGLRLLPGEKAQKLLQKVE-VFKASP 180  
Db 140 VGAANSLLDPLLVKAMVYVPIKARSCTPVAVKATAGLRLLDGAKSKILLSAVRDHLEKDY 199  
Qy 181 F-LVGDDCVSIMGTDGVSAMITINFLTGSLKTPGGS--SVGMLDLGGSTQIAFLPRV 237  
Db 200 PPVVEGDSVIMGDEGVFAWITTNVLLGNIGANGPKLPATAAVFDLGGSGTQVFEPTF 259  
Qy 238 EGTQASPPGVLTAALRMFNRTYKLYSYLGLGLMSARLAILGGVEGQPAKDGK----- 291  
Db 260 PINERMDGHEHFDLKFGEENTLYQFSLHLYGLKEGNKVNVLVENALDQKILKGDN 319  
Qy 292 ----ELVSPCLSPSPFKGEWE---HAEVTVRV-----SGOKAAASLHELCAARVSEV 335  
Db 320 TKTHQLSSPCLPPKVNATNEKVTLSEKETYIDFIDGPDPEPSGAQ-----CRFLTDEI 371  
Qy 336 LQ-----NRVHRTVEVKHV-----DFYAFSYYDLAAGVGLIDAEKGSLLVGD 379  
Db 372 LNKDAQCOSPPCSFNGVHQPSLVRTFKESNDIYFYSFYDRTPLGM-----PLSFTLNE 426  
Qy 380 FEIAAKVYCRLET-----QPOSSPSPSCMDLTY-VSLLQLQEFQFPFRSKVLK 425  
Db 427 LNDIARIVCKGEETWNSVFSGIAGSLDESDSHFCLDSFQVSLHLYGTQIDIPLOELRT 486  
Qy 426 TRKIDNVETSWALGA 440  
Db 487 GKTIANKSIGWCLGA 501

## RESULT 4

JC4616  
apyrase (EC 3.6.1.5) precursor - potato  
N;Alternate names: adenylypyrophosphatase; ATP-diphosphohydrolase  
C;Species: Solanum tuberosum (potato)  
C;Date: 10-May-1996 #sequence\_revision 19-Jul-1996 #text\_change 09-Jul-2004

C:Accession: JC4616; PC4147  
R:Handa, M.; Guidotti, G.

Biochem. Biophys. Res. Commun. 218, 916-923, 1996

A:Title: Purification and cloning of a soluble ATP-diphosphohydrolase (Apyrase) from potato tubers

A:Reference number: JC4616; MUID:96158985; PMID:8579614

A:Accession: JC4616

A:Molecule type: mRNA

A:Residues: 1-454 <HAN>

A:Cross-references: UNIPROT:P80595; NID:gl381632; PIDN:AA802720.1; PID:gl3816

A:Molecule type: protein

A:Residues: 59-95;96-131;132-160;236-253;332-345 <HA2>

A:Experimental source: tubers

A:Note: The authors translated the codon GCA for residue 215 as Gly

C:Comment: This enzyme belongs to a family of E-type ATPases, and it catalyzes the hydrolysis of ATP to ADP and inorganic phosphate. The enzyme has nucleotide substrate specificity, divalent cation requirement, and is insensitive to vanadate.

C:Genetics:

A:Gene: irop1

C:Superfamily: nucleoside triphosphatase chromatin-associated

C:Keywords: glycoprotein; hydrolase; transmembrane protein

F:1-30/Domain: signal sequence #status predicted <SIG>

F:8-25/Domain: transmembrane #status predicted <TM>

F:31-454/Product: ATP-diphosphohydrolase #status predicted <MAT>

F:44-65/Region: actin-heat shock protein 70-hexokinase beta-phosphate binding

F:192-212/Region: nucleotide binding #status predicted

F:192-212/Region: actin-heat shock protein 70-hexokinase gamma-phosphate binding

F:390-410/Region: nucleotide binding #status predicted

F:151,262/Binding site: carboxylic (Asn) (covalent) #status predicted

Query Match 20.5%; Score 485; DB 2; Length 454;

Best Local Similarity 31.9%; Pred. No. 1.6e-31;

Matches 138; Conservative 68; Mismatches 183; Indels 44; Gaps 12;

QY 59 AHSPLGTADGHE-VFYGIMFDAGSTGRVHVQFTRPPRTPTLTH-ETFAVKVPGLSA 116

Db 30 AQIPLRHLLSHSESHYAVIFDAGSTGRVHVFRFDEKLGILLPIGNIEYFATEPGLSS 89

QY 117 YADDVEKSAQGIREDLVAKQDIPDFWKATPLVLKATAGLRLLPGEKAQKLLQKVEVF 176

Db 90 YAEEDPKAANSLEPDLDAEGVVPQELQSETPLELGATAGLRMLKGDAAEKILQAVRLV 149

QY 177 K-ASPFLLVGGDCVSTMGNTDGVSAWITINFLTGLSKTPGGSSVGMGLDGGSTQIAFLP 235

Db 150 KNQSTFHSKQDWITLDGTQSGSYMAAINYLGNLGNKYKSTTATIDLGGSSVQMAIYAI 209

QY 236 RVEGTLOA----SPPGYLTALRMFNRTYKLYSYVLGLMSARLAILGGVEGQPAKDGK 291

Db 210 SNEQFAKAPQNEDEGPYVQQHLSKDYNLVHSLYNGQLAGRAEIF-----KASR 261

QY 292 ELVSPCLSPSPKGEWEHAETVYRVSQKAAASLHLCARVSEVLQ-NRVHRTREVK--- 347

Db 262 NESNFCALGCDGYSYGVGVYKVPKPGGS-WKRCRLRTHALKINAKNIEECTPNG 320

QY 348 -----HVDFYAFSYYYDLAAGVGLIDAEKGGSLVVG-DFEIAAKYVCKT----- 390

Db 321 VWNNGGGDGQKNIHASFFYDIGAQVGVDTKFPALAKPTQYLNAAKVAQCTNVADIKS 380

QY 391 --LETQSSSPSCMDLTY-VSLLLQEPFRPSKVLKTRKIDN-----VETSWALGAIFH 443

Db 381 IFPKTQDRNIPYLCMDLTYETLLVDGFGFLPHKEITVIHDVQYKNLYLVGAAPLGCAGD 440

QY 444 YIDSINRQKSPAS 456

Db 441 LVSTTNKIRVAS 453

RESULT 5

S48859

C:Species: Pisum sativum (garden pea)

C:Date: 13-Jan-1995 #sequence\_revision 13-Jan-1995 #text\_change 09-Jul-2004

C:Accession: S65147; S48859  
R:Hsieh, H.L.; Tong, C.G.; Thomas, C.; Roux, S.J.

Plant Mol. Biol. 30, 135-147, 1996

A:Title: Light-modulated abundance of an mRNA encoding a calmodulin-regulated, chromatin-associated nucleoside triphosphatase

A:Reference number: S65141; MUID:96197404; PMID:8616230

A:Accession: S65147

A:Molecule type: mRNA

A:Residues: 1-455 <HS2>

A:Cross-references: UNIPROT:P52914; EMBL:Z32743; NID:G563611; PIDN:CAA83655.1; PID:G56361

A:Superfamily: nucleoside triphosphatase chromatin-associated

C:Keywords: nucleus

Query Match 18.7%; Score 442.5; DB 2; Length 455;

Best Local Similarity 29.2%; Pred. No. 4.6e-28;

Matches 125; Conservative 79; Mismatches 145; Indels 79; Gaps 15;

QY 74 YGIMFDAGSTGRVHVQFTRPPRTPTLTH-----ETFAVKVPGLSAYADDVEKSAQGI 128

Db 44 YAVVFDAGSTGRVHVHF-----NQNLDDLHLGKGVYNYKITPGLSSYANNPEQAQSL 99

QY 129 RELDVAKQDIPDFWKATPLVLKATAGLRLLPGEKAQKLLQKVEVF-KASPFLLVGGDC 187

Db 100 IPLLQEAEDVVPDDLQPKTPVRLGATAGLRLLNGDASEKILQSVRDMLSNRSTENVQPD 159

QY 188 VSMNGTDBGVSAWITINFLTGLSKTPGGSSVGMGLDGGSTQIAF-----LPRVE 238

Db 160 VSIIDGTQEGSYLVVTVNVALGNLGNKYKTKTVGVIDLGGSSVQMAIYAVSKTKAKNAPKV- 218

QY 239 GTLOASPPGYLTALRMFNRTYKLYSYVLGLMSARLAILGGVEGQPAKDGKELVSPCL 298

Db 219 --ADGDDP-YIKKVVLGKIPYDLYVHSLHFGREASRAELLKLTFRSP-----NPCL 267

QY 299 SPSPKGEWEHAETVYRVSQKAAASLHLCARVSEVLQNRVHRTREVKH----- 348

Db 268 LAGFNGIYTSGEFEKATAYTSGANFNK-----CKNTIRKALKLNYPCYQNCFTFG 318

QY 349 -----VDFYAFSYYYDLAAGVGLIDAEKGGSLV-VGDFEIAAKYVCR-TLETQP 395

Db 319 GIWNGGGNGQKNIFASSFFYPEDTGMVDASTNFILRPVDTETKAKEACALNFEDAK 378

QY 396 QSSPF-----SCMDLTYVSLLLQEPFRPSKVLKLT--RKIDN-----VETSWALGA 440

Db 379 STYFPLDKKNVASYVCMGLIYQVLLVD-GFLDPLQKITSGKELEYQDAIVEAAWPLGN 437

QY 441 IFHVIDSL 448

Db 438 AVEAISAL 445

RESULT 6

G84442

probable nucleoside triphosphatase [imported] - Arabidopsis thaliana

C:Species: Arabidopsis thaliana (mouse-ear cress)

C:Date: 02-Feb-2001 #sequence\_revision 02-Feb-2001 #text\_change 09-Jul-2004

C:Accession: G84442

R:Lin, X.; Kaul, S.; Rounsley, S.D.; Shea, T.P.; Benito, M.I.; Town, C.D.; Fujii, C.Y.; Nuss, D.; Nietman, W.C.; White, O.; Eisen, J.A.; Salzberg, S.L.; Fraser, C.M.; Venter, J.

Nature 402, 761-768, 1999

A:Title: Sequence and analysis of chromosome 2 of the plant Arabidopsis thaliana.

A:Reference number: A84420; MUID:20083487; PMID:10617197

A:Accession: G84442

A>Status: preliminary

A:Molecule type: DNA

A:Residues: 1-516 <STO>

A:Cross-references: UNIPROT:O80612; GB:A8002093; NID:G3461821; PIDN:AA032915.1; GSPDB:GM

C:Genetics:

A:Gene: At2g02970

A:Map position: 2

C:Superfamily: nucleoside triphosphatase chromatin-associated

Query Match

Best Local Similarity

15.7%; Score 372; DB 2; Length 516;

Matches 29.0%; Pred. No. 3e-22;







C:Accession: T04439  
 R:Bevan, M.; Benes, V.; Rechmann, S.; Borkova, D.; Ansoorge, W.; Bancroft, I.; Mewes, H.W.  
 submitted to the Protein Sequence Database, April 1998  
 A:Reference number: Z15359  
 A:Accession: T04439  
 A:Molecule type: DNA  
 A:Residues: 1-1052 <BEV>  
 A:Cross-references: UNIPROT:O49676; EMBL:AL021687  
 A:Experimental source: cultivar Columbia; BAC clone T18B16  
 C:Genetics:  
 A:Map position: 4  
 A:Introns: 79/3; 118/3; 217/1; 295/3; 396/3; 531/2; 815/3  
 A:Note: T18B16.150

Query Match 10.4%; Score 245.5; DB 2; Length 1052;  
 Best Local Similarity 25.3%; Pred. No. 1.6e-11;  
 Matches 116; Conservative 60; Mismatches 185; Indels 97; Gaps 20;

```

QY 55 WCQQAHS-----PLGTAADGHE-----VFYGMFDAGSTGTRVHVQFT 93
Db ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
483 WCQGSFSEKSGSVFNGTPTTRKLRVAVTMVCLFLFAFLVIVTSITGTRAYVYQAS 542
QY 94 ---RPREPTLTTHETFKAV-----KPLSAYADDVEKSAQIGRELLDVAK 136
Db ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
543 INYKXDSLPIVWKSITGEGISKSGRAYDRMETEPFGDKLVNRTGLKTAIKPLIQWAE 602
QY 137 QDIPDFMKATPLVKATAGLRLLPGEKAQKLLQKVEFKASPPFLVGDGCVSIMNGTDE 196
Db ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
603 KQIPKNAHRTTSLFVYATAGVRLPADSSWILGNVMSILAKSPTCREWKVILSGTEE 662
QY 197 GVSAMITNLTGSL-KTPGGSSVGMLDLGGSGTQIAFLPRVEGTLOASPPGYLTALRMF 255
Db ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
663 AYFGWTALNYQTSMLGALPKKATFGALDGGSSLOVTF-----ENEERTHNETNLN-LRIG 717
QY 256 NRTYKLYSYLGLGIMSA-----RLAIIQGVGQPAKDGK-RLVSPCLSPSPKGEWE 307
Db ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
718 SVNHLSAYSLAGYGLNDAFRSVVHLLKPKVNMKSDLIEGLEKMKHPCLNSGYNGQVI 777
QY 308 HAEVTVRVSGQKAASLHEL-----CAARVSE---VLQNRVHTEEVKHVDEYAF 354
Db ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
778 CSQCASSVQGGKKGSGSVIKLVGAPNWGECALAKNAPCALPDGYPR-----PHGQFYAV 833
QY 355 S-----YYDLAAGVGLIDA-EKGGSLVVGDFEIAKYVVRTLETQPSQPPF---SCMD 404
Db ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
834 SGFFVYVYFFNLASAPASLDVLEK-----REFCDKAWQVART-SVSPQ--PFIEQYCFR 885
QY 405 LTYVSLLLQEFGRPSKVLKTRK---IDNVETSWALG 439
Db ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
886 APYIVSLURE-----GLYITDKQIILIGSGSITWTLG 916

```

RESULT 15  
 C86276  
 7A19.33 protein - Arabidopsis thaliana  
 C:Species: Arabidopsis thaliana (mouse-ear cress)  
 C:Date: 02-Mar-2001 #sequence\_revision 02-Mar-2001 #text\_change 09-Jul-2004  
 C:Accession: C86276  
 R:Theologis, A.; Ecker, J.R.; Palm, C.J.; Federspiel, N.A.; Kaul, S.; White, O.; Alonso,  
 ansen, N.F.; Hughes, B.; Huizar, L.  
 Nature 408, 816-820, 2000  
 A:Authors: Hunter, J.L.; Jenkins, J.; Johnson-Hopson, C.; Khan, S.; Khaykin, E.; Kim, C.  
 C.A.; Li, J.H.; Li, Y.; Lin, X.; Liu, S.X.; Liu, Z.A.; Luros, J.S.; Maiti, R.; Marziali,  
 Rizzo, M.; Rooney, T.; Rowley, D.; Sakano, H.  
 A:Authors: Salzberg, S.L.; Schwartz, J.R.; Shinn, P.; Southwick, A.M.; Sun, H.; Tallon,  
 Ker, M.; Wu, D.; Yu, G.; Fraser, C.M.; Venter, J.C.; Davis, R.W.  
 A:Title: Sequence and analysis of chromosome 1 of the plant Arabidopsis.  
 A:Reference number: A86141; MUID:21016719; PMID:11130712  
 A:Accession: C86276  
 A>Status: preliminary  
 A:Molecule type: DNA  
 A:Residues: 1-508 <STO>  
 A:Cross-references: UNIPROT:Q9XI63; GB:A8005172; NID:G5080800; PIDN:AAD39310.1; GSPDB:GN

C:Genetics:  
 A:Map position: 1  
 C:Superfamily: nucleoside triphosphatase chromatin-associated

Query Match 9.1%; Score 219; DB 2; Length 508;  
 Best Local Similarity 22.3%; Pred. No. 8.3e-10;  
 Matches 109; Conservative 83; Mismatches 196; Indels 100; Gaps 21;

```

QY 9 SLRVAKVAYPLGLCVGVFIYVAYIKWHRATATQAFFSITRAAPGARWGQQAHSPLGTAAD 68
Db ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
26 SKRTRKSIIFVIVACVTIALGLLFIG-----YSILRSGENRR----- 61
QY 69 GHEVFYGMFDAGSTGTRVHVQFTPPPTPLT--HETFKAVK--PGLSAYADVEKS 124
Db ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
62 -VSLHVSVIDGGSSGTRVHVFGY-RIESGKPVDFDGEENYASLKLSPGLSAYADNPEGV 119
QY 125 AQGIRELLDVAKQDIPDFMKATPLVKATAGLRLLPGEKAQKLLQKVEFKASPPFLVG 184
Db ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
120 SESVTLEVEFAKRVHKGLKSDIPLMATAGRLLELPVQEQIILDVTRVRKSSGDFR 179
QY 185 DDCVIMNGTDEGVSAWITINFLTGSLKTPGGSSVGMLDLGGSGTQIAFLPRVEGTLOAS 244
Db ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
180 DEWASVISILENFQDLMKV-YMLGLL-----LIMRSVRLEVTV-----STELV 223
QY 245 PPGYLTALRMFNRTYKLYSYLGLGIMSAARLAILGGVEGQPAKD-GKELV-SPCLS--- 299
Db ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
224 PSEFRTLAYGNVSYNLYSHSFLDFGQDAAQEKLSSELYNSAANSTGEGIVDPDPCIPKY 283
QY 300 -----PSFKGEWEHAEVTVRVSG-----QKAAASLHE---LCAARVSEV----- 335
Db ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
284 ILETNLQKDLPGFLADKKGKFTATLQAAGNFSECRSAAFAMLOEEKKGCTYKRCSIGIFT 343
QY 336 --LQNRVHRTBEVKHVDYFAYFYVYDLAAGVGLIDAEGGSLVVGDF--FEIAAKYVCRTL 391
Db ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
344 PNLQGSFLATE-----NFFHTSKPFLGCEKWLSEMLAGKRFCEGEWSKLVKYP---- 394
QY 392 ETQPSQSPFCMDLTY-VSLLLQEFGRP-RSKVLKTRKI--DNVETSWALGAI----- 441
Db ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
395 TFKDNLRLRYCFSSAYIISMLHDSLGVALDDDERIKYASKAGEEDIPLDWALGAFILNTAT 454
QY 442 --FHYIDS 447
Db ||| |||
455 ATFDYSDN 462

```

Search completed: November 16, 2004, 17:00:26  
 Job time : 44 secs





GenCore version 5.1.6  
Copyright (c) 1993 - 2004 Compugen Ltd.

OM protein - protein search, using sw model

Run on: November 16, 2004, 16:34:13 ; Search time 196 Seconds  
(without alignments)  
1338.627 Million cell updates/sec

Title: US-09-905-589A-2

Perfect score: 2364

Sequence: 1 MKTISNHGSLRVAKVAYPLG.....ALGAIFHYDLSLNROKSPAS 456

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 1825181 seqs, 575374646 residues

Total number of hits satisfying chosen parameters: 1825181

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database :

UniProt\_02.\*

1: uniprot\_sprot.\*

2: uniprot\_trembl.\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

# SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	2361	99.9	484	1 ENP6 HUMAN	O75354 homo sapien
2	2361	99.9	503	2 Q8N3H3	Q8n3h3 homo sapien
3	2063.5	87.3	455	1 ENP6 RAT	Q9er31 rattus norv
4	1943	82.2	445	2 Q6YHK4	Q6yhk4 cavia porce
5	1229.5	82.2	445	2 AAN72326	Aan72326 cavia por
6	1229.5	52.0	278	2 Q8CHZ3	Q8chz3 mus musculu
7	1021	43.2	427	2 Q6P6S9	Q6p6s9 rattus norv
8	1021	43.2	427	2 AAH62044	Aah62044 rattus no
9	1007	42.6	427	1 ENP5 MOUSE	Q9wuz9 mus musculu
10	1007	42.6	427	2 Q8CD29	Q8cd29 mus musculu
11	1007	42.6	427	2 AAK82949	Aak82949 mus muscu
12	1007	42.6	427	2 BAC229515	Bac229515 mus muscu
13	1007	42.6	427	2 BAC229861	Bac229861 mus muscu
14	1007	42.6	427	2 BAC37592	Bac37592 mus muscu
15	1007	42.6	427	2 BAC37862	Bac37862 mus muscu
16	1007	42.6	427	2 BAC38219	Bac38219 mus muscu
17	1007	42.6	427	2 BAC40362	Bac40362 mus muscu
18	1000	42.3	427	2 Q8BR23	Q8br23 mus musculu
19	999	42.3	428	1 ENP5 HUMAN	O75356 homo sapien
20	992	42.0	428	2 Q96RX0	Q96rx0 homo sapien
21	959	40.6	469	1 ENP5 MEGAU	Q9qyc8 mesocricetu
22	957	40.5	224	2 Q8CDX0	Q8cdx0 mus musculu
23	636.5	26.9	533	2 Q7PV18	Q7pv18 anopheles g
24	621	26.3	461	2 Q76288	Q76288 drosophila
25	621	26.3	464	2 Q9VQ18	Q9vq18 caenorhabdi
26	590.5	25.0	479	2 Q9XU84	Q9xu84 caenorhabdi
27	532.5	22.5	595	2 Q6BU56	Q6bu56 debaryomyce
28	531.5	22.5	522	1 GDAL KLJULA	Q8hem6 kluyveromyc
29	528	22.3	489	2 Q8HTJ6	Q8htj6 oryza sativ
30	525.5	22.2	467	2 Q9SPM7	Q9spm7 dolichos bi
31	509	21.5	455	2 Q84UE0	Q84ue0 medicago tr

32	508	21.5	556	1	GDAL SCHPO	Q9ut35 schizosacch
33	506	21.4	462	2	Q9XFC9	Q9xfc9 dolichos bi
34	505.5	21.4	467	2	Q84UD8	Q84ud8 medicago tr
35	504.5	21.3	467	2	Q8RV76	Q8rv76 pisum sativ
36	501.5	21.2	447	2	Q9FU11	Q9fui1 pisum sativ
37	501	21.2	455	2	Q9SPM6	Q9spm6 medicago sa
38	500	21.2	539	2	Q6CBK6	Q6cbk6 yarrowia li
39	498.5	21.1	541	2	Q6FLR7	Q6flr7 candida gla
40	498	21.1	518	1	GDAL YEAST	P32621 saccharomyc
41	495	20.9	467	2	Q6Z4P2	Q6z4p2 oryza sativ
42	495	20.9	467	2	BAC83798	Bac83798 oryza sat
43	490	20.7	510	2	Q753F2	Q753f2 ashbya goss
44	490	20.7	510	2	AAS53733	Aas53733 ashbya go
45	489.5	20.7	471	2	Q9SQG2	Q9sqg2 arabidopsis

## ALIGNMENTS

### RESULT 1

#### ENP6 HUMAN

ID ENP6 HUMAN STANDARD; PRT: 484 AA.  
AC O75354; Q7Z5B5; Q8TAS7; Q9UJD1;  
DT 16-OCT-2001 (Rel. 40, Created)  
DT 29-MAR-2004 (Rel. 43, Last sequence update)  
DT 05-JUL-2004 (Rel. 44, Last annotation update)  
DE Ectonucleoside triphosphate diphosphohydrolase 6 (EC 3.6.1.6)  
DE (NTPDase6) (CD39 antigen-like 2).  
GN Name=ENTPD6; Synonyms=CD39L2;  
OS Homo sapiens (Human).  
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
OX NCBI\_taxid=9606;  
[1]

RP SEQUENCE FROM N.A., AND VARIANT VAL-138.

RC TISSUE=Keratinocytes;

RX MEDLINE=98341119; PubMed=9676430;

RA Chadwick B.P., Frischauf A.-M.;

RT "The CD39-like gene family: identification of three new human members (CD39L2, CD39L3, and CD39L4), their murine homologues, and a member of the gene family from Drosophila melanogaster.";

RL Genomics 50:357-367(1998).

[2]

SEQUENCE FROM N.A.

RP MEDLINE=21638749; PubMed=11780052; DOI=10.1038/414865a;

RX Deloukas P., Matthews L.H., Ashurst J.L., Burton J., Gilbert J.G.R.,

RA Jones M., Stavrides G., Almeida J.P., Babbage A.K., Bagguley C.L.,

RA Bailey J., Barlow K.F., Bates K.N., Beard L.M., Beare D.M.,

RA Beasley O.P., Bird C.P., Blakey S.E., Bridgeman A.M., Brown A.J.,

RA Buck D., Burrill W.D., Butler A.P., Carder C., Carter N.P.,

RA Clegg S., Cobley V.B., Collier R.E., Connor R.E., Corby N.R.,

RA Coulson A., Coville G.J., Deadman R., Dhani P.D., Dunn M.,

RA Ellington A.G., Frankland J.A., Fraser A., French L., Garner P.,

RA Grafham D.V., Griffiths C., Griffiths M.N.D., Gwilliam R., Hall R.E.,

RA Huckle E., Hunt A.R., Hunt S.E., Jekosch K., Holden J.L., Howden P.J.,

RA Kay M.P., Kimberley A.M., King A., Knights A., Laird G.K., Lawlor S.,

RA Levaeslaih M.H., Leversha M.A., Lloyd C., Lloyd D.M., Lovell J.D.,

RA Marsh V.L., Martin S.L., McConachie L.J., McIlroy K., McMurray A.A.,

RA Milne S.A., Mistry D., Moore M.J.F., Mullikin J.C., Nickerson T.,

RA Oliver K., Parker A., Patel R., Pearce T.A.V., Peck A.I.,

RA Phillimore B.J.C.T., Prathalingam S.R., Plumb R.W., Ramsay H.,

RA Rice C.M., Ross M.T., Scott C.E., Sehra H.K., Showkeen R., Sims S.,

RA Skuce C.D., Smith M.L., Soderlund C., Steward C.A., Sulston J.E.,

RA Swann R.M., Sycamore N., Taylor R., Tee L., Thomas D.W., Thorpe A.,

RA Tracey A., Tromans A.C., Vaudin M., Wall M., Wallis J.M.,

RA Whitehead S.L., Whittaker P., Willey D.L., Williams L., Williams S.A.,

RA Wilming L., Wray P.W., Hubbard T., Durbin R.M., Bentley D.R., Beck S.,

RA Rogers J.;

RT "The DNA sequence and comparative analysis of human chromosome 20.";

RL Nature 414:865-871(2001).

[3]

SEQUENCE FROM N.A., AND SOLUBLE FORM DISULFIDE BONDS.  
 PubMed=14529283; DOI=10.1021/bi035137k; Kiley T.L.;  
 Ivanenkov V.V., Murphy-Piedmonte D.M., Kiley T.L.;  
 RA "Bacterial expression, characterization, and disulfide bond  
 RT determination of soluble human NTPase6 (CD39L2) nucleotidase:  
 RT implications for structure and function.";  
 RL Biochemistry 42:11726-11735 (2003).  
 RN [4]  
 RP SEQUENCE FROM N.A.  
 RC TISSUE=placenta;  
 RX MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;  
 RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,  
 RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,  
 RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,  
 RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Haieh F.,  
 RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,  
 RA Stapleton M., Soares M.B., Bonaldi M.F., Casavant T.L., Scheetz T.E.,  
 RA Brownstein M.J., Usdin T.B., Toshiyuki S., Carninci P., Prange C.,  
 RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullahy S.J.,  
 RA Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,  
 RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,  
 RA Villalón D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,  
 RA Fahey J., Helton E., Kettelman M., Madan A.C., Rodriguez S., Sanchez A.,  
 RA Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,  
 RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,  
 RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,  
 RA Butterfield Y.S.N., Krywinski M.I., Skalska U., Smailus D.E.,  
 RA Schnerch A., Schein J.E., Jones S.J.M., Marra M.A.;  
 RT "Generation and initial analysis of more than 15,000 full-length human  
 RT and mouse cDNA sequences.";  
 RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903 (2002).  
 RN [5]  
 RP SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.  
 RX PubMed=11041856; DOI=10.1021/bi009592;  
 RA Yeung G., Mulero J.J., McGowan D.W., Bajwa S.S., Ford J.E.;  
 RA "CD39L2, a gene encoding a human nucleoside diphosphatase,  
 RT predominantly expressed in the heart.";  
 RL Biochemistry 39:12916-12923 (2000).  
 CC -!- FUNCTION: Might support glycosylation reactions in the Golgi  
 CC apparatus and, when released from cells, might catalyze the  
 CC hydrolysis of extracellular nucleotides. Hydrolyzes preferentially  
 CC nucleoside 5'-diphosphates, nucleoside 5'-triphosphates are  
 CC hydrolyzed only to a minor extent, there is no hydrolysis of  
 CC nucleoside 5'-monophosphates. The order of activity with different  
 CC substrates is GDP > IDP > UDP = CDP >> ADP (By similarity).  
 CC -!- CATALYTIC ACTIVITY: A nucleoside diphosphate + H(2)O = a  
 CC nucleotide + phosphate.  
 CC -!- COFACTOR: Requires calcium and magnesium (By similarity).  
 CC -!- SUBCELLULAR LOCATION: Type II membrane protein. Golgi. But also  
 CC occurs in a soluble extracellular form.  
 CC -!- TISSUE SPECIFICITY: Expressed in most tissues, but predominantly  
 CC in heart.  
 CC -!- SIMILARITY: Belongs to the GDA1 / CD39 NTPase family.  
 CC -----  
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration  
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation  
 CC at the European Bioinformatics Institute. There are no restrictions on its  
 CC use by non-profit institutions as long as its content is in no way  
 CC modified and this statement is not removed. Usage by and for commercial  
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>  
 CC or send an email to [license@isb-sib.ch](mailto:license@isb-sib.ch)).  
 CC -----  
 CC EMBL: AF039916; AAC39883.1; -;  
 CC EMBL: AL035252; CAB41571.1; -;  
 CC EMBL: AY327581; AAP92131.1; -;  
 CC EMBL: BC025980; AAH25980.1; -;  
 CC EMBL: HGNC:3368; ENTDP6.  
 CC MIM: 603160; -;  
 CC InterPro: IPR000407; GDA1\_CD39\_NTPase.  
 CC Pfam: PF01150; GDA1\_CD39\_1.  
 CC PROSITE: PS01238; GDA1\_CD39\_NTPASE; FALSE NEG.  
 CC Calcium; Glycoprotein; Golgi stack; Hydrolase; Magnesium;  
 CC Polymorphism; Signal-anchor; Transmembrane.  
 CC KW

FT DOMAIN 1 39 Cytoplasmic (Potential).  
 FT TRANSMEM 40 60 Signal-anchor for type II membrane  
 FT protein (Potential).  
 FT Lumenal (Potential).  
 FT DISULFID 484 In soluble form.  
 FT DISULFID 325 In soluble form.  
 FT CARBOHYD 416 430 N-linked (GlcNAc...) (Potential).  
 FT CARBOHYD 220 220 N-linked (GlcNAc...) (Potential).  
 FT CARBOHYD 284 284 L -> V (in dbSNP:1044567).  
 FT VARIANT 138 138 /FTID=VAR.017863.  
 FT CONFLICT 14 14 S -> N (in Ref. 3).  
 FT CONFLICT 19 19 Missing (in Ref. 4).  
 FT CONFLICT 202 202 E -> K (in Ref. 2).  
 SQ SEQUENCE 484 AA; 53247 MW; 604C958953179089 CRC64;  
 Query Match 99.9%; Score 2361; DB 1; Length 484;  
 Best Local Similarity 99.8%; Pred. No. 1.6e-177;  
 Matches 455; Conservative 1; Mismatches 0; Indels 0; Gaps 0;  
 QY 1 MRKISNHGSLRVAKVAYPLGLCVGVFIYVAYIKWHRATATQAFPSITRAAPGARWGOAH 60  
 DB 29 MRKISNHGSLRVAKVAYPLGLCVGVFIYVAYIKWHRATATQAFPSITRAAPGARWGOAH 88  
 QY 61 SPLGTAADGHEVFYGVIMFDAGSTGTRVHVQFTRPRETPTLTHTFKAVKPGLSAYADD 120  
 DB 89 SPLGTAADGHEVFYGVIMFDAGSTGTRVHVQFTRPRETPTLTHTFKAVKPGLSAYADD 148  
 QY 121 VEKSAQGIREDLLVAKQDIPDFFWKATPLVLKATAGLRLPGEKAQKLLQKVKEVFKASP 180  
 DB 149 VEKSAQGIREDLLVAKQDIPDFFWKATPLVLKATAGLRLPGEKAQKLLQKVKEVFKASP 208  
 QY 181 FLVGDDCVSIMNGTDEGVSAWITINFLTGSILKTPGGSSVGMGLDGGSGTQAFLEPRVEGT 240  
 DB 209 FLVGDDCVSIMNGTDEGVSAWITINFLTGSILKTPGGSSVGMGLDGGSGTQAFLEPRVEGT 268  
 QY 241 LQASPPGYLTALRPNRTYKLYSYGLGLGMSARLAILGVEGQAPKDGKELVSPCLSP 300  
 DB 269 LQASPPGYLTALRPNRTYKLYSYGLGLGMSARLAILGVEGQAPKDGKELVSPCLSP 328  
 QY 301 SFKGEWEHAEVTVRVSGQAAASLHELCAARVSEVLQNRVHRTVEVKHVDYAFSYVDL 360  
 DB 329 SFKGEWEHAEVTVRVSGQAAASLHELCAARVSEVLQNRVHRTVEVKHVDYAFSYVDL 388  
 QY 361 AAGVGLIDAEKGGSLVWGDFFIAKYVCTLETOQSPSPSCMDLTYVSLLLQEGFPERS 420  
 DB 389 AAGVGLIDAEKGGSLVWGDFFIAKYVCTLETOQSPSPSCMDLTYVSLLLQEGFPERS 448  
 QY 421 KVLKTRKIDNVETSWALGAFHYIDSLNROKSPAS 456  
 DB 449 KVLKTRKIDNVETSWALGAFHYIDSLNROKSPAS 484  
 RESULT 2  
 Q8N3H3 PRELIMINARY; PRT; 503 AA.  
 ID Q8N3H3  
 AC Q8N3H3;  
 DT 01-OCT-2002 (TrEMBLrel. 22, Created)  
 DT 01-OCT-2002 (TrEMBLrel. 22, Last sequence update)  
 DT 01-MAR-2004 (TrEMBLrel. 26, Last annotation update)  
 DE Hypothetical protein DKFZp761J1915 (Fragment).  
 GN Name=DKFZp761J1915;  
 OS Homo sapiens (Human).  
 OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;  
 OC Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.  
 OX NCBI\_TaxID=9606;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RC TISSUE=Amygdala;  
 RA Ansonge W., Wirkner U., Mewes H.W., Weil B., Wiemann S.;  
 RL Submitted (JUL-2002) to the EMBL/GenBank/DBJ databases.  
 DR EMBL; AL834156; CAD38864.1; -;  
 DR GO; GO:0016787; F:hydrolase activity; IEA.  
 DR InterPro; IPR000407; GDA1\_CD39\_NTPase.

```

DR Pfam; PF01150; GDA1_CD39; 1.
KW Hypothetical protein.
FT NON_TER
SQ SEQUENCE 503 AA; 54763 MW; 163933PF9139D8DF9 CRC64;

Query Match 99.9%; Score 2361; DB 2; Length 503;
Best Local Similarity 99.8%; Pred. No. 1.7e-177;
Matches 455; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 MRKINHGSLRVAKVAYPLGLCVGVFIYVYIKWHRATATQAFPSITRAAPGARVGQQA 60
DB 48 MRKINHGSLRVAKVAYPLGLCVGVFIYVYIKWHRATATQAFPSITRAAPGARVGQQA 107
QY 61 SPLGTAADGHEVYFGIMFDAGSTGRVHVFOFTRPPRETPTLTHTFKAQKLSAYADD 120
DB 108 SPLGTAADGHEVYFGIMFDAGSTGRVHVFOFTRPPRETPTLTHTFKAQKLSAYADD 167
QY 121 VEKSAQGITRELLDVAKQDIPDFWKATPLVLKATAGLRLPGEKAQKLLQKVKEVFKASP 180
DB 168 VEKSAQGITRELLDVAKQDIPDFWKATPLVLKATAGLRLPGEKAQKLLQKVKEVFKASP 227
QY 181 FLVGDDCVSINMGTDGVSAMITINFLTGSLSKTPGSSVGMDLGGGSGTQIAFLPRVEGT 240
DB 228 FLVGDDCVSINMGTDGVSAMITINFLTGSLSKTPGSSVGMDLGGGSGTQIAFLPRVEGT 287
QY 241 LQASPPGYLTALRMFNRTYKLYSYLGLGMSARLAILGGVGPAPKDGKELVSPCLSP 300
DB 288 LQASPPGYLTALRMFNRTYKLYSYLGLGMSARLAILGGVGPAPKDGKELVSPCLSP 347
QY 301 SFKGEWEHAEVTVRVSGOKAAASLHELCAARVSEVLQNRVHRTERVHVDYAFSYYYDL 360
DB 348 SFKGEWEHAEVTVRVSGOKAAASLHELCAARVSEVLQNRVHRTERVHVDYAFSYYYDL 407
QY 361 AAGVGLIDAEGGSLVVGDFEIAAKYVCRTELETOQSSPFSCMDLTYSLLQLQEFPPRS 420
DB 408 AAGVGLIDAEGGSLVVGDFEIAAKYVCRTELETOQSSPFSCMDLTYSLLQLQEFPPRS 467
QY 421 KVLKTRKIDNVETSWALGAIFHYIDSLNRQKSPAS 456
DB 468 KVLKTRKIDNVETSWALGAIFHYIDSLNRQKSPAS 503

RESULT 3
ENP6 RAT STANDARD; PRT; 455 AA.
AC Q9ER31;
DT 16-OCT-2001 (Rel. 40, Created)
DT 16-OCT-2001 (Rel. 40, Last sequence update)
DT 05-JUL-2004 (Rel. 44, Last annotation update)
DE Ectonucleoside triphosphate diphosphohydrolase 6 (EC 3.6.1.6)
DE (NTPDase6) (CD39 antigen-like 2).
GN Name=Entpd6; Synonyms=Cd3912;
OS Rattus norvegicus (Rat);
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Rattus.
OX NCBI_TaxID=10116;
RN [1]
SEQUENCE FROM N.A.; SUBCELLULAR LOCATION, AND CHARACTERIZATION.
STRAIN=Sprague-Dawley; TISSUE=Brain;
MEDLINE=20498744; PubMed=11042116;
RA Braun N.; Fengler S.; Belling C.; Servos J.; Zimmermann H.;
RT "Sequencing, functional expression and characterization of rat
RT NTPDase6, a nucleoside diphosphatase and novel member of the ecto-
RT nucleoside triphosphate diphosphohydrolase family.";
RL Biochem. J. 351:639-647(2000)
CC
CC -!- FUNCTION: Might support glycosylation reactions in the Golgi
CC apparatus and, when released from cells, might catalyze the
CC hydrolysis of extracellular nucleotides. Hydrolyzes preferentially
CC nucleoside 5'-diphosphates, nucleoside 5'-triphosphates are
CC hydrolyzed only to a minor extent, there is no hydrolysis of
CC nucleoside 5'-monophosphates. The order of activity with different
CC substrates is GDP > IDP >> UDP = CDP >> ADP.
CC -!- CATALYTIC ACTIVITY: A nucleoside diphosphate + H(2)O = a

```

```

CC nucleotide + phosphate.
CC -!- COFACTOR: Requires calcium and magnesium.
CC -!- SUBCELLULAR LOCATION: Type II membrane protein. Golgi. But also
CC occurs in a soluble extracellular form.
CC -!- SIMILARITY: Belongs to the GDA1 / CD39 NTPase family.
CC
CC This SWISS-PROT entry is copyright.. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC or send an email to license@isb-sib.ch).
CC
CC EMBL; AJ277748; CAC16598.1; -.
DR RGD; 619725; Entrez.
DR InterPro; IPR00407; GDA1_CD39_NTPase.
DR Pfam; PF01150; GDA1_CD39; 1.
DR PROSITE; PS01238; GDA1_CD39_NTPASE; FALSE NEG.
KW Calcium; Glycoprotein; Golgi stack; Hydrolyase; Magnesium;
KW Signal-anchor; Transmembrane.
FT DOMAIN 1 12
FT TRANSMEM 13 32
FT SIGNAL 1 12
FT DOMAIN 33 455
FT DISULFD 297 327
FT DISULFD 387 401
FT CARBOHYD 192 192
FT CARBOHYD 256 256
FT SEQUENCE 455 AA; 49999 MW; 19A22E8BAEF0F77B CRC64;
SQ
Query Match 87.3%; Score 2063.5; DB 1; Length 455;
Best Local Similarity 86.6%; Pred. No. 4.3e-154;
Matches 394; Conservative 27; Mismatches 33; Indels 1; Gaps 1;
QY 1 MRKINHGSLRVAKVAYPLGLCVGVFIYVYIKWHRATATQAFPSITRAAPGARVGQQA 60
DB 1 MRKINHGSLRVAKVAYPLGLCVGVFIYVYIKWHRATATQAFPSITRAAPGARVGQQA 60
QY 61 SPLGTAADGHEVYFGIMFDAGSTGRVHVFOFTRPPRETPTLTHTFKAQKLSAYADD 120
DB 61 SPLGTAADGHEVYFGIMFDAGSTGRVHVFOFTRPPRETPTLTHTFKAQKLSAYADD 120
QY 121 VEKSAQGITRELLDVAKQDIPDFWKATPLVLKATAGLRLPGEKAQKLLQKVKEVFKASP 180
DB 121 VEKSAQGITRELLDVAKQDIPDFWKATPLVLKATAGLRLPGEKAQKLLQKVKEVFKASP 180
QY 181 FLVGDDCVSINMGTDGVSAMITINFLTGSLSKTPGSSVGMDLGGGSGTQIAFLPRVEGT 240
DB 181 FLVGDDCVSINMGTDGVSAMITINFLTGSLSKTPGSSVGMDLGGGSGTQIAFLPRVEGT 240
QY 241 LQASPPGYLTALRMFNRTYKLYSYLGLGMSARLAILGGVGPAPKDGKELVSPCLSP 300
DB 241 LQASPPGYLTALRMFNRTYKLYSYLGLGMSARLAILGGVGPAPKDGKELVSPCLSP 300
QY 301 SFKGEWEHAEVTVRVSGOKAAASLHELCAARVSEVLQNRVHRTERVHVDYAFSYYYDL 360
DB 301 SFKGEWEHAEVTVRVSGOKAAASLHELCAARVSEVLQNRVHRTERVHVDYAFSYYYDL 360
QY 361 AAGVGLIDAEGGSLVVGDFEIAAKYVCRTELETOQSSPFSCMDLTYSLLQLQEFPPRS 420
DB 361 AAGVGLIDAEGGSLVVGDFEIAAKYVCRTELETOQSSPFSCMDLTYSLLQLQEFPPRS 420
QY 421 KVLKTRKIDNVETSWALGAIFHYIDSLNRQKSPA 455
DB 420 KVLKTRKIDNVETSWALGAIFHYIDSLNRQKSPA 454
DB 420 KVLKTRKIDNVETSWALGAIFHYIDSLNRQKSPA 454
RESULT 4
Q6YHK4 PRELIMINARY; PRT; 445 AA.
ID Q6YHK4
AC Q6YHK4;
DT 05-JUL-2004 (TrEMBLrel. 27, Created)

```

```

DT 05-JUL-2004 (TrEMBLrel. 27, Last sequence update)
DT 05-JUL-2004 (TrEMBLrel. 27, Last annotation update)
DE Ectonucleoside triphosphate diphosphonhydrolase 6.
OS Cavia porcellus (Guinea pig).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Hystriognathi; Caviidae; Cavia.
OX NCBI_TaxID=10141;
RN [1]
RP SEQUENCE FROM N.A.
RC TISSUE=Brain;
RA Mihaylova-Todorova S.T., Choe S.M., Miller L.J., Horowitz B.,
RL Westfall D.P.;
RL Submitted (SEP-2002) to the EMBL/GenBank/DBJ databases.
DR EMBL; AY149906; AAN72326.1; -.
DR GO; GO:0016787; F:Hydrolase activity; IEA.
DR InterPro; IPR000407; GDAI_CD39_NTPase.
DR Pfam; PF01150; GDAI_CD39; 1.
KW Hydrolase.
SQ SEQUENCE 445 AA; 48357 MW; 890CEFD068405698 CRC64;

Query Match      82.2%; Score 1943; DB 2; Length 445;
Best Local Similarity 82.9%; Pred. No. 1.4e-144;
Matches 377; Conservative 31; Mismatches 37; Indels 10; Gaps 3;

QY 1 MRKISNHGSLRVAKVAYPLGLCVGVFIYVAYIKWHRATATQAFPSITRAAPGARWGOAH 60
DB 1 MRKIPSHGSLRMTRVAYLLGLCVGLFIYVAYIKWQASAPQVLSSI-----AH 51

QY 61 SPLGTAADGHEVFGYIMFDAGSTGTRVHVFOFTPRPTPTLTHETKAVKPGLSAYADD 120
DB 52 IPVGSAAHALEVFYIGIMFDAGSTGTRVHVFOFARPPGETPTLTHETKALKPGLSAYADD 111

QY 121 VEKSAQIGIRELLDVAKODIPDFWKATPLVLKATAGLRLLPGEKAQKLLQKVKEVFKASP 180
DB 112 VEKSAQIGIRELLDVAKODIPDFWKATPLVLKATAGLRLLPGEKAQKLLQKVKEVFKASP 171

QY 181 FLVGDDCVSIMGNDGVSAMITINFLTGSLKTPGGSSVGMGLDGGGSGTQITFLPRVGT 240
DB 172 FLVGDDCVSIMGNDGVSAMITINFLTGSLRAPSRSVGMGLDGGGSGTQITFLPRAGT 231

QY 241 LQASPPGYLTALRMFNRTYKLYSYGLGLMSARLAILGVGEGPAKDGKELVSPCLSP 300
DB 232 LEASPPGHLTSLQMFNRTYRLYSHSYGLGLMSARLAILGVGEGPAKDGKELVSPCLSP 291

QY 301 SFKGEWEHAEVTVRVSGQKAAASHLHCAARVSEVLQNRVHRTVEKHVDYAFSYYYDL 360
DB 292 GFRGEWEHAGITYRISGPK-AGRLHEPCASRVSEVLQSKVHRAEAGHVDYAFSYYYDL 350

QY 361 AAGVGLIDAEGKGSVLVGDPEIAAKYVCTLTETPOQSPFSCMDLTYVSLLLQEGFPPRS 420
DB 351 AASVGLIDAEGKGSVSLDEFEIAAKYVCTLTGAQPHHSPFLCMLDITYVSLLLREFGPPGD 410

RESULT 5
AAN72326 ID AAN72326 PRELIMINARY; PRT; 445 AA.
AC AAN72326;
DT 02-MAR-2004 (TrEMBLrel. 27, Created)
DT 02-MAR-2004 (TrEMBLrel. 27, Last sequence update)
DT 02-MAR-2004 (TrEMBLrel. 27, Last annotation update)
DE Ectonucleoside triphosphate diphosphonhydrolase 6.
OS Cavia porcellus (Guinea pig).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Hystriognathi; Caviidae; Cavia.
OX NCBI_TaxID=10141;
RN [1]
RP SEQUENCE FROM N.A.
RC TISSUE=Brain;
RA Mihaylova-Todorova S.T., Choe S.M., Miller L.J., Horowitz B.,
RA

```

```

RA Westfall D.P.;
RA "Sequencing of an ectonucleoside triphosphate diphosphonhydrolase
RT homolog of NTPase6 from Guinea pig.";
RL Submitted (SEP-2002) to the EMBL/GenBank/DBJ databases.
DR EMBL; AY149906; AAN72326.1; -.
KW Hydrolase.
SQ SEQUENCE 445 AA; 48357 MW; 890CEFD068405698 CRC64;

Query Match      82.2%; Score 1943; DB 2; Length 445;
Best Local Similarity 82.9%; Pred. No. 1.4e-144;
Matches 377; Conservative 31; Mismatches 37; Indels 10; Gaps 3;

QY 1 MRKISNHGSLRVAKVAYPLGLCVGVFIYVAYIKWHRATATQAFPSITRAAPGARWGOAH 60
DB 1 MRKIPSHGSLRMTRVAYLLGLCVGLFIYVAYIKWQASAPQVLSSI-----AE 51

QY 61 SPLGTAADGHEVFGYIMFDAGSTGTRVHVFOFTPRPTPTLTHETKAVKPGLSAYADD 120
DB 52 IPVGSAAHALEVFYIGIMFDAGSTGTRVHVFOFARPPGETPTLTHETKALKPGLSAYADD 111

QY 121 VEKSAQIGIRELLDVAKODIPDFWKATPLVLKATAGLRLLPGEKAQKLLQKVKEVFKASP 180
DB 112 VEKSAQIGIRELLDVAKODIPDFWKATPLVLKATAGLRLLPGEKAQKLLQKVKEVFKASP 171

QY 181 FLVGDDCVSIMGNDGVSAMITINFLTGSLKTPGGSSVGMGLDGGGSGTQITFLPRVGT 240
DB 172 FLVGDDCVSIMGNDGVSAMITINFLTGSLRAPSRSVGMGLDGGGSGTQITFLPRAGT 231

QY 241 LQASPPGYLTALRMFNRTYKLYSYGLGLMSARLAILGVGEGPAKDGKELVSPCLSP 300
DB 232 LEASPPGHLTSLQMFNRTYRLYSHSYGLGLMSARLAILGVGEGPAKDGKELVSPCLSP 291

QY 301 SFKGEWEHAEVTVRVSGQKAAASHLHCAARVSEVLQNRVHRTVEKHVDYAFSYYYDL 360
DB 292 GFRGEWEHAGITYRISGPK-AGRLHEPCASRVSEVLQSKVHRAEAGHVDYAFSYYYDL 350

QY 361 AAGVGLIDAEGKGSVLVGDPEIAAKYVCTLTETPOQSPFSCMDLTYVSLLLQEGFPPRS 420
DB 351 AASVGLIDAEGKGSVSLDEFEIAAKYVCTLTGAQPHHSPFLCMLDITYVSLLLREFGPPGD 410

RESULT 6
Q8CHZ3 ID Q8CHZ3 PRELIMINARY; PRT; 278 AA.
AC Q8CHZ3;
DT 01-MAR-2003 (TrEMBLrel. 23, Created)
DT 01-MAR-2003 (TrEMBLrel. 23, Last sequence update)
DT 01-JUN-2003 (TrEMBLrel. 24, Last annotation update)
DE Ectonucleoside triphosphate diphosphonhydrolase 6.
GN Name=Entp6;
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
OX NCBI_TaxID=10090;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=C57BL/6J; TISSUE=Mammary gland;
RX MEDLINE=22388257; PubMed=12477932;
RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
RA Altshul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,
RA Diatchenko L., Marusina K., Farmer A.F., Rubin G.M., Hong L.,
RA Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
RA Brownstein M.J., Udwin T.B., Toshiyuki S., Carninci P., Prange C.,
RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullany S.J.,
RA Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA Villalón D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,

```

```

RA Fahey J., Helton E., Kettelman M., Madan A., Rodrigues S., Sanchez A.,
RA Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
RA Blakesley R.W., Touchman M., Madan A.C., Shevchenko Y., Bouffard G.G.,
RA Rodriguez A.C., Grinwood J., Schmutz J., Myers R.M., Butterfield Y.S.,
RA Krzywinski M.I., Skalska U., Smailus D.E., Schnerch A., Schein J.E.,
RA Jones S.J., Marra M.A.;
RA "Generation and initial analysis of more than 15,000 full-length human
RT and mouse cDNA sequences.";
RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
RN [2]
RP SEQUENCE FROM N.A.
RC STRAIN=C57BL/6J; TISSUE=Mammary gland;
RA Strausberg R.;
RL Submitted (SEP-2002) to the EMBL/GenBank/DBJ databases.
DR EMBL; BC038126; AAH38126.1; -.
MGD; MGI:1202295; Entp66.
DR GO; GO:0016787; F:hydrolase activity; IEA.
DR InterPro; IPR000407; GDAI_CD39_NTPase.
DR Pfam; PF01150; GDAI_CD39; 1.
KW Hydrolase.
SQ SEQUENCE 278 AA; 30130 MW; 75A92DD1AC76297F CRC64;

Query Match 52.0%; Score 1229.5; DB 2; Length 278;
Best Local Similarity 85.6%; Pred. No. 1.4e-88;
Matches 237; Conservative 17; Mismatches 18; Indels 5; Gaps 1;

QY 1 MRKISNHGSLRVAKVAYPLGLCVGVFIYVAYIKWHRATATQAFSITRAAPGARWQQAQ 60
DB 1 MRKIPNHGTLRMWKVAYPLGLCVGLFIYVAYIKWHRASAAQAFITIAAGASGARTQQAF 60
QY 61 SPLGTADGHEVYFGIMFDAGSTGRVHVQFTTRPPRETPTLTTHETFKAVKPLGSAYADD 120
DB 61 SSPGSAARGHEVYFGIMFDAGSTGRVHVQFTTRPPRETPTLTTHETFKALKPLGSAYADD 120
QY 121 VEKSAQGIREFLLDVAKODIPDFWKATPLVLKATAGLLPCKEAKQLLQKVKEVFKASP 180
DB 121 VEKSAQGIREFLLDVAKODIPDFWKATPLVLKATAGLLPCKEAKQLLQKVKEVFKASP 180
QY 181 FLVGGDDCVSINMGTDGVSAMITINFLTGSLKTPGSSVGMGLDLGGSGTQTAFILPRVSGT 240
DB 181 FLVGGDDCVSINMGTDGVSAMITINFLTGSLKTPGSSVGMGLDLGGSGTQTAFILPRVSGT 240
QY 241 LQASPPGYLTALRMFNRTYKLYSYLGLGLMSAPLA 277
DB 241 LQASPPGYLTALQWENRTYKLYSYRW-----VCSRLA 272

RESULT 7
Q6P6S9 ID Q6P6S9 PRELIMINARY; PRT; 427 AA.
AC Q6P6S9;
DT 05-JUL-2004 (TrEMBLrel. 27, Created)
DT 05-JUL-2004 (TrEMBLrel. 27, Last sequence update)
DT 05-JUL-2004 (TrEMBLrel. 27, Last annotation update)
DE Ectonucleoside triphosphate diphosphohydrolase 5.
GN Name=Entp65;
OS Rattus norvegicus (Rat).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Rattus.
OX NCBI_TaxID=10116;
RN [1]
RP SEQUENCE FROM N.A.
RC TISSUE=Prostate;
RX MEDLINE=22388257; PubMed=12477932;
RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,
RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
RA Brownstein W.J., Usdin T.B., Toshiyuki S., Carninci P., Prange C.,
RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullany S.J.,
RA Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,

```

```

RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA Villalón D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA Fahey J., Helton E., Kettelman M., Madan A.C., Rodrigues S., Sanchez A.,
RA Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
RA Blakesley R.W., Touchman M., Madan A.C., Shevchenko Y., Bouffard G.G.,
RA Rodriguez A.C., Grinwood J., Schmutz J., Myers R.M., Butterfield Y.S.,
RA Krzywinski M.I., Skalska U., Smailus D.E., Schnerch A., Schein J.E.,
RA Jones S.J., Marra M.A.;
RA "Generation and initial analysis of more than 15,000 full-length human
RT and mouse cDNA sequences.";
RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
RN [2]
RP SEQUENCE FROM N.A.
RC TISSUE=Prostate;
RA Strausberg R.;
RL Submitted (NOV-2003) to the EMBL/GenBank/DBJ databases.
DR EMBL; BC062044; AAH62044.1; -.
GO; GO:0016787; F:hydrolase activity; IEA.
DR InterPro; IPR000407; GDAI_CD39_NTPase.
DR Pfam; PF01150; GDAI_CD39; 1.
KW Hydrolase.
SQ SEQUENCE 427 AA; 47372 MW; 6CBBC44D96A0211 CRC64;

Query Match 43.2%; Score 1021; DB 2; Length 427;
Best Local Similarity 53.2%; Pred. No. 6.9e-72;
Matches 207; Conservative 58; Mismatches 118; Indels 6; Gaps 4;

QY 62 PLGTADGHEVYFGIMFDAGSTGRVHVQFTTRPPRETPTLTTHETFKAVKPLGSAYADD 120
DB 39 PNVNSAG---TFYIGIMFDAGSTGRVHVQFTTRPPRETPTLTTHETFKAVKPLGSAYADD 95
QY 121 VEKSAQGIREFLLDVAKODIPDFWKATPLVLKATAGLLPCKEAKQLLQKVKEVFKASP 180
DB 96 PQGAETVQELLEVAKOSIPRSHMKRTPEVLKATAGLLPCKEAKQLLQKVKEVFKASP 155
QY 181 FLVGGDDCVSINMGTDGVSAMITINFLTGSLKTPGSSVGMGLDLGGSGTQTAFILPRVSGT 240
DB 156 FLVPPDDSVSINDGSEYEGILAWTVNFLTGLHGRGQETVGLDLGGSGTQTAFILPRVSGT 215
QY 241 LQASPPGYLTALRMFNRTYKLYSYLGLGLMSAPLA 300
DB 216 LEQTPKGYLASFEFNFSTFKLYTHSYLGFGLKARLATIGALEAE-GTDGHTFRSACLPR 274
QY 301 SFKGWEHAEVTVYVSGQAAASHLCAARVSEVLQNRVHRTVEVKHVDYFASYYDL 360
DB 275 WLEAEWIFGGVKYQYGGNGEGEMGFECYAEVRVWQKLGHPPEIRGSSFYAFSYYDR 334
QY 361 AAGVGLIDAEGKGSILVVGDFEIAAKYVCRTLETQPSPPSCMDLTYYVSLLOE-FGPPR 419
DB 335 AAETHLIDYEKGGVLYKVEDFERKAREVCDNLESFSSGSPFLCMDSYITALLKDGFGFED 394
QY 420 SKVLKTRKIDNVETSWALGAIFHYIDSL 448
DB 395 GTLLQLTKVNNIETGWALGATPHLLQSL 423

RESULT 8
AAH62044 ID AAH62044 PRELIMINARY; PRT; 427 AA.
AC AAH62044;
DT 02-MAR-2004 (TrEMBLrel. 27, Created)
DT 02-MAR-2004 (TrEMBLrel. 27, Last sequence update)
DT 02-MAR-2004 (TrEMBLrel. 27, Last annotation update)
DE Ectonucleoside triphosphate diphosphohydrolase 5.
OS Rattus norvegicus (Rat).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Rattus.
OX NCBI_TaxID=10116;
RN [1]
RP SEQUENCE FROM N.A.
RC TISSUE=Prostate;
RX MEDLINE=22388257; PubMed=12477932;
RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,

```



298 GFEPYAEVLRVQKHLQPEVRGSAFYAFSYYYDRAADTHLIDYEKGVKVEDFERK 357

384 AKYVCRTLETQPSQSPFSCMDLTIVYVLLQE-FGPPSRKVLKTRKIDNVETSWALGAF 442

358 AREVCDNLGSPSSGSPFLCMDLTVITALLKDGFGFADGTLQLTKKVNNIETGWALGAF 417

443 HYIDSL 448  
| | | | |

418 HLLQSL 423  
| | | | |

RESULT 10

Q8CD29 PRELIMINARY; PRT; 427 AA.

AC O8CD29;

DT 01-MAR-2003 (TrEMBLrel. 23, Created)

DT 01-MAR-2003 (TrEMBLrel. 23, Last sequence update)

DT 01-MAR-2004 (TrEMBLrel. 26, Last annotation update)

DE Mus musculus 13 days embryo male testis cDNA, RIKEN full-length

DE enriched library, clone:6030456F04 product:ectonucleoside triphosphate

DE di-phosphohydrolase 5, full insert sequence.

GN Name=Entpd5;

OS Mus musculus (Mouse).

OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;

OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.

OC NCBI\_TaxID=10090;

[1]

RP SEQUENCE FROM N.A.

RC STRAIN=C57BL/6J; TISSUE=Testis;

RX MEDLINE=99279253; PubMed=10349636;

RA Carninci P., Hayashizaki Y.;

RT "High-efficiency full-length cDNA cloning.;"

RL Meth. Enzymol. 303:19-44 (1999).

[2]

RP SEQUENCE FROM N.A.

RC STRAIN=C57BL/6J; TISSUE=Testis;

RX MEDLINE=21085660; PubMed=11217851;

RA RIKEN FANTOM Consortium;

RT "Functional annotation of a full-length mouse cDNA collection.;"

RL Nature 409:685-690 (2001).

[3]

RP SEQUENCE FROM N.A.

RC STRAIN=C57BL/6J; TISSUE=Testis;

RA The FANTOM Consortium,

RA the RIKEN Genome Exploration Research Group Phase I & II Team;

RT "Analysis of the mouse transcriptome based on functional annotation of

RT 60,770 full-length cDNAs.;"

RL Nature 420:563-573 (2002).

[4]

RP SEQUENCE FROM N.A.

RC STRAIN=C57BL/6J; TISSUE=Testis;

RX MEDLINE=20493374; PubMed=11042159;

RA Carninci P., Shibata K., Hayatsu N., Sugahara Y., Shibata K., Itoh M.,

RA Konno H., Okazaki Y., Muramatsu M., Hayashizaki Y.;

RT "Normalization and subtraction of cap-trapper-selected cDNAs to

RT prepare full-length cDNA libraries for rapid discovery of new genes.;"

RL Genome Res. 10:11617-1630 (2000).

[5]

RP SEQUENCE FROM N.A.

RC STRAIN=C57BL/6J; TISSUE=Testis;

RX MEDLINE=20530913; PubMed=11076861;

RA Shibata K., Itoh M., Aizawa K., Nagaoka S., Sasaki N., Carninci P.,

RA Konno H., Akiyama J., Nishi K., Kitsuai T., Taishiro H., Itoh M.,

RA Sumi N., Ishii Y., Nakamura S., Hazama M., Nishine T., Harada A.,

RA Yamamoto R., Matsumoto H., Sakaguchi S., Ikegami T., Kashiwagi K.,

RA Fujitake S., Inoue K., Togawa Y., Izawa M., Ohara E., Watabiki M.,

RA Yoneda Y., Ishikawa T., Ozawa K., Tanaka T., Matsuura S., Kawai J.,

RA Okazaki Y., Muramatsu M., Inoue Y., Kira A., Hayashizaki Y.;

RT "RIKEN integrated sequence analysis (RISA) system-384-format

RT sequencing pipeline with 384 multicapillary sequencer.;"

RL Genome Res. 10:1757-1771 (2000).

[6]

RP SEQUENCE FROM N.A.



```

RC STRAIN=C57BL/6J; TISSUE=Testis;
RA Adachi J., Aizawa K., Akimura T., Arakawa T., Bono H., Carninci P.,
RA Fukuda S., Furuno M., Hanaoka T., Hara A., Hashizume W.,
RA Hayashida K., Hayatsu N., Hiramoto K., Hiraoka T., Hirozane T.,
RA Hori F., Imotani K., Ishii Y., Itoh M., Kagawa I., Kasukawa T.,
RA Katoh H., Kawai J., Kojima Y., Kondo S., Konno H., Kouda M., Koya S.,
RA Kurihara C., Matsuyama T., Miyazaki A., Murata M., Nakamura M.,
RA Nishi K., Nomura K., Numazaki R., Ohno M., Ohsato N., Okazaki Y.,
RA Saito K., Saiton H., Sakai C., Sakai K., Sakazume N., Sano H.,
RA Sasaki D., Shibata K., Shingawa A., Shiraki T., Sogabe Y., Tagami M.,
RA Tagawa A., Takahashi F., Takaku-Akahira S., Takeda Y., Tanaka T.,
RA Tomaru A., Toya T., Yasunishi A., Muramatsu M., Hayashizaki Y.;
RL Submitted (JUL-2001) to the EMBL/GenBank/DBJ databases.
DR EMBL; AK031581; BAC27461.1; -.
DR MGD; MGI:1321385; Entrez.
DR GO; GO:0016787; F:hydrolase activity; IEA.
DR InterPro; IPR000407; GDA1_CD39_NTPase.
DR Pfam; PF01150; GDA1_CD39; 1.
KW Hydrolase.
SQ
SEQUENCE 427 AA; 47101 MW; 653773C842B58477 CRC64;
Query Match 42.6%; Score 1007; DB 2; Length 427;
Best Local Similarity 50.0%; Pred. No. 8.8e-71;
Matches 213; Conservative 62; Mismatches 133; Indels 18; Gaps 6;
37 ATATQAFFSITRAAPGA-----RWGQ----QAHSPLGTAADGHEVFFGIMFDAGSTG 84
2 ATSWGAVFMLIIACVGSITVYRQQTWFEGVFLSSMCPINVSAG---TFYGIMFDAGSTG 58
85 TRVHVFOFT-RPPEPTLTTHETFKAVKPGLSAYADDEKSAQGIKRELLDVAKODIPDF 143
59 TRIHVYTFVQKTAGQLPFLGEIFDSVKPGLSAFVDQPKQGAETVQELLEVAKDSIPRSH 118
144 WKATPLVKTAGLRLLPGEKAQKLLQKVKEFKASPLFLVGGDDCVSIMNGTDEGVSAWIT 203
119 WERTPVVVKTAGLRLLPGEKAQALLLEVEEIEFNSEFLVPDGSVIMDGSYEGILAWVT 178
204 INFLTGSLKTPGGSSVGMGLDGGSTQIAFLPRVEGTLOASPPGYLTALRMFNRTYKLYS 263
179 VNFLTGQHGQGTGTGTLDLGGASTQITFLPQPEKTELETPRGYLTSEFMFNSTFKLYT 238
85 TRVHVFOFT-RPPEPTLTTHETFKAVKPGLSAYADDEKSAQGIKRELLDVAKODIPDF 143
59 TRIHVYTFVQKTAGQLPFLGEIFDSVKPGLSAFVDQPKQGAETVQELLEVAKDSIPRSH 118
144 WKATPLVKTAGLRLLPGEKAQKLLQKVKEFKASPLFLVGGDDCVSIMNGTDEGVSAWIT 203
119 WERTPVVVKTAGLRLLPGEKAQALLLEVEEIEFNSEFLVPDGSVIMDGSYEGILAWVT 178
204 INFLTGSLKTPGGSSVGMGLDGGSTQIAFLPRVEGTLOASPPGYLTALRMFNRTYKLYS 263
179 VNFLTGQHGQGTGTGTLDLGGASTQITFLPQPEKTELETPRGYLTSEFMFNSTFKLYT 238
264 YSYLGGLGMSARLAILGGVEGQPAKDGKELVSPCLSPFKGEWEHAEVTVYRVSQKAAAS 323
239 HSYLGFGLKAARLATLGALEAK-GTDGHTFRSACLPRWLEAEWIFGGVKYQYGNQEGEM 297
324 LHELCARVSEVLQNRVHRTVEVKHDFYAFSYYYDLAAGVGLIDAEGKSLVVGDEFEIA 383
298 GFEPCTAEVLVWQKHLQHPVEVRGSAFYAFSYYYDRAADTHLIDYEKGGVLYKVEDFERK 357
384 AKYVCRTELETQPSPPSCMDLTYVSLLOE-FGFPRSKVLKLRKIDNVETSWALGAIF 442
358 AREVCDNLGSSPSPFLCMLDLYITALLKDGFGFADGTTLLQLTKVNNIETGWALGATF 417
443 HYIDSL 448
418 HLLQSL 423
RESULT 11
AAK82949
ID AAK82949 PRELIMINARY; PRT; 427 AA.
AC AAK82949;
DT 02-MAR-2004 (TrEMBLrel. 27, Created)
DT 02-MAR-2004 (TrEMBLrel. 27, Last sequence update)
DE Pcpn proto-oncogene protein.
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
OX NCBI_TaxID=10090;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=C57BL/6J; TISSUE=thymus;

```

```

RX MEDLINE=99437879; PubMed=10506756;
RA Recio J.A., Zambiano N., de La Pena L., Powers C., Siwarski D.,
RA Huppi K., Notario V.;
RT "cDNA isolation, expression, and chromosomal localization of the mouse
RT pcpn proto-oncogene.";
RL Mol. Carcinog. 26:130-136(1999).
DR EMBL; AF136571; AAK82949.1; -.
SQ SEQUENCE 427 AA; 47101 MW; 2F9DA2C342C55577 CRC64;
Query Match 42.6%; Score 1007; DB 2; Length 427;
Best Local Similarity 50.0%; Pred. No. 8.8e-71;
Matches 213; Conservative 62; Mismatches 133; Indels 18; Gaps 6;
37 ATATQAFFSITRAAPGA-----RWGQ----QAHSPLGTAADGHEVFFGIMFDAGSTG 84
2 ATSWGAVFMLIIACVGSITVYRQQTWFEGVFLSSMCPINVSAG---TFYGIMFDAGSTG 58
85 TRVHVFOFT-RPPEPTLTTHETFKAVKPGLSAYADDEKSAQGIKRELLDVAKODIPDF 143
59 TRIHVYTFVQKTAGQLPFLGEIFDSVKPGLSAFVDQPKQGAETVQELLEVAKDSIPRSH 118
144 WKATPLVKTAGLRLLPGEKAQKLLQKVKEFKASPLFLVGGDDCVSIMNGTDEGVSAWIT 203
119 WERTPVVVKTAGLRLLPGEKAQALLLEVEEIEFNSEFLVPDGSVIMDGSYEGILAWVT 178
204 INFLTGSLKTPGGSSVGMGLDGGSTQIAFLPRVEGTLOASPPGYLTALRMFNRTYKLYS 263
179 VNFLTGQHGQGTGTGTLDLGGASTQITFLPQPEKTELETPRGYLTSEFMFNSTFKLYT 238
264 YSYLGGLGMSARLAILGGVEGQPAKDGKELVSPCLSPFKGEWEHAEVTVYRVSQKAAAS 323
239 HSYLGFGLKAARLATLGALEAK-GTDGHTFRSACLPRWLEAEWIFGGVKYQYGNQEGEM 297
324 LHELCARVSEVLQNRVHRTVEVKHDFYAFSYYYDLAAGVGLIDAEGKSLVVGDEFEIA 383
298 GFEPCTAEVLVWQKHLQHPVEVRGSAFYAFSYYYDRAADTHLIDYEKGGVLYKVEDFERK 357
384 AKYVCRTELETQPSPPSCMDLTYVSLLOE-FGFPRSKVLKLRKIDNVETSWALGAIF 442
358 AREVCDNLGSSPSPFLCMLDLYITALLKDGFGFADGTTLLQLTKVNNIETGWALGATF 417
443 HYIDSL 448
418 HLLQSL 423
RESULT 12
BAC29515
ID BAC29515 PRELIMINARY; PRT; 427 AA.
AC BAC29515;
DT 14-APR-2004 (TrEMBLrel. 27, Created)
DT 14-APR-2004 (TrEMBLrel. 27, Last sequence update)
DT 14-APR-2004 (TrEMBLrel. 27, Last annotation update)
DE Adult male bone cDNA, RIKEN full-length enriched library,
DE clone:9830144N04 product:ectonucleoside triphosphate
DE diphosphohydrolase 5, full insert sequence.
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
OX NCBI_TaxID=10090;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=C57BL/6J; TISSUE=Bone;
RX MEDLINE=22354683; PubMed=12466851;
RA The FANTOM Consortium,
RA the RIKEN Genome Exploration Research Group Phase I & II Team;
RT "Analysis of the mouse transcriptome based on functional annotation of
RT 60,770 full-length cDNAs.";
RL Nature 420:563-573(2002).
RN [2]
RP SEQUENCE FROM N.A.
RC STRAIN=C57BL/6J; TISSUE=Bone;
RX MEDLINE=21085660; PubMed=11217851;

```



```

RA RIKEN FANTOM Consortium;
RT "Functional annotation of a full-length mouse cDNA collection.";
RN [3]
RP SEQUENCE FROM N.A.
RC STRAIN=C57BL/6J; TISSUE=Bone;
RX MEDLINE=99279253; PubMed=10349636;
RA Carninci P., Hayashizaki Y.;
RT "High-efficiency full-length cDNA cloning.";
RN [4]
RP SEQUENCE FROM N.A.
RC STRAIN=C57BL/6J; TISSUE=Bone;
RX MEDLINE=20499374; PubMed=11042159;
RA Carninci P., Shibata Y., Hayatsu N., Sugahara Y., Shibata K., Itoh M.,
RA Konno H., Okazaki Y., Muramatsu M., Hayashizaki Y.;
RT "Normalization and subtraction of cap-trapper-selected cDNAs to
RT prepare full-length cDNA libraries for rapid discovery of new genes.";
RN [5]
RP SEQUENCE FROM N.A.
RC STRAIN=C57BL/6J; TISSUE=Bone;
RX MEDLINE=20530913; PubMed=11076861;
RA Shibata K., Itoh M., Aizawa K., Nagaoka S., Sasaki N., Carninci P.,
RA Sumi N., Akiyama J., Nishi K., Kitsuai T., Tashiro H., Itoh M.,
RA Yamamoto R., Matsumoto H., Sakaguchi S., Ikegami T., Kashiwagi K.,
RA Fujiwaka S., Inoue K., Togawa Y., Izawa M., Ohara E., Watahiki M.,
RA Yoneda Y., Ishikawa T., Ozawa K., Tanaka T., Matsuura S., Kawai J.,
RA Okazaki Y., Muramatsu M., Inoue Y., Kira A., Hayashizaki Y.;
RT "RIKEN integrated sequence analysis (RISA) system-384-format
RT sequencing pipeline with 384 multicapillary sequencer.";
RN [6]
RP SEQUENCE FROM N.A.
RC STRAIN=C57BL/6J; TISSUE=Bone;
RX MEDLINE=22354683; PubMed=12466851;
RA The FANTOM Consortium,
RA the RIKEN Genome Exploration Research Group Phase I & II Team;
RT "Analysis of the mouse transcriptome based on functional annotation of
RT 60,770 full-length cDNAs.";
RN [2]
RP SEQUENCE FROM N.A.
RC STRAIN=C57BL/6J; TISSUE=Thymus;
RX MEDLINE=21085660; PubMed=11217851;
RA RIKEN FANTOM Consortium;
RT "Functional annotation of a full-length mouse cDNA collection.";
RN [3]
RP SEQUENCE FROM N.A.
RC STRAIN=C57BL/6J; TISSUE=Thymus;
RX MEDLINE=99279253; PubMed=10349636;
RA Carninci P., Hayashizaki Y.;
RT "High-efficiency full-length cDNA cloning.";
RN [4]
RP SEQUENCE FROM N.A.
RC STRAIN=C57BL/6J; TISSUE=Thymus;
RX MEDLINE=20499374; PubMed=11042159;
RA Carninci P., Shibata Y., Hayatsu N., Sugahara Y., Shibata K., Itoh M.,
RA Konno H., Okazaki Y., Muramatsu M., Hayashizaki Y.;
RT "Normalization and subtraction of cap-trapper-selected cDNAs to
RT prepare full-length cDNA libraries for rapid discovery of new genes.";
RN [5]
RP SEQUENCE FROM N.A.
RC STRAIN=C57BL/6J; TISSUE=Thymus;
RX MEDLINE=20530913; PubMed=11076861;
RA Shibata K., Itoh M., Aizawa K., Nagaoka S., Sasaki N., Carninci P.,
RA Konno H., Akiyama J., Nishi K., Kitsuai T., Tashiro H., Itoh M.,
RA Yamamoto R., Matsumoto H., Sakaguchi S., Ikegami T., Kashiwagi K.,
RA Fujiwaka S., Inoue K., Togawa Y., Izawa M., Ohara E., Watahiki M.,
RA Yoneda Y., Ishikawa T., Ozawa K., Tanaka T., Matsuura S., Kawai J.,
RA Okazaki Y., Muramatsu M., Inoue Y., Kira A., Hayashizaki Y.;

```

```
RT "RIKEN integrated sequence analysis (RISA) system-384-format
RT sequencing pipeline with 384 multicapillary sequencer.";
RL Genome Res. 10:1757-1771 (2000).
RN
RN SEQUENCE FROM N.A.
RP STRAIN=C57BL/6J; TISSUE=Thymus;
RC Adachi J., Aizawa K., Akimura T., Arakawa T., Bono H., Carninci P.,
RA Fukuda S., Furuno M., Hanagaki T., Hara A., Hashizume W.,
RA Hayashida K., Hayatsu N., Hiramoto K., Hiraoka T., Hirozane T.,
RA Katoh H., Kawai J., Kojima Y., Kondo S., Konno H., Kouda M., Koya S.,
RA Kurihara C., Matsuyama T., Miyazaki A., Murata M., Nakamura M.,
RA Nishi K., Nomura K., Numazaki R., Ohno M., Ohsato N., Okazaki Y.,
RA Saito R., Saitoh H., Sakai C., Sakai K., Sakazume N., Sano H.,
RA Sasaki D., Shibata K., Shinagawa A., Shiraki T., Sogabe Y., Tagami M.,
RA Tomaru A., Toya T., Yasunishi A., Muramatsu M., Hayashizaki Y.,
RL Submitted (JUL-2001) to the EMBL/GenBank/DBJ databases.
DR EMBL; AK037736; BAC29861.1; -.
KW Hydrolase.
SQ SEQUENCE 427 AA; 47101 MW; 2F9DA2C342C55577 CRC64;
Query Match 42.6%; Score 1007; DB 2; Length 427;
Best Local Similarity 50.0%; Pred. No. 8.8e-71;
Matches 213; Conservative 62; Mismatches 133; Indels 18; Gaps 6;
QY 37 ATATQAFFSITRAAPGA-----RWGQ-----QAHSPLGTAAADGHEVFYGMFDAGSTG 84
Db 2 ATSWGAVFMLIIACVGTSTVFYREQQTWFEGVFLSSMCPINVSAG---TFYGMFDAGSTG 58
QY 85 TRHVFOFT-RPPRETPTLTHTFPKAVKPGLSAYADVEKSAQGIREDLLDVAKODIPDF 143
Db 59 TRIHYVTFVQKTAQQLPFECEIFDSVKPGLSAFVDQPKQGAETVQSELLEVAKDSIPRSH 118
QY 144 WKATPLVLKATAGURLLPGEKAQKLKQVEVFASFLVGDCCVSIMNGTDEGVSAWIT 203
Db 119 WERTPVVLKATAGURLLPGEKAQALLLEVEIFKNSPLFPDVGVSIMDGSYEGILAWVT 178
QY 204 INFLTGSIKTPGSSVGMLDLGGSGSTOAFUPRVEGTLOASPPGVLTAIRMFNKTYKLYS 263
Db 179 VNFUTGQLHKGQSTVTGLDGGASTQITFLPQEKILEQTPRGYLSFEMFNSTFKLYT 238
QY 264 YSYLGLGIMSARLAILGSGVEQPQAKGKELVSPCLSPFSFKGEWBAEYTVRVSGQKAAS 323
Db 239 HSYLGFGLKARLALTLGALAK-GTGDHTPRSACLPRWLEAWIFGGVKYQVGGNQGEM 297
QY 324 LHELCAARVSEVLQNRVHRTEEVKHVDIFYAFSYYYDLAAGVGLIDAEGKGSILVGDREIA 383
Db 298 GFEPFYAEVLRVQGLHQPEVRGSAFYAFSYYYDRAADTHLIDYKGGVLRKVEDFERK 357
QY 384 AKYVCRTLETQPSQSPSCMDLTYSVLLQBF-FGPPRSKVLKTRKIDNVETSWALGAIF 442
Db 358 AREVCDNLGSPSSGSPFLCMDLTIVITALLKDGFGADGTLLQLKKNVNIETGALGATF 417
QY 443 HYIDSL 448
Db 418 HLLQSL 423
RESULT 14
BAC37592
ID BAC37592 PRELIMINARY; PRT; 427 AA.
AC BAC37592;
DT 14-APR-2004 (TrEMBLrel. 27, Created)
DT 14-APR-2004 (TrEMBLrel. 27, Last sequence update)
DE Adult male urinary bladder cDNA, RIKEN full-length enriched library,
DE clone:9530068a17 product:ectonucleoside triphosphate
DE diphosphohydrolase 5, full insert sequence.
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Mus.
NCBI_TaxID=10090;
```



us-09-905-589a-2.rup

Tue Nov 16 17:15:08 2004

Job time : 201 secs

GenCore version 5.1.6  
Copyright (c) 1993 - 2004 Compugen Ltd.

OM protein - protein search, using sw model

Run on: November 16, 2004, 16:32:53 ; Search time 156 Seconds  
(without alignments)  
1048.593 Million cell updates/sec

Title: US-09-905-589A-2

Perfect score: 2364

Sequence: 1 MKISNHSRLRVAKVAYPLG.....ALGAIFHYIDSLNRQKSPAS 456

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 2002273 seqs, 358729299 residues

Total number of hits satisfying chosen parameters: 2002273

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : A\_Geneseq\_23Sep04:\*

- 1: Geneseqpl980s:\*
- 2: Geneseqpl990s:\*
- 3: Geneseqpl2000s:\*
- 4: Geneseqpl2001s:\*
- 5: Geneseqpl2002s:\*
- 6: Geneseqpl2003as:\*
- 7: Geneseqpl2003bs:\*
- 8: Geneseqpl2004s:\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

## SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	2364	100.0	456	5	AAE19881 Human CD3
2	2364	100.0	456	8	ADQ99442 Human CD3
3	2364	100.0	484	4	AAE19881 Human CD3
4	2364	100.0	484	8	ADQ99442 Human CD3
5	2361	99.9	463	5	ABO06124 Human CD3
6	2361	99.9	467	5	ABJ04657 Human NS
7	2351	99.5	456	4	AAE19881 Human CD3
8	2351	99.5	456	8	ADQ99442 Human CD3
9	2152	91.0	450	7	ADQ14220 Human pro
10	2135	90.3	462	4	AAE19881 Human CD3
11	2116	89.5	446	5	ABJ04658 Human CD3
12	2003	84.7	471	4	AAE19881 Human CD3
13	999	42.3	428	3	AAE19881 Human CD3
14	999	42.3	428	4	AAE19881 Human CD3
15	999	42.3	428	4	AAE19881 Human CD3
16	999	42.3	428	5	AAE19881 Human CD3
17	999	42.3	428	8	ADP07487 Human CD3
18	999	42.3	428	8	ADP07487 Human CD3
19	999	42.3	428	8	ADQ99446 Human CD3
20	999	42.3	428	8	ADQ99446 Human CD3
21	996	42.1	428	3	AAE19881 Human CD3
22	996	42.1	428	4	AAE19881 Human CD3
23	992	42.0	428	7	ADP07489 Human CD3
24	992	42.0	428	8	ADP07489 Human CD3
25	909	38.5	405	3	AAE19881 Human CD3

26	909	38.5	405	4	AAE19881 Human CD3
27	909	38.5	407	8	ADP07491 Human CD3
28	904	38.2	465	5	AAE19881 Human CD3
29	904	38.2	465	8	ADQ99448 Mouse CD3
30	823	34.8	330	3	AAE19881 Human CD3
31	621	26.3	461	4	ABE66213 Human col
32	621	26.3	461	8	ADQ99472 Human NTP
33	621	26.3	464	4	ABE66213 Human NTP
34	596	25.2	141	4	AAU30879 Novel hum
35	596	25.2	144	4	AAU30881 Novel hum
36	518.5	21.9	467	2	AAW85687 DBX oligo
37	506	21.4	462	5	AAU78818 Dolichos
38	506	21.4	462	5	AAU78818 Dolichos
39	501	21.2	486	2	AAW85685 NBP46 roo
40	501	21.2	486	5	AAU78819 Lotus jap
41	495	20.9	139	5	ADK36500 Novel hum
42	490	20.7	455	8	ADO60417 Toxic sub
43	488.5	20.7	472	6	ABP81286 Arabidops
44	486	20.6	457	7	ABM74049 DNA clone
45	485	20.5	454	7	ADJ57264 Potato ap

## ALIGNMENTS

## RESULT 1

AAE19881  
ID AAE19881 standard; protein; 456 AA.

XX AC AAE19881;

XX 18-JUN-2002 (first entry)

XX Human CD39L2 protein.

XX Human; CD-39-like protein; CD39L2 protein; therapy; immune deficiency; autoimmune disorder; multiple sclerosis; systemic lupus erythematosus; rheumatoid arthritis; autoimmune thyroiditis; allergic reaction; asthma; insulin dependent diabetes mellitus; periodontal disease; osteoporosis; osteoarthritis; wound healing; tissue repair; Alzheimer's disease; ulcer; Parkinson's disease; amyotrophic lateral sclerosis; Huntington's disease; nervous system disease; nerve injury; ischaemia-reperfusion injury; endotoxin lethality; arthritis; nephritis; inflammatory bowel disease; Crohn's disease; virucide; antibacterial; antifungal; neuroprotective; dermatological; immunosuppressive; vulnery; anticonvulsant; antiinflammatory; nephrotropic; gastrointestinal; vasotropic.

XX Homo sapiens.

XX US6350447-B1.

XX 26-FEB-2002.

XX 29-JAN-1999; 99US-00240639.

XX 29-JAN-1999; 99US-00240639.

XX (HYSE-) HYSEQ INC.

XX Chadwick BP, Frischauf A;

XX WPI: 2002-215262/27.

XX N-PSDB; AAD31693.

XX An isolated polypeptide with phosphohydrolase activity, designated CD39L2, useful to identify other proteins with which binding occurs or identify inhibitors and for treatment of, e.g., Alzheimer's, multiple sclerosis and osteoporosis.

XX Claim 1; Fig 4; 101pp; English.

XX The present invention relates to novel proteins with phosphohydrolase activity, designated CD-39-like (CD39L) proteins and polynucleotides

CC encoding such proteins. CD39L proteins are useful to treat infectious  
CC diseases caused by viral, bacterial, fungal or other infection that may  
CC be treatable with CD39L. They are useful in the treatment of various  
CC immune deficiencies and disorders, autoimmune disorders such as multiple  
CC sclerosis, systemic lupus erythematosus, rheumatoid arthritis, autoimmune  
CC thyroiditis and insulin dependent diabetes mellitus, allergic reactions  
CC and conditions such as asthma and other respiratory problems, periodontal  
CC disease, osteoporosis, osteoarthritis and other tooth repair processes.  
CC They may have utility in compositions used for bone, cartilage, tendon,  
CC ligament and/or nerve tissue growth or regeneration as well as for wound  
CC healing and tissue repair and replacement and in the treatment of burns,  
CC incisions and ulcers. CD39L proteins may also be useful for proliferation  
CC of neural cells and for regeneration of nerve and brain tissue, i.e. for  
CC the treatment of central nervous system diseases such as Alzheimer's  
CC disease, Parkinson's disease, amyotrophic lateral sclerosis, Huntington's  
CC disease, peripheral nervous system diseases peripheral nerve injuries,  
CC peripheral neuropathy and localised neuropathies. They are also used to  
CC treat mechanical and traumatic disorders which involve degeneration,  
CC death or trauma to neural cells or nerve tissue. CD39L proteins of the  
CC invention are also useful to promote better or faster closure of non-  
CC healing wounds, including pressure ulcers, ulcers associated with  
CC vascular insufficiency and surgical and traumatic wounds. They also  
CC exhibit anti-inflammatory activity and may be used to treat inflammatory  
CC conditions including chronic or acute conditions), including ischaemia-  
CC reperfusion injury, endotoxin lethality, arthritis, nephritis, cytokine  
CC or chemokine-induced lung injury, inflammatory bowel disease or Crohn's  
CC disease. The present sequence is human CD39L2 protein  
XX  
SQ Sequence 456 AA;

Query Match 100.0%; Score 2364; DB 5; Length 456;  
Best Local Similarity 100.0%; Pred. No. 1.2e-215;  
Matches 456; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MRKISNHGSLRVAKVAYPLGLCVGVFIYVAYIKWHRATATQAFPSITRAAPGARWGQOAH 60  
DB 1 MRKISNHGSLRVAKVAYPLGLCVGVFIYVAYIKWHRATATQAFPSITRAAPGARWGQOAH 60  
QY 61 SPLGTAADGHEVFGIMFDAGSTGTRVHVFOFTRPPRETPTLTHETFAVKPGLSAYADD 120  
DB 61 SPLGTAADGHEVFGIMFDAGSTGTRVHVFOFTRPPRETPTLTHETFAVKPGLSAYADD 120  
QY 121 VEKSAQGIREDLDVAKQDIPDFFWKATPLVLKATAGLRLPGKAKQLLQKVEVFKAASP 180  
DB 121 VEKSAQGIREDLDVAKQDIPDFFWKATPLVLKATAGLRLPGKAKQLLQKVEVFKAASP 180  
QY 181 FLVGDDCVSIMNGTDEGVSAWITINFLTGSIKTPGGSSVGMLDLGGGSTQIAFLPRVEGT 240  
DB 181 FLVGDDCVSIMNGTDEGVSAWITINFLTGSIKTPGGSSVGMLDLGGGSTQIAFLPRVEGT 240  
QY 241 LQASPPGYLTALRMFNRTYKLYSYGLGLMSARLAILGGVEGQPAKDGKELVSPCLSP 300  
DB 241 LQASPPGYLTALRMFNRTYKLYSYGLGLMSARLAILGGVEGQPAKDGKELVSPCLSP 300  
QY 301 SPKGEWEHAEVTVYVSGQKAAASLHELCAARVSEVLQNRVHRTTEEVKHVDYFAFSYYDL 360  
DB 301 SPKGEWEHAEVTVYVSGQKAAASLHELCAARVSEVLQNRVHRTTEEVKHVDYFAFSYYDL 360  
QY 361 AAGVGLIDAEKGGSLVGVDFEIAAKYVCRITLQTOFQSSPFCMDLTVVSLLLQBFGRPS 420  
DB 361 AAGVGLIDAEKGGSLVGVDFEIAAKYVCRITLQTOFQSSPFCMDLTVVSLLLQBFGRPS 420  
QY 421 KVLKLRKIDNVEVTSWALGALFHYIDSLNRQKSPAS 456  
DB 421 KVLKLRKIDNVEVTSWALGALFHYIDSLNRQKSPAS 456

RESULT 2  
ADQ99442  
ID ADQ99442 standard; protein; 456 AA.  
XX  
ADQ99442;  
XX

DT 23-SEP-2004 (first entry)  
XX Human CD39-like protein, CD39L2.  
DE  
XX CD39-like protein; gene mapping; molecular weight marker;  
KW food supplement; anti-thrombotic; anti-tissue graft rejection agent;  
KW ATP neurotransmission; ecto-ATPase activity; nucleotide triphosphatase;  
KW NTPase; human; enzyme.  
XX  
OS Homo sapiens.  
XX  
XX Key Location/Qualifiers  
FH Region 100..121  
FT /note= "Apyrase region (ACR) I"  
FT Region 175..190  
FT /note= "Apyrase region (ACR) II"  
FT Region 219..239  
FT /note= "Apyrase region (ACR) III"  
FT Region 245..266  
FT /note= "Apyrase region (ACR) IV"  
XX  
XX US6759214-B1.  
XX  
XX 06-JUL-2004.  
XX  
XX 13-JUL-2001; 2001US-00908510.  
XX  
XX 29-JAN-1999; 99US-00240639.  
XX  
XX (NUVE-) NUVELO INC.  
PA  
XX Chadwick BP, Frischauf A;  
XX  
XX WPI; 2004-515395/49.  
XX N-PSDB; ADQ99441.  
XX  
XX New CD-39-like polypeptides and polynucleotides, useful in chromosome and  
PT gene mapping, as molecular weight markers, as food supplements, or as  
PT anti-thrombotic or anti-tissue graft rejection agents.  
XX  
XX Claim 2; SEQ ID NO 2; 104pp; English.  
XX  
XX The invention relates to novel CD39-like polypeptides (CD39-like  
CC nucleotide triphosphatase; NTPase) and nucleic acid molecules encoding  
CC such polypeptides. CD39-like polynucleotides may be used as hybridisation  
CC probes, PCR primers and in chromosome and gene mapping. Polypeptides of  
CC the invention may be used as molecular weight markers, as food  
CC supplements, in generating an antibody that specifically binds the  
CC polypeptide, as anti-thrombotic or anti-tissue graft rejection agents, or  
CC for regulating ATP neurotransmission in smooth muscle, peripheral ganglia  
CC or brain. Sequences of the invention are useful in modulating ecto-ATPase  
CC activity and for identifying compounds that modulate ecto-ATPase  
CC activity. The present sequence is human CD39-like protein, CD39L2. Note:  
CC This sequence is stated to be the same as that shown in Figures 8 and 9,  
CC however the sequence is truncated at it's N-terminal. The longer sequence  
CC is represented in ADQ99473.  
XX  
SQ Sequence 456 AA;

Query Match 100.0%; Score 2364; DB 8; Length 456;  
Best Local Similarity 100.0%; Pred. No. 1.2e-215;  
Matches 456; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MRKISNHGSLRVAKVAYPLGLCVGVFIYVAYIKWHRATATQAFPSITRAAPGARWGQOAH 60  
DB 1 MRKISNHGSLRVAKVAYPLGLCVGVFIYVAYIKWHRATATQAFPSITRAAPGARWGQOAH 60  
QY 61 SPLGTAADGHEVFGIMFDAGSTGTRVHVFOFTRPPRETPTLTHETFAVKPGLSAYADD 120  
DB 61 SPLGTAADGHEVFGIMFDAGSTGTRVHVFOFTRPPRETPTLTHETFAVKPGLSAYADD 120  
QY 121 VEKSAQGIREDLDVAKQDIPDFFWKATPLVLKATAGLRLPGKAKQLLQKVEVFKAASP 180  
DB 121 VEKSAQGIREDLDVAKQDIPDFFWKATPLVLKATAGLRLPGKAKQLLQKVEVFKAASP 180

Db 121 VEKSAQGIREDLVAKQDIPDFWKATPLVLKATAGLRLPGEKAQKLLQKVKEVFKASP 180  
 Qy 181 FLVGDDCVSINMGTDGVSAMITINFLTSGLSKTPGGSSVGMGLDGGGSGTQIAFLPRVEGT 240  
 Db 181 FLVGDDCVSINMGTDGVSAMITINFLTSGLSKTPGGSSVGMGLDGGGSGTQIAFLPRVEGT 240  
 Qy 241 LQASPPGYLTALRMFNRTYKLYSYSLGGLMSARLAILGGVEGQPAKDGKELVSPCLSP 300  
 Db 241 LQASPPGYLTALRMFNRTYKLYSYSLGGLMSARLAILGGVEGQPAKDGKELVSPCLSP 300  
 Qy 301 SFKGEWEHAEVTVYRVSGQKAAASLHELCAARVSEVLQNRVHRTVEVKHVDYFAYSYYDL 360  
 Db 301 SFKGEWEHAEVTVYRVSGQKAAASLHELCAARVSEVLQNRVHRTVEVKHVDYFAYSYYDL 360  
 Qy 361 AAGVGLIDAEKGGSLVVGDDFEIAAKYVCRITLETQSSPFSFSCMDLTVVSLLLQEGFPFRS 420  
 Db 361 AAGVGLIDAEKGGSLVVGDDFEIAAKYVCRITLETQSSPFSFSCMDLTVVSLLLQEGFPFRS 420  
 Qy 421 KVLKTRKIDNVETSWALGAIFHYIDSLNRQKSPAS 456  
 Db 421 KVLKTRKIDNVETSWALGAIFHYIDSLNRQKSPAS 456

RESULT 3  
 AAB72241  
 ID AAB72241 standard; protein; 484 AA.  
 XX AAB72241;  
 AC AAB72241;  
 XX AAB72241;  
 DT 14-MAY-2001 (first entry)  
 XX 14-MAY-2001 (first entry)  
 DE Human CD39 like protein CD39-L2 amino acid sequence.  
 XX Human CD39-L2 like protein CD39-L2 amino acid sequence.  
 KW Human CD39-like protein; apyrase; NDPase; platelet function inhibitor;  
 KW myocardial infarction; cerebral ischaemia; angina; arterial thrombosis;  
 KW cerebral artery thrombosis; platelet aggregation; inflammation;  
 KW apoptosis; autoimmune disorder; neurological disorder;  
 KW Alzheimer's disease; Parkinson's disease; cancer; CD39-L2.  
 XX Homo sapiens.  
 OS Homo sapiens.  
 XX Homo sapiens.  
 PN WO200110205-A1.  
 XX WO200110205-A1.  
 PD 15-FEB-2001.  
 PF 09-AUG-2000; 2000WO-US021790.  
 XX 09-AUG-2000; 2000WO-US021790.  
 PR 09-AUG-1999; 99US-00370265.  
 PR 11-JAN-2000; 2000US-00481238.  
 PR 25-APR-2000; 2000US-00557800.  
 PR 26-MAY-2000; 2000US-00583231.  
 PR 30-JUN-2000; 2000US-00608285.  
 XX 30-JUN-2000; 2000US-00608285.  
 PA (HYSE-) HYSEQ INC.  
 XX (HYSE-) HYSEQ INC.  
 PI Ford J, Mulero JJ, Yeung G;  
 XX Ford J, Mulero JJ, Yeung G;  
 DR WPI; 2001-147489/15.  
 DR N-PSDB; AAF63386.  
 XX N-PSDB; AAF63386.

Polynucleotides encoding human CD39-like polypeptides, with apyrase and/or NDPase activity, which are useful in the treatment of pathological conditions caused by thrombosis (e.g. myocardial infarction) and inflammatory disorders.

Claim 39; Page 162-164; 203pp; English.

This invention relates to polynucleotides encoding human CD39-like polypeptides with apyrase and/or NDPase activity. The polypeptides having ATPase, including NDPase, activity are useful for inhibiting platelet function and can therefore be used in the prophylaxis or treatment of pathological conditions caused by or involving thrombosis or excessive coagulation or excessive platelet aggregation, such as myocardial

CC infarction, cerebral ischaemia, angina, arterial thrombosis, cerebral artery thrombosis or intracardiac thrombosis, and conditions associated with venous thrombosis. CD39-L2 and CD39-L2 polypeptides are useful in modulating disease states (including platelet aggregation, inflammation and apoptosis) associated with ADP or other purinergic signalling by reducing the levels of NDPs. The polypeptides are also useful for prophylaxis or treatment of inflammation related disorders, such as disorders involving sepsis or systemic inflammatory response syndrome or SIRS (and associated conditions such as fever, tachycardia, tachypnea, cytokine overstimulation); autoimmune disorders such as thrombosis, atherosclerosis, acute pancreatitis, dermatitis, including psoriasis, cirrhosis, reperfusion injury, asthma, multiple sclerosis, arthritis; neurological disorders including neurodegenerative diseases, epilepsy, depression, Alzheimer's disease, Parkinson's disease, Huntington's disease, and amyotrophic lateral sclerosis; and cancer. The present sequence represents human CD39 like protein CD39-L2

XX Sequence 484 AA;

Query Match 100.0%; Score 2364; DB 4; Length 484;  
 Best Local Similarity 100.0%; Pred. NO. 1.3e-215;  
 Matches 456; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MRKISNHGSLRVAKVAYPLGLCVGVFIYVAYIKWHRATATQAFSITRAAPGARWGOAH 60  
 Db 29 MRKISNHGSLRVAKVAYPLGLCVGVFIYVAYIKWHRATATQAFSITRAAPGARWGOAH 88  
 Qy 61 SPLGTAADGHEVFYGINFMDAGSTGTRVHVQFTRPPRETPTLTHTETKAVKPGLSAYADD 120  
 Db 89 SPLGTAADGHEVFYGINFMDAGSTGTRVHVQFTRPPRETPTLTHTETKAVKPGLSAYADD 148  
 Qy 121 VEKSAQGIREDLVAKQDIPDFWKATPLVLKATAGLRLPGEKAQKLLQKVKEVFKASP 180  
 Db 149 VEKSAQGIREDLVAKQDIPDFWKATPLVLKATAGLRLPGEKAQKLLQKVKEVFKASP 208  
 Qy 181 FLVGDDCVSINMGTDGVSAMITINFLTSGLSKTPGGSSVGMGLDGGGSGTQIAFLPRVEGT 240  
 Db 209 FLVGDDCVSINMGTDGVSAMITINFLTSGLSKTPGGSSVGMGLDGGGSGTQIAFLPRVEGT 268  
 Qy 241 LQASPPGYLTALRMFNRTYKLYSYSLGGLMSARLAILGGVEGQPAKDGKELVSPCLSP 300  
 Db 269 LQASPPGYLTALRMFNRTYKLYSYSLGGLMSARLAILGGVEGQPAKDGKELVSPCLSP 328  
 Qy 301 SFKGEWEHAEVTVYRVSGQKAAASLHELCAARVSEVLQNRVHRTVEVKHVDYFAYSYYDL 360  
 Db 329 SFKGEWEHAEVTVYRVSGQKAAASLHELCAARVSEVLQNRVHRTVEVKHVDYFAYSYYDL 388  
 Qy 361 AAGVGLIDAEKGGSLVVGDDFEIAAKYVCRITLETQSSPFSFSCMDLTVVSLLLQEGFPFRS 420  
 Db 389 AAGVGLIDAEKGGSLVVGDDFEIAAKYVCRITLETQSSPFSFSCMDLTVVSLLLQEGFPFRS 448  
 Qy 421 KVLKTRKIDNVETSWALGAIFHYIDSLNRQKSPAS 456  
 Db 449 KVLKTRKIDNVETSWALGAIFHYIDSLNRQKSPAS 484

RESULT 4  
 ADQ99473

ID ADQ99473 standard; protein; 484 AA.

XX ADQ99473;

AC ADQ99473;

DT 23-SEP-2004 (first entry)

XX 23-SEP-2004 (first entry)

DE Human CD39-like protein, CD39L2.

XX Human CD39-like protein, CD39L2.

KW CD39-like protein; gene mapping; molecular weight marker;

KW food supplement; anti-thrombotic; anti-tissue graft rejection agent;

KW ATP neurotransmission; ecto-ATPase activity; nucleotide triphosphatase;

KW NDPase; human; enzyme.

OS Homo sapiens.

XX Homo sapiens.

PN US6759214-B1.  
 XX 06-JUL-2004.  
 PD 13-JUL-2001; 2001US-00908510.  
 XX 29-JAN-1999; 99US-00240639.  
 PR (NUVE-) NUVELO INC.  
 PA Chadwick BP, Frischauf A;  
 PI WPI; 2004-515395/49.  
 XX N-PSDB; ADQ99441, ADQ99441.  
 DR New CD-39-like polypeptides and polynucleotides, useful in chromosome and  
 XX gene mapping, as molecular weight markers, as food supplements, or as  
 PT anti-thrombotic or anti-tissue graft rejection agents.  
 XX Claim 2; Fig 8A-D; 104pp; English.  
 PS The invention relates to novel CD39-like polypeptides (CD39-like  
 CC nucleotide triphosphatase; NTPase) and nucleic acid molecules encoding  
 CC such polypeptides. CD39-like polynucleotides may be used as hybridisation  
 CC probes, PCR primers and in chromosome and gene mapping. Polypeptides of  
 CC the invention may be used as molecular weight markers, as food  
 CC supplements, in generating an antibody that specifically binds the  
 CC polypeptide, as anti-thrombotic or anti-tissue graft rejection agents, or  
 CC for regulating ATP neurotransmission in smooth muscle, peripheral ganglia  
 CC or brain. Sequences of the invention are useful in modulating ecto-ATPase  
 CC activity and for identifying compounds that modulate ecto-ATPase  
 CC activity. The present sequence is human CD39-like protein, CD39L2. Note:  
 CC This sequence is stated to be the same as that shown in SEQ ID 2 of the  
 CC sequence listing, however this sequence is longer at the N-terminal. The  
 CC shorter sequence is represented in ADQ99442.  
 XX  
 SQ Sequence 484 AA:  
 Query Match 100.0%; Score 2364; DB 8; Length 484;  
 Best Local Similarity 100.0%; Pred. No. 1.3e-215;  
 Matches 456; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 1 MRKISNHGSLRVAKVAYPLGLCVGVFIYVYIKWHRATATQAFPSITRAAPGARWGOAH 60  
 Db 29 MRKISNHGSLRVAKVAYPLGLCVGVFIYVYIKWHRATATQAFPSITRAAPGARWGOAH 88  
 QY 61 SPLGTAADGHEVFGIMFDAGSTGTRVHVQFTRPPRETTLTHETPKAVKPGLSAYADD 120  
 Db 89 SPLGTAADGHEVFGIMFDAGSTGTRVHVQFTRPPRETTLTHETPKAVKPGLSAYADD 148  
 QY 121 VEKSAQGIREDLDVAKODIPDFWKATPLVLKATAGLRLLPGEKAQKLLQKVKEVFKASP 180  
 Db 149 VEKSAQGIREDLDVAKODIPDFWKATPLVLKATAGLRLLPGEKAQKLLQKVKEVFKASP 208  
 QY 181 FLVGDDCVSIMNGTDEGVSAWITINFLTGLSKTPGSSVGMGLDGGSGTQIAFLPRVEGT 240  
 Db 209 FLVGDDCVSIMNGTDEGVSAWITINFLTGLSKTPGSSVGMGLDGGSGTQIAFLPRVEGT 268  
 QY 241 LQASPPGLTALRMFNRTYKLYSYLGLMSARLAILGGVEGQPAKDGKELVSPCLSP 300  
 Db 269 LQASPPGLTALRMFNRTYKLYSYLGLMSARLAILGGVEGQPAKDGKELVSPCLSP 328  
 QY 301 SPKGEWEHAEVTVRSQKAAASLHELCAARVSEVLQNRVHRTBEVKHVDVFYAFSYIYDL 360  
 Db 329 SPKGEWEHAEVTVRSQKAAASLHELCAARVSEVLQNRVHRTBEVKHVDVFYAFSYIYDL 388  
 QY 361 AAGVGLIDAEKGGSLVGVDFEIAAKYVCRTLETQPSQSPSCMDLTYSLLQLQBFPPRS 420  
 Db 389 AAGVGLIDAEKGGSLVGVDFEIAAKYVCRTLETQPSQSPSCMDLTYSLLQLQBFPPRS 448  
 QY 421 KVLKLTIKIDNVETSWALGAIFHVIDSLNRQKSPAS 456  
 Db 449 KVLKLTIKIDNVETSWALGAIFHVIDSLNRQKSPAS 484

RESULT 5  
 ABB06124  
 ID ABB06124 standard; protein; 463 AA.  
 XX  
 AC ABB06124;  
 XX  
 DT 10-MAY-2002 (first entry)  
 XX  
 DE Human NS protein sequence SEQ ID NO:216.  
 XX  
 KW Human; cytostatic; osteopathic; gynaecological; neuroprotective;  
 KW antirheumatic; antiarthritic; antipsoriatic; ophthalmological; anti-HIV;  
 KW vasotropic; antiarteriosclerotic; antiinflammatory; dermatological;  
 KW anorectic; muscular; antiinfertility; cardiovascular; anticoagulant;  
 KW antifibrinolytic; hypotension; antiasthmatic; immunomodulator; cardiant;  
 KW anticonvulsant; antidiabetic; tranquilliser; antidepressant; neuroleptic;  
 KW gastrointestinal; virucide; antiulcer; antitumor; cerebroprotective; nootropic;  
 KW contraceptive; vaccine; gene therapy; cancer; osteoporosis; dystonia;  
 KW endometriosis; degenerative disease; multiple sclerosis; psoriasis;  
 KW rheumatoid arthritis; cataract; restenosis; atherosclerosis; glaucoma;  
 KW inflammation; skin disorder; obesity; muscular dystrophy; AIDS;  
 KW infertility; cardiovascular disease; coagulation disease; hypertension;  
 KW ischaemia; asthma; immune disease; epilepsy; angina; neurodegeneration;  
 KW diabetes; anxiety; depression; schizophrenia; viral disease; stroke;  
 KW gastric ulcer; Alzheimer's disease.  
 XX  
 OS Homo sapiens.  
 XX  
 XX WO200206315-A2.  
 XX 24-JAN-2002.  
 PD 17-JUL-2001; 2001WO-IL000653.  
 PF 18-JUL-2000; 2000IL-00137345.  
 PR 15-DEC-2000; 2000IL-00140354.  
 XX (COMP-) COMPUGEN LTD.  
 PA Mintz L, Freilich S, Bernstein J;  
 PI WPI; 2002-155037/20.  
 XX N-PSDB; ABL39778.  
 DR  
 DR One hundred and twenty eight novel nucleic acid sequences, useful for  
 PT treating and diagnosing e.g. cancer, asthma and Alzheimer's.  
 XX Claim 6; Page 251-253; 290pp; English.  
 PS ABL39691 to ABL39818 represent novel human nucleic acid sequences  
 CC encoding the proteins given in ABB06037 to ABB06164. The novel sequences  
 CC (NS) can have cytostatic, osteopathic, gynaecological, neuroprotective,  
 CC antirheumatic, antiarthritic, antipsoriatic, ophthalmological, virucide,  
 CC vasotropic, antiarteriosclerotic, antiinfertility, cardiovascular, cardiant,  
 CC anorectic, muscular, anti-HIV, antiinfertility, antiasthmatic, cardiant,  
 CC anticoagulant, antifibrinolytic, hypotension, antiasthmatic, cardiant,  
 CC immunomodulator, anticonvulsant, antidiabetic, tranquilliser, antitumor,  
 CC antidepressant, gastrointestinal, neuroleptic, cerebroprotective,  
 CC nootropic and contraceptive activities. The NS can be used in vaccines,  
 CC gene therapy and antitense therapy. Nucleic acids, expression vectors and  
 CC antibodies from the present invention can be used for treating and  
 CC diagnosing e.g. cancer, osteoporosis, endometriosis, degenerative  
 CC diseases, dystonia, multiple sclerosis, rheumatoid arthritis, psoriasis,  
 CC cataracts, restenosis, atherosclerosis, inflammation, skin disorders,  
 CC glaucoma, obesity, muscular dystrophy, AIDS, infertility, cardiovascular  
 CC disease, coagulation disease, ischaemia, hypertension, asthma, immune  
 CC disease, epilepsy, angina, neurodegeneration, diabetes, anxiety,  
 CC depression, schizophrenia, viral disease, gastric ulcers, stroke,  
 CC Alzheimer's disease and as a contraceptive  
 XX Sequence 463 AA;  
 SQ



Query Match	99.9%;	Score 2361;	DB 5;	Length 463;
Best Local Similarity	99.8%;	Pred. No. 2.3e-215;		
Matches 455;	Conservative 1;	Mismatches 0;	Indels 0;	Gaps 0;
QY	1	MRKISNHGSLRVAKVAYPLGLCVGVFIYVAYIKWHRATATQAFPSITRAAPGARWQQA	60	
DB	8	MRKISNHGSLRVAKVAYPLGLCVGVFIYVAYIKWHRATATQAFPSITRAAPGARWQQA	67	
QY	61	SPLGTAADGHEVFGIMFDAGSTGTRVHFQFTRPPRETPTLTHTFKAQKLLQKVEFKASP	120	
DB	68	SPLGTAADGHEVFGIMFDAGSTGTRVHFQFTRPPRETPTLTHTFKAQKLLQKVEFKASP	127	
QY	121	VEKSAQGIREDLVAKQDIPDFFWKATPLVLKATAGLRLPGEKAQKLLQKVEFKASP	180	
DB	128	VEKSAQGIREDLVAKQDIPDFFWKATPLVLKATAGLRLPGEKAQKLLQKVEFKASP	187	
QY	181	FLVGDDCVSIMGTDGVSAMITINFLTGLSKLTPGGSSVGMLDLGGGSGTQIAFLPRVEGT	240	
DB	188	FLVGDDCVSIMGTDGVSAMITINFLTGLSKLTPGGSSVGMLDLGGGSGTQIAFLPRVEGT	247	
QY	241	LQASPPGYLTALRMFNRTYKLYSYLGLGMSARLAILGGVGPAPKDGKELVSPCLSP	300	
DB	248	LQASPPGYLTALRMFNRTYKLYSYLGLGMSARLAILGGVGPAPKDGKELVSPCLSP	307	
QY	301	SFKGEWEHAETVRYSGQKAAASLHELCAARVSEVLQNRVHRTVEKHVDFYAFSYYIDL	360	
DB	308	SFKGEWEHAETVRYSGQKAAASLHELCAARVSEVLQNRVHRTVEKHVDFYAFSYYIDL	367	
QY	361	AAGVGLIDAEKGGSLVGDFFIAKYVCTLETQPSFFSCMDLTYVSLLLQFPGFRS	420	
DB	368	AAGVGLIDAEKGGSLVGDFFIAKYVCTLETQPSFFSCMDLTYVSLLLQFPGFRS	427	
QY	421	KVLKTRKIDNVEVSWALCAIFHYIDSLNRQKSPAS	456	
DB	428	KVLKTRKIDNVEVSWALCAIFHYIDSLNRQKSPAS	463	
RESULT 6				
ABJ04657				
ID	ABJ04657	standard; protein; 467 AA.		
XX				
AC	ABJ04657;			
XX				
DT	11-OCT-2002	(first entry)		
XX				
DE	Protein of NOVX 15a	SEQ ID No 36.		
XX				
KW	Cytostatic; antidiabetic; anorectic; metabolic; nootropic; antilipemic;			
KW	neuroprotective; antiparkinsonian; anticonvulsant; cerebroprotective;			
KW	tranquiliser; neuroleptic; antidiabetic; antiulcer; antiinflammatory;			
KW	anti-HIV; antiallergic; antirheumatic; antiarthritic; NOVX; diabetes;			
KW	metabolic disorder; obesity; infectious disease; Alzheimer's disease;			
KW	anorexia; neurodegenerative disorder; Parkinson's disorder; obesity;			
KW	immune disorder; haematopoietic disorder; dyslipidaemia; chronic disease;			
KW	metabolic syndrome X; wasting disorder; cancer; neurological disorder;			
KW	epilepsy; stroke; mental disorder; schizophrenia; goiter;			
KW	vesicular transport; cystic fibrosis; gastrointestinal disorder;			
KW	diabetes mellitus; ulcerative colitis; AIDS; allergic reaction;			
KW	multiple sclerosis; rheumatoid arthritis; transgenic animal;			
XX	gene therapy.			
OS	Unidentified.			
XX				
PN	WO200246409-A2.			
XX				
PD	13-JUN-2002.			
XX				
PF	06-DEC-2001; 2001WO-US046586.			
XX				
PR	06-DEC-2000; 2000US-0251660P.			
PR	12-DEC-2000; 2000US-0255029P.			
PR	08-JAN-2001; 2001US-0260326P.			

24-JAN-2001; 2001US-0263800P.

20-FEB-2001; 2001US-0269942P.

24-APR-2001; 2001US-0286183P.

20-AUG-2001; 2001US-0313627P.

12-SEP-2001; 2001US-0318712P.

(CURA-) CURAGEN CORP.

Guo X, Li L, Patturajan M, Shinkets RA, Casman SJ, Malyankar UM; Tchernev VT, Vernet CAM, Spytek KA, Shency SG, Alsobrook JP; Edinger S, Peyman JA, Stone DJ, Ellerman K, Gangolli EA, Boldog FL; Colman SD, Eisen AJ, Liu X, Padigar M, Spaderna SK, Zerhusen BD; WPI: 2002-547774/58.

N-PSDB; ABT05470.

Novel isolated polypeptide, designated NOVX, useful for treating or preventing cancer, diabetes, obesity, dyslipidemia, anorexia, and metabolic, neurodegenerative, immune and hematopoietic disorders.

Claim 1; Page 140; 42pp; English.

The invention relates to an isolated polypeptide, designated NOVX, comprising a sequence fully defined in the specification. The isolated protein, its encoding polynucleotide or an antibody created from the protein is useful in the manufacture of a medicament for treating a syndrome associated with a human disease, preferably a NOVX-associated disorder, or for treating or preventing a NOVX-associated disorder in a subject, preferably human. The isolated protein, its encoding polynucleotide or an antibody created from the protein are also useful for treating or preventing metabolic disorders, diabetes, obesity, infectious disease, anorexia, neurodegenerative disorder, Alzheimer's disease, Parkinson's disorder, immune disorders, haematopoietic disorders, and various dyslipidaemias, metabolic disturbances associated with obesity, the metabolic syndrome X, wasting disorders associated with chronic diseases, and cancer. The isolated protein, its encoding polynucleotide or an antibody created from the protein are useful for treating or preventing neurological disorders such as epilepsy, stroke, mental disorders including mood, anxiety, schizophrenic disorders, disorders of vesicular transport such as cystic fibrosis, diabetes mellitus, goiter, gastrointestinal disorders including ulcerative colitis, other conditions associated with abnormal vesicle trafficking including AIDS, allergic reactions, multiple sclerosis and rheumatoid arthritis. A cell comprising the vector of the invention is useful for producing non-human transgenic animals. The polynucleotide of the invention can be used to treat disorders by gene therapy. This sequence represents one of the isolated NOVX proteins of the invention

Sequence 467 AA;

Query Match 99.9%; Score 2361; DB 5; Length 467;

Best Local Similarity 99.8%; Pred. No. 2.4e-215;

Matches 455; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 MRKISNHGSLRVAKVAYPLGLCVGVFIYVAYIKWHRATATQAFPSITRAAPGARWQQA 60

DB 12 MRKISNHGSLRVAKVAYPLGLCVGVFIYVAYIKWHRATATQAFPSITRAAPGARWQQA 71

QY 61 SPLGTAADGHEVFGIMFDAGSTGTRVHFQFTRPPRETPTLTHTFKAQKLLQKVEFKASP 120

DB 72 SPLGTAADGHEVFGIMFDAGSTGTRVHFQFTRPPRETPTLTHTFKAQKLLQKVEFKASP 131

QY 121 VEKSAQGIREDLVAKQDIPDFFWKATPLVLKATAGLRLPGEKAQKLLQKVEFKASP 180

DB 132 VEKSAQGIREDLVAKQDIPDFFWKATPLVLKATAGLRLPGEKAQKLLQKVEFKASP 191

QY 181 FLVGDDCVSIMGTDGVSAMITINFLTGLSKLTPGGSSVGMLDLGGGSGTQIAFLPRVEGT 240

DB 192 FLVGDDCVSIMGTDGVSAMITINFLTGLSKLTPGGSSVGMLDLGGGSGTQIAFLPRVEGT 251

QY 241 LQASPPGYLTALRMFNRTYKLYSYLGLGMSARLAILGGVGPAPKDGKELVSPCLSP 300

DB 252 LQASPPGYLTALRMFNRTYKLYSYLGLGMSARLAILGGVGPAPKDGKELVSPCLSP 311

```

QY 301 SPKGEWEHAETVYRVSGQKAAASLHELCAARVSEVLQNRVHRTTEEVKHVDVFAFSYYDL 360
DB 312 SPKGEWEHAETVYRVSGQKAAASLHELCAARVSEVLQNRVHRTTEEVKHVDVFAFSYYDL 371
QY 361 AAGVGLIDAEKGGSLVVGDFEIAAKVVCRTLETQPOSSPFSCMDLTYVSLLLQEFQFPRS 420
DB 372 AAGVGLIDAEKGGSLVVGDFEIAAKVVCRTLETQPOSSPFSCMDLTYVSLLLQEFQFPRS 431
QY 421 KVLKLRKIDNVETSWALGAIFHYIDSLNRQKSPAS 456
DB 432 KVLKLRKIDNVETSWALGAIFHYIDSLNRQKSPAS 467

RESULT 7
AAM93929
ID AAM93929 standard; protein; 456 AA.
XX AC AAM93929;
XX DT 06-NOV-2001 (first entry)
XX DE Human polypeptide, SEQ ID NO: 4100.
XX KW Human; full length cDNA; cDNA synthesis; oligo-capping.
XX OS Homo sapiens.
XX PN EP1130094-A2.
XX PD 05-SEP-2001.
XX PF 07-JUL-2000; 2000EP-00114089.
XX PR 08-JUL-1999; 99JP-00194486.
XX PR 11-JAN-2000; 2000JP-00118774.
XX PR 02-MAY-2000; 2000JP-00183765.
XX PA (HELI-) HELIX RES INST.
XX Qta T, Nishikawa T, Isogai T, Hayashi K, Ishii S, Kawai Y;
PI Wakamatsu A, Sugiyama T, Nagai K, Kojima S, Otsuki T, Koga H;
XX WPI: 2001-524255/58.
XX N-PSDB; AAK94892.
XX 830 Primers useful for synthesizing full length cDNA clones and their use
in genetic manipulation.
XX Claim 8; SEQ ID NO 4100; 1380pp + Sequence Listing; English.
XX The invention relates to primers for synthesizing full length cDNA
clones. 830 cDNA molecules encoding a human protein have been isolated
and nucleotide sequences of 5'- and 3'-ends of the cDNA molecules have
been determined. Primers for synthesizing the full length cDNA are useful
for clarifying the function of the protein encoded by the cDNA. The full
length clones were obtained by construction of full length enriched cDNA
libraries that were synthesised by the oligo-capping method. The primers
enable the production of the full length cDNA easily without any special
methods. The present sequence is a polypeptide encoded by a full length
human cDNA of the invention. Note: The sequence data for this patent did
not form part of the printed specification, but was obtained in CD-ROM
format directly from EPO
XX Sequence 456 AA;
XX Query Match 99.5%; Score 2351; DB 4; Length 456;
XX Best Local Similarity 99.3%; Pred. No. 2e-214;
XX Matches 453; Conservative 1; Mismatches 2; Indels 0; Gaps 0;
QY 1 MKKINHGSLRVAKVAYPLGLCVGVFIYVAYIKWHRATATQAFFSITRAAPGARWQQA 60
DB 1 MKKINHGSLRVAKVAYPLGLCVGVFIYVAYIKWHRATATQAFFSITRAAPGARWQQA 60

```

```

QY 61 SPLGTAADGHEVYFYGIMFDAGSTGTRVHVQFQTRPPRETPTLTHTFKAVKPGLSAYADD 120
DB 61 SPLGTAADGHEVYFYGIMFDAGSTGTRVHVQFQTRPPRETPTLTHTFKAVKPGLSAYADD 120
QY 121 VEKSAQGIARELLDVAQDIPDFFWKATPLVLKATAGLRLPGKAKQLLQKVEVKFASP 180
DB 121 VEKSAQGIARELLDVAQDIPDFFWKATPLVLKATAGLRLPGKAKQLLQKVEVKFASP 180
QY 181 FLVGDDCVSLMNGTDEGVSAWITINFLTGSLKTPGGSSVGMGLDGGGSGTQIAFLPRVEGT 240
DB 181 FLVGDDCVSLMNGTDEGVSAWITINFLTGSLKTPGGSSVGMGLDGGGSGTQIAFLPRVEGT 240
QY 241 LQASPPGYLTALRMFNRTYKLYSYLGLGMSARLAILGGVGGQPAKQKVEVSPCLSP 300
DB 241 LQASPPGYLTALRMFNRTYKLYSYLGLGMSARLAILGGVGGQPAKQKVEVSPCLSP 300
QY 301 SPKGEWEHAETVYRVSGQKAAASLHELCAARVSEVLQNRVHRTTEEVKHVDVFAFSYYDL 360
DB 301 SPKGEWEHAETVYRVSGQKAAASLHELCAARVSEVLQNRVHRTTEEVKHVDVFAFSYYDL 360
QY 361 AAGVGLIDAEKGGSLVVGDFEIAAKVVCRTLETQPOSSPFSCMDLTYVSLLLQEFQFPRS 420
DB 361 AAGVGLIDAEKGGSLVVGDFEIAAKVVCRTLETQPOSSPFSCMDLTYVSLLLQEFQFPRS 420
QY 421 KVLKLRKIDNVETSWALGAIFHYIDSLNRQKSPAS 456
DB 421 KVLKLRKIDNVETSWALGAIFHYIDSLNRQKSPAS 456

RESULT 8
ADL32067
ID ADL32067 standard; protein; 456 AA.
XX AC ADL32067;
XX DT 20-MAY-2004 (first entry)
XX DE Human protein encoded by a full length cDNA clone SeqID 4100.
XX KW human; medicine; signal transduction; glycoprotein; transcription;
XX oligo-capping method.
XX OS Homo sapiens.
XX PN EP1396543-A2.
XX PD 10-MAR-2004.
XX PF 07-JUL-2000; 2003EP-00025638.
XX PR 08-JUL-1999; 99JP-00194486.
XX PR 11-JAN-2000; 2000JP-00118774.
XX PR 02-MAY-2000; 2000JP-00183865.
XX PR 07-JUL-2000; 2000EP-00114089.
XX PA (REAS-) RES ASSOC BIOTECHNOLOGY.
XX Ota T, Nishikawa T, Isogai T, Hayashi K, Ishii S, Kawai Y;
PI Wakamatsu A, Sugiyama T, Nagai K, Kojima S, Otsuki T, Koga H;
XX WPI: 2004-204755/20.
XX N-PSDB; ADL32066.
XX PT New oligonucleotide primers (830 cDNAs) useful for synthesizing full
length human cDNAs.
XX Example 1; SEQ ID NO 4100; 1340pp; English.
XX This invention relates to a novel primers useful for synthesising full
length cDNA molecules that encode human proteins. Specifically, it refers
to secretory or membrane proteins that are potential therapeutic agents/
target molecules in the field of medicine, and in particular genes

```

CC encoding proteins that are associated with signal transduction,  
 CC glycoproteins and transduction. The present invention describes a method  
 CC for efficiently cloning a full length human cDNA from both the 5' and 3'  
 CC ends using the oligo-capping method. This polypeptide sequence is a full  
 CC length human protein of the invention.

XX Sequence 456 AA;

Query Match 99.5%; Score 2351; DB 8; Length 456;  
 Best Local Similarity 99.3%; Pred. No. 28-214; 2; Mismatches 0; Gaps 0;  
 Matches 453; Conservative 1; Indels 0;

QY 1 MRKISNHGSLRVAKVAYPLGLCVGVFIYVAYIKWHRATATQAFSITRAAPGARWGQQA 60  
 DB 1 MRKISNHGSLRVAKVAYPLGLCVGVFIYVAYIKWHRATATQAFSITRAAPGARWGQQA 60

QY 61 SPLGTAAAGCHEVFYIGIMFDAGSTGRVHVQFTTRPPRETPTLTHTFKAKPGLSAYADD 120  
 DB 61 SPLGTAAAGCHEVFYIGIMFDAGSTGRVHVQFTTRPPRETPTLTHTFKAKPGLSAYADD 120

QY 121 VEKSAQGIREDLDVAKQDIPDFWKATPLVLKATAGLRLLPGEKAQKLLQKVEFKASP 180  
 DB 121 VEKSAQGIREDLDVAKQDIPDFWKATPLVLKATAGLRLLPGEKAQKLLQKVEFKASP 180

QY 181 FLVGDDCVSIMNGTDEGVSAMITINFLTGSLKTPGSSVGMLDLGGGSTQIAFLPRVEGT 240  
 DB 181 FLVGDDCVSIMNGTDEGVSAMITINFLTGSLKTPGSSVGMLDLGGGSTQIAFLPRVEGT 240

QY 241 LOASPPGYLTALRMFNRYKYLSYGLGLMSARLAILGGVEGQAPKAGKELVSPCLSP 300  
 DB 241 LOASPPGYLTALRMFNRYKYLSYGLGLMSARLAILGGVEGQAPKAGKELVSPCLSP 300

QY 301 SFKEWEHAEVTVYRVSQKAAASHELCAARVSEVLQNRVHRTKRVHVDVFAESYYVDL 360  
 DB 301 SFKEWEHAEVTVYRVSQKAAASHELCAARVSEVLQNRVHRTKRVHVDVFAESYYVDL 360

QY 361 AAGVGLIDAEGGSLVVGDFEIAAKYVCRTLETQPSFPSCMDLTYVSLLLQEFGRPS 420  
 DB 361 AAGVGLIDAEGGSLVVGDFEIAAKYVCRTLETQPSFPSCMDLTYVSLLLQEFGRPS 420

QY 421 KVLKLTTRKIDNVETSWALGAIFYHIDSLNRQKSPAS 456  
 DB 421 KVLKLTTRKIDNVETSWALGAIFYHIDSLNRQKSPAS 456

RESULT 9  
 ID ADCL4220 standard; protein; 450 AA.

XX AC ADCL4220;

XX DT 18-DEC-2003 (first entry)

XX DE Human enzyme ENZM-26.

XX enzyme; human; ENZM; cytostatic; antiarteriosclerotic; antidiabetic;  
 KW anticonvulsant; neuroprotective; cerebroprotective; anti-HIV;  
 KW antiallergic; antiinflammatory; thymometric; gene therapy;  
 KW cell proliferative disorder; endocrine disorder; neurological disorder;  
 KW immune system disorder; inflammatory disorder; developmental disorder;  
 KW reproductive disorder; vesicle-trafficking disorder; infection.

XX Homo sapiens.

XX WO2003042357-A2.

XX 22-MAY-2003.

XX 26-SEP-2002; 2002WO-05031096.

XX 28-SEP-2001; 2001US-0326388P.

XX 12-OCT-2001; 2001US-0328979P.

XX 19-OCT-2001; 2001US-0346034P.

PR 26-OCT-2001; 2001US-0348284P.  
 PR 08-NOV-2001; 2001US-0338048P.  
 PR 16-NOV-2001; 2001US-0332340P.  
 PR 14-DEC-2001; 2001US-0340357P.  
 PR 29-MAR-2002; 2002US-0368722P.  
 PR 29-MAR-2002; 2002US-0368799P.  
 PR 17-MAY-2002; 2002US-0381558P.  
 PR 07-JUN-2002; 2002US-0387119P.  
 PR 21-JUN-2002; 2002US-0390662P.  
 XX (INCY-) INCYTE GENOMICS INC.  
 XX Yang J, Lu DAM, Yue H, Elliott VS, Warren BA, Duggan BM,  
 PI Forsythe LJ, Lee EA, Hafalia AJA, Ramkumar J, Chawla NK, Baughn MR;  
 PI Becha SD, Gorvad AE, Tran UK, Li JX, Yao MG, Ison CH, Griffin JA;  
 PI Lee SY, Chang H, Emerling BM, Tang YT, Lal PG, Kable AE;  
 PI Marquis JP, Jiang X, Jackson AA, Zebajradian Y, Swarnakar A;  
 PI Wilson AD, Jin P, Richardson TW, Bhatia U, Burrill JD, Lee S;  
 PI Blake JJ, Ho A, Zheng W, Gao J;  
 XX WPI; 2003-449567/42.  
 DR N-PSDB; ADCL4273.  
 XX New human enzymes (ENZM), useful for diagnosing, treating and preventing  
 PT diseases or conditions associated with the aberrant ENZM expression e.g.  
 PT cancer, diabetes, epilepsy, or infections.  
 XX Claim 1; SEQ ID NO 26; 416pp; English.  
 XX The invention relates to a novel isolated human enzyme (ENZM)  
 CC polypeptide. A polypeptide of the invention has cytostatic,  
 CC antiarteriosclerotic, antidiabetic, anticonvulsant, neuroprotective,  
 CC neuroprotective, cerebroprotective, anti-HIV, antiallergic,  
 CC antiinflammatory, and thymometric activity. A polynucleotide encoding a  
 CC polypeptide of the invention may have a use in gene therapy. The  
 CC polypeptides and polynucleotides are useful in diagnosing, treating and  
 CC preventing diseases or conditions associated with the decreased  
 CC expression or overexpression of ENZM, such as cell proliferative (e.g.  
 CC cancer, atherosclerosis), endocrine (e.g. diabetes), neurological (e.g.  
 CC epilepsy, Huntington's disease, stroke), immune/inflammatory (e.g. AIDS,  
 CC allergies), developmental (e.g. Hypothyroidism, Cushing's syndrome),  
 CC reproductive and vesicle-trafficking disorders, or infections. These are  
 CC also useful in assessing the effects of exogenous compounds on the  
 CC expression of nucleic acid and amino acid sequences of ENZM. The ENZM or  
 CC its fragments are useful in screening compounds for effectiveness as  
 CC agonist or antagonist of the polypeptides, or in altering the expression  
 CC of the target polynucleotide and compounds that specifically bind to or  
 CC modulate the activity of the polypeptide. The microarray is useful in  
 CC monitoring or measuring protein-protein interactions, drug-target  
 CC interactions, and gene expression profiles. The sequences shown in  
 CC ADCL4195-ADCL4247 represent ENZM proteins of the invention.

XX Sequence 450 AA;

Query Match 91.0%; Score 2152; DB 7; Length 450;  
 Best Local Similarity 92.3%; Pred. No. 1.7e-195;  
 Matches 421; Conservative 1; Mismatches 0; Indels 34; Gaps 1;

QY 1 MRKISNHGSLRVAKVAYPLGLCVGVFIYVAYIKWHRATATQAFSITRAAPGARWGQQA 60  
 DB 29 MRKISNHGSLRVAKVAYPLGLCVGVFIYVAYIKWHRATATQAFSITRAAPGARWGQQA 88

QY 61 SPLGTAAAGCHEVFYIGIMFDAGSTGRVHVQFTTRPPRETPTLTHTFKAKPGLSAYADD 120  
 DB 89 SPLGTAAAGCHEVFYIGIMFDAGSTGRVHVQFTTRPPRETPTLTHTFKAKPGLSAYADD 148

QY 121 VEKSAQGIREDLDVAKQDIPDFWKATPLVLKATAGLRLLPGEKAQKLLQKVEFKASP 180  
 DB 149 VEKSAQGIREDLDVAKQDIPDFWKATPLVLKATAGLRLLPGEKAQKLLQKVEFKASP 208

QY 181 FLVGDDCVSIMNGTDEGVSAMITINFLTGSLKTPGSSVGMLDLGGGSTQIAFLPRVEGT 240  
 DB 209 FLVGDDCVSIMNGTDEGVSAMITINFLTGSLKTPGSSVGMLDLGGGSTQIAFLPRVEGT 268

QY 241 LQASPPGYLTALRMFNRTYKLYSYGLGLMSARLAILGGVEGQPAKDGKELVSPCLSP 300  
 Db 269 LQASPPGYLTALRMFNRTYKLYSYGLGLMSARLAILGGVEGQ----- 314  
 QY 301 SFKGEWEHAEVTVYRVSGQKAAASLHELCAARVSEVLQNRVHRTVEEVKHVDVFAFSYYDL 360  
 Db 315 -----AASLHELCAARVSEVLQNRVHRTVEEVKHVDVFAFSYYDL 354  
 QY 361 AAGVGLIDAEKGGSLVVGDFEIAAKYVCRITLFTQSSPSCMDLTYVSLLLQEFGFP 420  
 Db 355 AAGVGLIDAEKGGSLVVGDFEIAAKYVCRITLFTQSSPSCMDLTYVSLLLQEFGFP 414  
 QY 421 KVLKLTTRKIDNVETSWALGAIHFHYIDSLNRQKSPAS 456  
 Db 415 KVLKLTTRKIDNVETSWALGAIHFHYIDSLNRQKSPAS 450  
 RESULT 10  
 AAU30882  
 ID AAU30882 standard; protein; 462 AA.  
 AC AAU30882;  
 XX  
 DT 18-DEC-2001 (first entry)  
 DE Novel human secreted protein #1373.  
 XX Human; vaccination; gene therapy; nutritional supplement;  
 KW stem cell proliferation; haematopoiesis; nerve tissue regeneration;  
 KW immune suppression; immune stimulation; anti-inflammatory; leukaemia.  
 KW Homo sapiens.  
 OS  
 XX WO200179449-A2.  
 PN 25-OCT-2001.  
 PD  
 XX 16-APR-2001; 2001WO-US008656.  
 XX  
 PR 18-APR-2000; 2000US-00552929.  
 PR 26-JAN-2001; 2001US-00770160.  
 XX  
 PA (HYSE-) HYSEQ INC.  
 XX  
 PI Tang YT, Liu C, Drmanac RT;  
 XX  
 DR WPI; 2001-611725/70.  
 XX  
 CC Nucleic acids encoding a range of human polypeptides, useful in genetic  
 CC vaccination, testing and therapy.  
 CC  
 PS Claim 20; Page 365; 765pp; English.  
 XX  
 CC The invention relates to novel human secreted polypeptides. The  
 CC polypeptides and antibodies to the polypeptides are useful for  
 CC determining the presence of or predisposition to a disease associated  
 CC with altered levels of polypeptide. The polypeptides are also useful for  
 CC identifying agents (agonists and antagonists) that bind to them. Cells  
 CC expressing the proteins are useful for identifying a therapeutic agent  
 CC for use in treatment of a pathology related to aberrant expression or  
 CC physiological interactions of the polypeptide. Vectors comprising the  
 CC nucleic acids encoding the polypeptides and cells genetically engineered  
 CC to express them are also useful for producing the proteins. The proteins  
 CC are useful in genetic vaccination, testing and therapy, and can be used  
 CC as nutritional supplements. They may be used to increase stem cell  
 CC proliferation; to regulate haematopoiesis; and in bone, cartilage, tendon  
 CC and/or nerve tissue growth or regeneration; immune suppression and/or  
 CC stimulation; as anti-inflammatory agents; and in treatment of leukaemias.  
 CC AAU29510-AAU33304 represent the amino acid sequences of novel human  
 CC secreted proteins of the invention  
 XX  
 SQ Sequence 462 AA;

Query Match 90.3%; Score 2135; DB 4; Length 462;  
 Best Local Similarity 92.1%; Pred. No. 7.5e-194;  
 Matches 422; Conservative 2; Mismatches 8; Indels 26; Gaps 3;  
 QY 1 MRKISNHSGLRVAKVAYPLGLCVGVFIYVYIKWHIRATATQAFPSITRAAPGARWGOAH 60  
 Db 29 MRKISNHSGLRVAKVAYPLGLCVGVFIYVYIKWHIRANATQAFPSITRAAPGARWGOAH 88  
 QY 61 SPLGTADAGHEVFVGMEDAGSTGTRVHVQFTRPPRETPLTTHETKAVKPGLSAYADD 120  
 Db 89 SPLGTADAGHEVFVGMEDAGSTGTRVHVQF-----YADD 124  
 QY 121 VEKSAQGIREDLDVAKODIPDFWKATPLVLKATAGLRLLPGEKAQKLLQKVEVFKASP 180  
 Db 125 VEKSAQGIREDLDVAKODIPDFWKATPLVLKATAGLRLLPGEKAQKLLQKVEVFKASP 194  
 QY 181 FLVGDDCVSIMNGTDEGVSAWITINFLTGSLKTPGSSVGMLDLGGSTQIAFLPRVEGT 240  
 Db 185 FLVGDDCVSIMNGTDEGVSAWITINFLTGSLKTPRNSVGMLDLGGSTQIVFLTHVEGT 244  
 QY 241 LQASPPGYLTALRMFNRTYKLYSYGLGLMSARLAILGGVEGQPAKDGKELVSPCLSP 300  
 Db 245 LQASPPGYLTALRMFNRTYKLYSYGLGLMSARLAILGGVEGQPAKDGKELVSPCLSP 304  
 QY 301 SFKGEWEHAEVTVYRVSGQKAAASLHELCAARVSEVLQNRVHRTVEEVKHVDVFAFSYYDL 360  
 Db 305 SFKGEWEHAEVTVYRVSGQKAAASLHELCAARVSEVLQNRVHRTVEEVKHVDVFAFSYYDL 364  
 QY 361 AAGVGLIDAEKGGSLVVGDFEIAAKYVCRITLFTQSSPSCMDLTYVSLLLQEFGFP 418  
 Db 365 AAGVGLIDAEKGGSLVVGDFEIAAKYVCRITLFTQSSPSCMDLTYVSLLLQEFGFP 424  
 QY 419 RSKVLKLTTRKIDNVETSWALGAIHFHYIDSLNRQKSPAS 456  
 Db 425 RSKVLKLTTRKIDNVETSWALGAIHFHYIDSLNRQKSPAS 462  
 RESULT 11  
 ABJ04658  
 ID ABJ04658 standard; protein; 446 AA.  
 XX  
 AC ABJ04658;  
 XX  
 DT 11-OCT-2002 (first entry)  
 XX  
 DE Protein of NOVX 15b SEQ ID No 38.  
 XX  
 KW Cytostatic; antidiabetic; anorectic; metabolic; neurotropic; antilipaeamic;  
 KW neuroprotective; antiparkinsonian; anticonvulsant; cerebroprotective;  
 KW tranquiliser; neuroleptic; antidiabetic; antitumor; antiinflammatory;  
 KW anti-HIV; antiallergic; antirheumatic; antithrombotic; NOX; diabetes;  
 KW metabolic disorder; obesity; infectious disease; Alzheimer's disease;  
 KW anorexia; neurodegenerative disorder; Parkinson's disorder; obesity;  
 KW immune disorder; haematopoietic disorder; dyslipidaemia; chronic disease;  
 KW metabolic syndrome X; wasting disorder; cancer; neurological disorder;  
 KW epilepsy; stroke; mental disorder; schizophrenic disorders; goiter;  
 KW vesicular transport; cystic fibrosis; gastrointestinal disorder;  
 KW diabetes mellitus; ulcerative colitis; AIDS; allergic reaction;  
 KW multiple sclerosis; rheumatoid arthritis; transgenic animal;  
 KW gene therapy.  
 XX  
 OS Unidentified.  
 XX  
 PN WO200246409-A2.  
 XX  
 PD 13-JUN-2002.  
 XX  
 XX 06-DEC-2001; 2001WO-US046586.  
 XX 06-DEC-2000; 2000US-0251660P.  
 PR 12-DEC-2000; 2000US-0255029P.  
 PR 08-JAN-2001; 2001US-0260326P.  
 PR

PR 24-JAN-2001; 2001US-0263800P.  
 PR 20-FEB-2001; 2001US-0269942P.  
 PR 24-APR-2001; 2001US-0286183P.  
 PR 20-AUG-2001; 2001US-0313627P.  
 PR 12-SEP-2001; 2001US-0318712P.  
 XX (CURA-) CURAGEN CORP.  
 PA Guo X, Li L, Patturajan M, Shimkets RA, Casman SJ, Malyankar UM;  
 PI Tchernev VT, Vernet CM, Spytek KA, Shenoy SG, Alsobrook JP;  
 PI Edinger S, Feyman JA, Stone DJ, Ellerman K, Gangoli EA, Boldog FI;  
 PI Colman SD, Eisen AJ, Liu X, Padigaru M, Spaderna SK, Zerhusen BD;  
 XX WPI; 2002-547774/58.  
 DR N-PSDB; ABT05471.  
 XX Novel isolated polypeptide, designated NOVX, useful for treating or  
 PT preventing cancer, diabetes, obesity, dyslipidemia, anorexia, and  
 PT metabolic, neurodegenerative, immune and hematopoietic disorders.  
 XX Claim 1; Page 141; 421pp; English.  
 XX The invention relates to an isolated polypeptide, designated NOVX,  
 CC comprising a sequence fully defined in the specification. The isolated  
 CC protein, its encoding polynucleotide or an antibody created from the  
 CC protein is useful in the manufacture of a medicament for treating a  
 CC syndrome associated with a human disease, preferably a NOVX-associated  
 CC disorder, or for treating or preventing a NOVX-associated disorder in a  
 CC subject, preferably human. The isolated protein, its encoding  
 CC polynucleotide or an antibody created from the protein are also useful  
 CC for treating or preventing metabolic disorders, diabetes, obesity,  
 CC infectious disease, anorexia, neurodegenerative disorder, Alzheimer's  
 CC disease, Parkinson's disorder, immune disorders, haematopoietic  
 CC disorders, and various dyslipidaemias, metabolic disturbances associated  
 CC with obesity, the metabolic syndrome X, wasting disorders associated with  
 CC chronic diseases, and cancer. The isolated protein, its encoding  
 CC polynucleotide or an antibody created from the protein are useful for  
 CC treating or preventing neurological disorders such as epilepsy, stroke,  
 CC mental disorders including mood, anxiety, schizophrenic disorders,  
 CC disorders of vesicular transport such as cystic fibrosis, diabetes  
 CC mellitus, goiter, gastrointestinal disorders including ulcerative  
 CC colitis, other conditions associated with abnormal vesicle trafficking  
 CC including AIDS, allergic reactions, multiple sclerosis and rheumatoid  
 CC arthritis. A cell comprising the vector of the invention is useful for  
 CC producing non-human transgenic animals. The polynucleotide of the  
 CC invention can be used to treat disorders by gene therapy. This sequence  
 CC represents one of the isolated NOVX proteins of the invention  
 XX SQ Sequence 446 AA;

Query Match 89.5%; Score 2116; DB 5; Length 446;  
 Best Local Similarity 91.0%; Pred. No. 4.6e-192;  
 Matches 415; Conservative 1; Mismatches 2; Indels 38; Gaps 1;

QY 1 MKTISNHSGLRVAKVAYPLGLCVGVFIYVAYIKWHRATATQAFPSITRAAPCARWGQOAH 60  
 DB 29 MKTISNHSGLRVAV-----ARWGQOAH 50

QY 61 SPLGTAADGHEVFGIMFDAGSTGRVHVFOFTPPRETPTLTHTFKAVKPGLSAYADD 120  
 DB 51 SPLGTAADGHEVFGIMFDAGSTGRVHVFOFTPPRETPTLTHTFKALKPGLSAYADD 110

QY 121 VEKSAQGIREDLLDAKQDIPDFWKATPLVLKATAGRLPLGPEKAQKLLQKVGVFKASP 180  
 DB 111 VEKSAQGIREDLLDAKQDIPDFWKATPLVLKATAGRLPLGPEKAQKLLQKVGVFKASP 170

QY 181 FLVGDDCVSINMGTDGVSAMITINFLTSGSLKTPGSSVGMGLDGGGQSTQIAFLPRVEGT 240  
 DB 171 FLVGDDCVSINMGTDGVSAMITINFLTSGSLKTPGSSVGMGLDGGGQSTQIAFLPRVEGT 230

QY 241 LQASPPGYLTALRMFNRTYKLYSYSLGLGLMSARLAILGGVEGQPAKDGKELVSPCLSP 300  
 DB 231 LQASPPGYLTALRMFNRTYKLYSYSLGLGLMSARLAILGGVEGQPAKDGKELVSPCLSP 290

QY 301 SFGGEWEHAETVYRVSGQKAAASLHELCAARVSEVLQNRVHRTTEVKHVDVFYAFSYIDL 360  
 DB 291 SFGGEWEHAETVYRVSGQKAAASLHELCAARVSEVLQNRVHRTTEVKHVDVFYAFSYIDL 350

QY 361 AAGVGLIDAEGKGSVLVGDFFIAAKYVCTTETOPQSSPFSCMDLTYVSLLLQEGFPKPS 420  
 DB 351 AAGVGLIDAEGKGSVLVGDFFIAAKYVCTTETOPQSSPFSCMDLTYVSLLLQEGFPKPS 410

QY 421 KVLKTRKIDNVETSWALGAIPHYSIDSLNRQKSPAS 456  
 DB 411 KVLKTRKIDNVETSWALGAIPHYSIDSLNRQKSPAS 446

## RESULT 12

AAB72242  
 ID AAB72242 standard; protein; 471 AA.

XX AC AAB72242;

XX DT 14-MAY-2001 (first entry)

XX DE Mature human CD39 like protein CD39-L2 amino acid sequence.

XX KW Human CD39-like protein; apyrase; NPase; platelet function inhibitor;  
 myocardial infarction; cerebral ischaemia; angina; arterial thrombosis;  
 cerebral artery thrombosis; platelet aggregation; inflammation;  
 apoptosis; autoimmune disorder; neurological disorder;  
 Alzheimer's disease; Parkinson's disease; cancer; CD39-L2.

XX OS Homo sapiens.

XX PN WO2000110205-A1.

XX PD 15-FEB-2001.

XX PF 09-AUG-2000; 2000WO-US021790.

XX PR 09-AUG-1999; 99US-00370265.

XX PR 11-JAN-2000; 2000US-00481238.

XX PR 25-APR-2000; 2000US-00557800.

XX PR 26-MAY-2000; 2000US-00583231.

XX PR 30-JUN-2000; 2000US-00608285.

XX PA (HYSE-) HYSEQ INC.

XX PI Ford J, Mulero JJ, Yeung G;

XX DR WPI; 2001-147489/15.

XX DR N-PSDB; AAF63387.

XX PT Polynucleotides encoding human CD39-like polypeptides, with apyrase  
 and/or NPase activity, which are useful in the treatment of pathological  
 conditions caused by thrombosis (e.g. myocardial infarction) and  
 inflammatory disorders.

XX PT Claim 53; Page 192-194; 203pp; English.

XX This invention relates to polynucleotides encoding human CD39-like  
 polypeptides with apyrase and/or NPase activity. The polypeptides having  
 ATPase, including NPase, activity are useful for inhibiting platelet  
 function and can therefore be used in the prophylaxis or treatment of  
 pathological conditions caused by or involving thrombosis or excessive  
 coagulation or excessive platelet aggregation, such as myocardial  
 infarction, cerebral ischaemia, angina, arterial thrombosis, cerebral  
 artery thrombosis or intracardiac thrombosis, and conditions associated  
 with venous thrombosis. CD39-L4 and CD39-L2 polypeptides are useful in  
 modulating disease states (including platelet aggregation, inflammation  
 and apoptosis) associated with ADP or other purinergic signalling by  
 reducing the levels of NDPs. The polypeptides are also useful for  
 prophylaxis or treatment of inflammation related disorders, such as  
 disorders involving sepsis or systemic inflammatory response syndrome or  
 SIRS (and associated conditions such as fever, tachycardia, tachypnea,

```
CC cytokine overstimulation); autoimmune disorders such as thrombosis,
CC atherosclerosis, acute pancreatitis, dermatitis, including psoriasis,
CC cirrhosis, reperfusion injury, asthma, multiple sclerosis, arthritis,
CC neurological disorders including neurodegenerative diseases, epilepsy,
CC depression, Alzheimer's disease, Parkinson's disease, Huntington's
CC disease, and amyotrophic lateral sclerosis; and cancer. The present
CC sequence represents mature D39 like protein CD39-L2
XX
SQ Sequence 471 AA;

Query Match      84.7%; Score 2003; DB 4; Length 471;
Best Local Similarity 98.5%; Pred. No. 2.8e-181;
Matches 388; Conservative 1; Mismatches 5; Indels 0; Gaps 0;

QY 1 MRKISNHSGLRVAKVAVPLGLCVGVFTYVAYIKWHRATATQAFPSITRAAPGARWGOAH 60
DB | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
QY 61 SPLGTAADGHEVFGIMFDAGSTGRVHVFOFTPPRETPTLTHTETKAVKPGLSAYADD 120
DB | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
QY 89 SPLGTAADGHEVFGIMFDAGSTGRVHVFOFTPPRETPTLTHTETKAVKPGLSAYADD 148
DB | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
QY 121 VEKSAQGITRELLDVAKODIPDFWKATPLVLKATAGLRLLPGEKAQKLLQKVKEVKASP 180
DB | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
QY 149 VEKSAQGITRELLDVAKODIPDFWKATPLVLKATAGLRLLPGEKAQKLLQKVKEVKASP 208
DB | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
QY 181 FLVGDDCVSIMGNDGVSAMITINFLTGLSKTPGSSVGMGLDLGGGSGTQIAFLPRVEGT 240
DB | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
QY 209 FLVGDDCVSIMGNDGVSAMITINFLTGLSKTPGSSVGMGLDLGGGSGTQIAFLPRVEGT 268
DB | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
QY 241 LQASPPGYLTALRMFNRTYKLYSYSLGLGMSARLAILGGVEGQPAKDGKELVSPCLSP 300
DB | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
QY 269 LQASPPGYLTALRMFNRTYKLYSYSLGLGMSARLAILGGVEGQPAKDGKELVSPCLSP 328
DB | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
QY 301 SFKGEWEHAETVYRVSGOKAAASLHELCAARVSEVLQNRVHRTBEVKHVDYFAFSYYDL 360
DB | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
QY 329 SFKGEWEHAETVYRVSGOKAAASLHELCAARVSEVLQNRVHRTBEVKHVDYFAFSYYDL 388
DB | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
QY 361 AAGVGLIDAEKGGSLVWGDFFIAAKYVCRTLEQ 394
DB | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
QY 389 AAGVGLIDAEKGGSLVWGDFFIAAKYGGSHLRE 422
DB | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |

RESULT 13
AAV44849
ID AAV44849 standard; protein; 428 AA.
XX
AC AAV44849;
XX
DT 18-MAY-2000 (first entry)
DE Human CD39-L4 protein.
XX
KW CD39-L4; human; apyrase; nucleotide diphosphatase; NDPase;
KW ATP Diphosphohydrolase; ATPase; adenosine diphosphate; ADP; treatment;
KW platelet aggregation; antithrombotic; thrombosis; myocardial infarction;
KW cerebral ischaemia; angina; vascular graft; extracorporeal circulation;
KW molecular weight marker; nutritional supplement; tumour; prevention;
KW drug targeting; Apyrase Conserved Region; ACR.
XX
OS Homo sapiens.
XX
FH Key Location/Qualifiers
FT Peptide 1..22
FT Protein 23..428
FT /label= Leader_peptide
FT /label= Mature human CD39-L4 protein
FT /note= "Homologous to human and murine CD39"
FT Binding-site 54..58
FT 129..134
FT /label= ATP_Binding_region
FT Region 169..173
FT /label= Apyrase_Conserved_Region
FT Region 169..173
```

```
FT /label= Apyrase_Conserved_Region
FT 199..206
FT /note= "Conserved motif in ATPases"
XX
XX WO200004041-A2.
XX
XX 27-JAN-2000.
XX
XX 16-JUL-1999; 99WO-US016180.
XX
XX 16-JUL-1998; 98US-00118205.
XX
XX 24-JUL-1998; 98US-00122449.
XX
XX 04-FEB-1999; 99US-00244444.
XX
XX 19-MAR-1999; 99US-00273447.
XX
XX 09-JUL-1999; 99US-00350836.
XX
XX (HYSE-) HYSEQ INC.
XX
XX Ford J, Mulero J;
XX
XX WPI; 2000-182397/16.
XX
XX N-PSDB; AAZ50356, AAZ50359.
XX
XX New nucleic acid encoding human CD39-like protein, useful for treating
XX and preventing thrombotic disease.
XX
XX Claim 15; Fig 2; 125pp; English.
XX
XX The present amino acid sequence is the CD39-L4 protein, an apyrase and/or
XX nucleotide diphosphatase (NDPase). It is isolated from the human foetal
XX liver-spleen cDNA library, B2HFLS20W. It is a soluble ATP
XX Diphosphohydrolase (ATPase) and is involved in the hydrolysis of
XX adenosine diphosphate (ADP), the agonist that causes platelet
XX aggregation. CD39-L4 protein has 30% and 80% homology to human and murine
XX CD39. It has platelet aggregation inhibition and antithrombotic activity.
XX CD39-L4 is used to treat or prevent thrombosis, myocardial infarction,
XX cerebral ischaemia and angina. It is also used in vitro, to maintain
XX vascular grafts or during extracorporeal circulation, to hydrolyse NDP,
XX as molecular weight markers and as nutritional supplements. It is used to
XX identify therapeutic agents that bind and modulate CD39-L4. It is coupled
XX to toxins for targeting drugs to tumours or other cells that express CD39
XX -L4
XX
XX Sequence 428 AA;

Query Match      42.3%; Score 999; DB 3; Length 428;
Best Local Similarity 52.4%; Pred. No. 8.6e-86;
Matches 204; Conservative 56; Mismatches 123; Indels 6; Gaps 4;

QY 62 PLGTAADGHEVFGIMFDAGSTGRVHVFOFT-PPRETPTLTHTETKAVKPGLSAYADD 120
DB | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
DB 40 PINVSA---STLYGIMFDAGSTGRVHVFOFT-PPRETPTLTHTETKAVKPGLSAFVDQ 96
QY 121 VEKSAQGITRELLDVAKODIPDFWKATPLVLKATAGLRLLPGEKAQKLLQKVKEVKASP 180
DB | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
DB 97 PKQGAETVQGLELVAKOSIPRSHWKKTPVLKATAGLRLLPGEKAQKLLQKVKEVKASP 156
QY 181 FLVGDDCVSIMGNDGVSAMITINFLTGLSKTPGSSVGMGLDLGGGSGTQIAFLPRVEGT 240
DB | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
DB 157 FLVPKGSVSIINDGSDGILAWTVNFTGLQHGHRQETVGTGLDGGASTQITFLPQPEKT 216
QY 241 LQASPPGYLTALRMFNRTYKLYSYSLGLGMSARLAILGGVEGQPAKDGKELVSPCLSP 300
DB | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
DB 217 LEQTPRGYLTSEFMFNSTYKLYTHSYLGFGLKAARLATLGALETE-GTDDGHTFFSACUPR 275
QY 301 SFKGEWEHAETVYRVSGOKAAASLHELCAARVSEVLQNRVHRTBEVKHVDYFAFSYYDL 360
DB | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
DB 276 WLEAEWIFGGVYQYGGNQEVEGVEFCYAEVLVVRGKLHQPEVQSGVFAYFYYDR 335
QY 361 AAGVGLIDAEKGGSLVWGDFFIAAKYVCRTLETOPQSSFFSCMDLTYVSLLOE-FGPRPR 419
DB | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
DB 336 AVDTDMIDYKGGILKVEDFERKAREVCNLENFTSGSPFLCMDLSYITALLKDGFGFAD 395
```



Job time : 160 secs



GenCore version 5.1.1.6  
Copyright (c) 1993 - 2004 Compugen Ltd.

OM protein - protein search, using sw model

Run on: November 16, 2004, 16:59:49 ; Search time 142 Seconds  
(without alignments)  
1136.208 Million cell updates/sec

Title: US-09-905-589A-2

Perfect score: 2364

Sequence: 1 MKTSHHSLRVAKVAYPLG.....ALGAIFHYDLSLRKQSPAS 456

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 1568699 seqs, 353819137 residues

Total number of hits satisfying chosen parameters: 1568699

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : Published Applications AA:\*

1: /cgn2\_6/ptodata/1/pubpaa/US07\_PUBCOMB.pep.\*  
2: /cgn2\_6/ptodata/1/pubpaa/PCT\_NEW\_PUB.pep.\*  
3: /cgn2\_6/ptodata/1/pubpaa/US06\_NEW\_PUB.pep.\*  
4: /cgn2\_6/ptodata/1/pubpaa/US06\_PUBCOMB.pep.\*  
5: /cgn2\_6/ptodata/1/pubpaa/US07\_NEW\_PUB.pep.\*  
6: /cgn2\_6/ptodata/1/pubpaa/PCTUS\_PUBCOMB.pep.\*  
7: /cgn2\_6/ptodata/1/pubpaa/US08\_NEW\_PUB.pep.\*  
8: /cgn2\_6/ptodata/1/pubpaa/US08\_PUBCOMB.pep.\*  
9: /cgn2\_6/ptodata/1/pubpaa/US09A\_PUBCOMB.pep.\*  
10: /cgn2\_6/ptodata/1/pubpaa/US09B\_PUBCOMB.pep.\*  
11: /cgn2\_6/ptodata/1/pubpaa/US09C\_PUBCOMB.pep.\*  
12: /cgn2\_6/ptodata/1/pubpaa/US09\_NEW\_PUB.pep.\*  
13: /cgn2\_6/ptodata/1/pubpaa/US10A\_PUBCOMB.pep.\*  
14: /cgn2\_6/ptodata/1/pubpaa/US10B\_PUBCOMB.pep.\*  
15: /cgn2\_6/ptodata/1/pubpaa/US10C\_PUBCOMB.pep.\*  
16: /cgn2\_6/ptodata/1/pubpaa/US10D\_PUBCOMB.pep.\*  
17: /cgn2\_6/ptodata/1/pubpaa/US10\_NEW\_PUB.pep.\*  
18: /cgn2\_6/ptodata/1/pubpaa/US11\_NEW\_PUB.pep.\*  
19: /cgn2\_6/ptodata/1/pubpaa/US60\_NEW\_PUB.pep.\*  
20: /cgn2\_6/ptodata/1/pubpaa/US60\_PUBCOMB.pep.\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

#### SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	2364	100.0	484	13	US-10-092-063-27
2	2364	100.0	484	14	US-10-286-926-27
3	2364	100.0	484	15	US-10-231-913-123
4	2361	99.9	467	15	US-10-231-913-36
5	2357	99.7	484	15	US-10-231-913-124
6	2116	89.5	446	15	US-10-231-913-38
7	2083.5	87.3	455	15	US-10-231-913-125
8	1954	82.7	379	15	US-10-231-913-271
9	1007	42.6	427	15	US-10-231-913-126
10	999	42.3	428	13	US-10-091-085-3
11	999	42.3	428	13	US-10-091-085-5
12	999	42.3	428	13	US-10-092-063-3
13	999	42.3	428	13	US-10-092-063-5

14	999	42.3	428	14	US-10-286-926-3	Sequence 3, Appli
15	999	42.3	428	14	US-10-286-926-5	Sequence 5, Appli
16	999	42.3	428	15	US-10-231-913-127	Sequence 127, App
17	996	42.1	428	13	US-10-091-085-7	Sequence 7, Appli
18	996	42.1	428	13	US-10-092-063-7	Sequence 7, Appli
19	996	42.1	428	14	US-10-286-926-7	Sequence 2, Appli
20	992	42.0	428	16	US-10-408-765A-2296	Sequence 2296, Ap
21	909	38.5	405	13	US-10-092-063-25	Sequence 25, Appl
22	909	38.5	405	14	US-10-286-926-25	Sequence 25, Appl
23	909	38.5	465	13	US-10-092-063-39	Sequence 39, Appl
24	823	34.8	330	9	US-09-925-299-876	Sequence 876, App
25	823	34.8	330	10	US-09-925-299-876	Sequence 876, App
26	590.5	25.0	479	14	US-10-369-493-6447	Sequence 6447, Ap
27	525.5	22.2	467	9	US-09-129-112-19	Sequence 19, Appl
28	508.5	21.5	433	15	US-10-425-114-36762	Sequence 36762, A
29	508	21.5	556	14	US-10-369-493-2169	Sequence 2169, Ap
30	506	21.4	462	9	US-09-129-112-2	Sequence 2, Appli
31	504	21.3	467	15	US-10-425-114-45875	Sequence 45875, A
32	501	21.2	459	9	US-09-129-112-9	Sequence 9, Appli
33	500.5	21.2	562	17	US-10-425-115-334052	Sequence 334052,
34	500	21.2	467	15	US-10-424-599-230158	Sequence 230158,
35	498	21.1	518	14	US-10-369-493-1713	Sequence 1713, Ap
36	491	20.8	534	16	US-10-437-963-132351	Sequence 132351, A
37	490.5	20.7	443	15	US-10-425-114-49933	Sequence 49933, A
38	489	20.7	464	17	US-10-425-115-185050	Sequence 185050,
39	483	20.4	457	15	US-10-425-114-51762	Sequence 51762, A
40	483	20.4	459	15	US-10-424-599-145076	Sequence 145076,
41	478.5	20.2	410	15	US-10-231-913-272	Sequence 272, App
42	467	19.8	469	17	US-10-739-930-10227	Sequence 10227, A
43	463	19.6	462	9	US-09-129-112-15	Sequence 15, Appl
44	452.5	19.1	516	17	US-10-425-115-338300	Sequence 338300,
45	447	18.9	463	17	US-10-425-115-213115	Sequence 213115,

#### ALIGNMENTS

#### RESULT 1

US-10-092-063-27  
; Sequence 27, Application US/10092063  
; Publication No. US20020173005A1  
; GENERAL INFORMATION:  
; APPLICANT: Ford, John  
; APPLICANT: Mulero, Julio  
; TITLE OF INVENTION: METHODS AND MATERIALS RELATING TO NOVEL CD39-LIKE POLYPEPTIDES  
; FILE REFERENCE: 28110/35908  
; CURRENT APPLICATION NUMBER: US/10/092,063  
; PRIOR FILING DATE: 2002-03-05  
; PRIOR APPLICATION NUMBER: 09/370,265  
; PRIOR FILING DATE: 2002-01-31  
; PRIOR APPLICATION NUMBER: PCT/US99/16180  
; PRIOR FILING DATE: 1999-07-16  
; PRIOR APPLICATION NUMBER: 09/350,836  
; PRIOR FILING DATE: 1999-07-09  
; PRIOR APPLICATION NUMBER: 09/273,447  
; PRIOR FILING DATE: 1999-03-19  
; PRIOR APPLICATION NUMBER: 09/244,444  
; PRIOR FILING DATE: 1999-02-04  
; PRIOR APPLICATION NUMBER: 09/122,449  
; PRIOR FILING DATE: 1998-07-24  
; PRIOR APPLICATION NUMBER: 09/118,205  
; NUMBER OF SEQ ID NOS: 39  
; SOFTWARE: PatentIn Ver. 2.0  
; SEQ ID NO 27  
; LENGTH: 484  
; TYPE: PRT  
; ORGANISM: Homo sapiens  
US-10-092-063-27

Query Match 100.0%; Score 2364; DB 13; Length 484;  
Best Local Similarity 100.0%; Pred. No. 8.7e-218;  
Matches 456; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Query Match 100.0%; Score 2364; DB 14; Length 484;  
Best Local Similarity 100.0%; Pred. No. 8,7e-218;  
Matches 456; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MRKISHGSLRVAKVAYPLGLCVGVFIYVAYIKWHRATATQAFPSITRAAPGARWGOAH 60  
DB 29 MRKISHGSLRVAKVAYPLGLCVGVFIYVAYIKWHRATATQAFPSITRAAPGARWGOAH 88  
QY 61 SPLGTAAADGHEVYGYIMFDAGSTGTRVHVQFTRPPRETPTLTHTETFKAVKPGLSAYADD 120  
DB 89 SPLGTAAADGHEVYGYIMFDAGSTGTRVHVQFTRPPRETPTLTHTETFKAVKPGLSAYADD 148  
QY 121 VEKSAQGIREDLLVAKODIPDFWKATPLVLKATAGRLLLPGEKAQKLLQKVKEVFKASP 180  
DB 149 VEKSAQGIREDLLVAKODIPDFWKATPLVLKATAGRLLLPGEKAQKLLQKVKEVFKASP 208  
QY 181 FLVGDDCVSIMGNTDEGVSAWITINFLTGSLKTPGGSSVGMULDGGGSGTOIAFLPRVEGT 240  
DB 209 FLVGDDCVSIMGNTDEGVSAWITINFLTGSLKTPGGSSVGMULDGGGSGTOIAFLPRVEGT 268  
QY 241 LQASPPGYLTALRMFNRTYKLYSYLGLGMSARLAILGGVEGQPAKDGKELVSPCLSP 300  
DB 269 LQASPPGYLTALRMFNRTYKLYSYLGLGMSARLAILGGVEGQPAKDGKELVSPCLSP 328  
QY 301 SFKGEWEHAEVTVRVSGQKAAASLHELCAARVSEVLQNRVHRTBEVKHVDVFAFSYYIDL 360  
DB 329 SFKGEWEHAEVTVRVSGQKAAASLHELCAARVSEVLQNRVHRTBEVKHVDVFAFSYYIDL 388  
QY 361 AAGVGLIDAEGKGLSVGVDFEIAAKYVCRITLQTOQSSPFCMDLTVVSLLLQBFGRPS 420  
DB 389 AAGVGLIDAEGKGLSVGVDFEIAAKYVCRITLQTOQSSPFCMDLTVVSLLLQBFGRPS 448  
QY 421 KVLKTRKIDNVETSWALGAIFHYIDSINRQKSPAS 456  
DB 449 KVLKTRKIDNVETSWALGAIFHYIDSINRQKSPAS 484

## RESULT 2

US-10-286-926-27  
; Sequence 27, Application US/10286926  
; Publication No. US20030175752A1  
; GENERAL INFORMATION:  
; APPLICANT: Ford, John  
; APPLICANT: Mulero, Julio  
; APPLICANT: Yeung, George  
; TITLE OF INVENTION: Methods and Materials Relating to CD39-Like  
; TITLE OF INVENTION: Polypeptides  
; FILE REFERENCE: 28110/36457CON  
; CURRENT APPLICATION NUMBER: US/10/286,926  
; PRIOR FILING DATE: 2002-11-01  
; PRIOR APPLICATION NUMBER: 09/557,800  
; PRIOR FILING DATE: 2000-04-25  
; PRIOR APPLICATION NUMBER: 09/481,238  
; PRIOR FILING DATE: 2000-01-11  
; PRIOR APPLICATION NUMBER: 09/370,265  
; PRIOR FILING DATE: 1999-08-09  
; PRIOR APPLICATION NUMBER: PCT/US99/16180  
; PRIOR FILING DATE: 1999-07-16  
; PRIOR APPLICATION NUMBER: 09/350836  
; PRIOR FILING DATE: 1998-07-09  
; PRIOR APPLICATION NUMBER: 09/273447  
; PRIOR FILING DATE: 1999-03-19  
; PRIOR APPLICATION NUMBER: 09/122449  
; PRIOR FILING DATE: 1998-07-24  
; PRIOR APPLICATION NUMBER: 09/244444  
; PRIOR FILING DATE: 1999-02-04  
; PRIOR APPLICATION NUMBER: 09/118,205  
; PRIOR FILING DATE: 1998-07-16  
; NUMBER OF SEQ ID NOS: 54  
; SOFTWARE: PatentIn Ver. 2.0  
; SEQ ID NO 27  
; LENGTH: 484  
; TYPE: PRT  
; ORGANISM: Homo sapiens  
US-10-286-926-27

## RESULT 3

US-10-231-913-123  
; Sequence 123, Application US/10231913  
; Publication No. US20040005576A1  
; GENERAL INFORMATION:  
; APPLICANT: Guo, Xiaojia S.  
; APPLICANT: Li, Li  
; APPLICANT: Patturajan, Meera  
; APPLICANT: Shinkets, Richard A.  
; APPLICANT: Casman, Stacie J.  
; APPLICANT: Malyankar, Uriel M.  
; APPLICANT: Tchernev, Velizar T.  
; APPLICANT: Vernet, Corine A.  
; APPLICANT: Spytek, Kimberly A.  
; APPLICANT: Shenoy, Suresh G.  
; APPLICANT: Alsobrook II, John P.  
; APPLICANT: Edinger, Schlomit  
; APPLICANT: Peyman, John A.  
; APPLICANT: Stone, David J.  
; APPLICANT: Ellerman, Karen  
; APPLICANT: Gangolli, Esha A.  
; APPLICANT: Boldog, Ference L.  
; APPLICANT: Colman, Steven D.  
; APPLICANT: Eisen, Andrew J.  
; APPLICANT: Liu, Xiaohong  
; APPLICANT: Padigaru, Muralidhara  
; APPLICANT: Spaderina, Steven K.  
; APPLICANT: Zerhusen, Bryan D.  
; TITLE OF INVENTION: Proteins and Nucleic Acids Encoding Same  
; FILE REFERENCE: 21402-216  
; CURRENT APPLICATION NUMBER: US/10/231,913  
; CURRENT FILING DATE: 2002-08-30  
; PRIOR APPLICATION NUMBER: 60/251,660  
; PRIOR FILING DATE: 2000-12-06  
; PRIOR APPLICATION NUMBER: 60/255,029  
; PRIOR FILING DATE: 2000-12-12

```
; PRIOR APPLICATION NUMBER: 60/260,326
; PRIOR FILING DATE: 2001-01-08
; PRIOR APPLICATION NUMBER: 60/263,800
; PRIOR FILING DATE: 2001-01-24
; PRIOR APPLICATION NUMBER: 60/269,942
; PRIOR FILING DATE: 2001-02-20
; PRIOR APPLICATION NUMBER: 60/286,183
; PRIOR FILING DATE: 2001-04-24
; PRIOR APPLICATION NUMBER: 60/313,627
; PRIOR FILING DATE: 2001-08-20
; PRIOR APPLICATION NUMBER: 60/318,712
; PRIOR FILING DATE: 2001-09-12
; NUMBER OF SEQ ID NOS: 292
; SOFTWARE: Patent in Ver. 2.1
; SEQ ID NO 123
; LENGTH: 484
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-231-913-123

Query Match      100.0%; Score 2364; DB 15; Length 484;
Best Local Similarity 100.0%; Pred. No. 8,7e-218;
Matches 456; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MRKISNHGSLRVAKVAPLGLCVGVFIYVAYIKWHRATATQAFSITRAAPGARWGQQA 60
Db 29 MRKISNHGSLRVAKVAPLGLCVGVFIYVAYIKWHRATATQAFSITRAAPGARWGQQA 88

QY 61 SPLGTAADGHEVFGIMFDAGSTGTRVHVFOFTRPPRETPTLTHETFKAVKPGLSAYADD 120
Db 89 SPLGTAADGHEVFGIMFDAGSTGTRVHVFOFTRPPRETPTLTHETFKAVKPGLSAYADD 148

QY 121 VEKSAQGIREDLDVAKQDIPDFWKATPLVLKATAGLRLLPGEKAQKLQKVKEVFKASP 180
Db 149 VEKSAQGIREDLDVAKQDIPDFWKATPLVLKATAGLRLLPGEKAQKLQKVKEVFKASP 208

QY 181 FLVGDDCVSINMGTDGVSAMITINFLTGSUKTPGSSVGMLDLGGGSTQIAFLPRVEGT 240
Db 209 FLVGDDCVSINMGTDGVSAMITINFLTGSUKTPGSSVGMLDLGGGSTQIAFLPRVEGT 268

QY 241 LQASPPGYLTALRMFNRTYKLYSYLGLGMSARLAILGGVEGQPAKDGKELVSPCLSP 300
Db 269 LQASPPGYLTALRMFNRTYKLYSYLGLGMSARLAILGGVEGQPAKDGKELVSPCLSP 328

QY 301 SFKGEWEHAETVTVRSVGGKAAASLHELCAARVSEVLQNRVHRTVEVKHVDFAFSYYIDL 360
Db 329 SFKGEWEHAETVTVRSVGGKAAASLHELCAARVSEVLQNRVHRTVEVKHVDFAFSYYIDL 388

QY 361 AAGVGLIDAEKGGSLVVGDFEIAAKYVCRTELETQPSPPSCMDLTYVSLLLQEFGRPS 420
Db 389 AAGVGLIDAEKGGSLVVGDFEIAAKYVCRTELETQPSPPSCMDLTYVSLLLQEFGRPS 448

QY 421 KVLKLRKIDNVETSWALGAIFHYIDSLNRQKSPAS 456
Db 449 KVLKLRKIDNVETSWALGAIFHYIDSLNRQKSPAS 484

RESULT 4
US-10-231-913-36
; Sequence 36, Application US/10231913
; Publication No. US20040005576A1
; GENERAL INFORMATION:
; APPLICANT: Guo, Xiaojia S.
; APPLICANT: Li, Li
; APPLICANT: Patturajan, Meera
; APPLICANT: Shimkets, Richard A.
; APPLICANT: Casman, Stacie J.
; APPLICANT: Malyankar, Uriel M.
; APPLICANT: Tchernev, Velizar T.
; APPLICANT: Vernet, Corine A.
; APPLICANT: Spytek, Kimberly A.
; APPLICANT: Shenoy, Suresh G.
; APPLICANT: Alsbrook II, John P.
```

```
; APPLICANT: Edinger, Schlomit
; APPLICANT: Reyman, John A.
; APPLICANT: Stone, David J.
; APPLICANT: Ellerman, Karen
; APPLICANT: Gangolli, Esha A.
; APPLICANT: Boldog, Ference L.
; APPLICANT: Colman, Steven D.
; APPLICANT: Eisen, Andrew J.
; APPLICANT: Liu, Xiaohong
; APPLICANT: Padigaru, Muralidhara
; APPLICANT: Spaderma, Steven K.
; APPLICANT: Zerhusen, Bryan D.
; TITLE OF INVENTION: Proteins and Nucleic Acids Encoding Same
; FILE REFERENCE: 21402-216
; CURRENT APPLICATION NUMBER: US/10/231,913
; CURRENT FILING DATE: 2002-08-30
; PRIOR APPLICATION NUMBER: 60/251,660
; PRIOR FILING DATE: 2000-12-06
; PRIOR APPLICATION NUMBER: 60/255,029
; PRIOR FILING DATE: 2000-12-12
; PRIOR APPLICATION NUMBER: 60/260,326
; PRIOR FILING DATE: 2001-01-08
; PRIOR APPLICATION NUMBER: 60/263,800
; PRIOR FILING DATE: 2001-01-24
; PRIOR APPLICATION NUMBER: 60/269,942
; PRIOR FILING DATE: 2001-02-20
; PRIOR APPLICATION NUMBER: 60/286,183
; PRIOR FILING DATE: 2001-04-24
; PRIOR APPLICATION NUMBER: 60/313,627
; PRIOR FILING DATE: 2001-08-20
; PRIOR APPLICATION NUMBER: 60/318,712
; PRIOR FILING DATE: 2001-09-12
; NUMBER OF SEQ ID NOS: 292
; SOFTWARE: Patent in Ver. 2.1
; SEQ ID NO 36
; LENGTH: 467
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-231-913-36

Query Match      99.9%; Score 2361; DB 15; Length 467;
Best Local Similarity 99.8%; Pred. No. 1.6e-217;
Matches 455; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 MRKISNHGSLRVAKVAPLGLCVGVFIYVAYIKWHRATATQAFSITRAAPGARWGQQA 60
Db 12 MRKISNHGSLRVAKVAPLGLCVGVFIYVAYIKWHRATATQAFSITRAAPGARWGQQA 71

QY 61 SPLGTAADGHEVFGIMFDAGSTGTRVHVFOFTRPPRETPTLTHETFKAVKPGLSAYADD 120
Db 72 SPLGTAADGHEVFGIMFDAGSTGTRVHVFOFTRPPRETPTLTHETFKAVKPGLSAYADD 131

QY 121 VEKSAQGIREDLDVAKQDIPDFWKATPLVLKATAGLRLLPGEKAQKLQKVKEVFKASP 180
Db 132 VEKSAQGIREDLDVAKQDIPDFWKATPLVLKATAGLRLLPGEKAQKLQKVKEVFKASP 191

QY 181 FLVGDDCVSINMGTDGVSAMITINFLTGSUKTPGSSVGMLDLGGGSTQIAFLPRVEGT 240
Db 192 FLVGDDCVSINMGTDGVSAMITINFLTGSUKTPGSSVGMLDLGGGSTQIAFLPRVEGT 251

QY 241 LQASPPGYLTALRMFNRTYKLYSYLGLGMSARLAILGGVEGQPAKDGKELVSPCLSP 300
Db 252 LQASPPGYLTALRMFNRTYKLYSYLGLGMSARLAILGGVEGQPAKDGKELVSPCLSP 311

QY 301 SFKGEWEHAETVTVRSVGGKAAASLHELCAARVSEVLQNRVHRTVEVKHVDFAFSYYIDL 360
Db 312 SFKGEWEHAETVTVRSVGGKAAASLHELCAARVSEVLQNRVHRTVEVKHVDFAFSYYIDL 371

QY 361 AAGVGLIDAEKGGSLVVGDFEIAAKYVCRTELETQPSPPSCMDLTYVSLLLQEFGRPS 420
Db 372 AAGVGLIDAEKGGSLVVGDFEIAAKYVCRTELETQPSPPSCMDLTYVSLLLQEFGRPS 431

QY 421 KVLKLRKIDNVETSWALGAIFHYIDSLNRQKSPAS 456
```

```
Db 432 KVLKLRKIDNVETSWALGAIFHYIDSLNRQKSPAS 467
|||||
RESULT 5
US-10-231-913-124
; Sequence 124, Application US/10231913
; Publication No. US20040005576A1
; GENERAL INFORMATION:
; APPLICANT: Guo, Xiaojia S.
; APPLICANT: Li, Li
; APPLICANT: Patturajan, Meera
; APPLICANT: Shimkets, Richard A.
; APPLICANT: Casman, Stacie J.
; APPLICANT: Malyankar, Uriel M.
; APPLICANT: Tchernev, Velizar T.
; APPLICANT: Vernet, Corine A.
; APPLICANT: Spytek, Kimberly A.
; APPLICANT: Shenoy, Suresh G.
; APPLICANT: Alsobrook II, John P.
; APPLICANT: Edinger, Schlomit
; APPLICANT: Peyman, John A.
; APPLICANT: Stone, David J.
; APPLICANT: Ellerman, Karen
; APPLICANT: Gangolli, Esha A.
; APPLICANT: Boldog, Ference L.
; APPLICANT: Colman, Steven D.
; APPLICANT: Eisen, Andrew J.
; APPLICANT: Liu, Xiaohong
; APPLICANT: Padigaru, Muralidhara
; APPLICANT: Spaderna, Steven K.
; APPLICANT: Zerhusen, Bryan D.
; TITLE OF INVENTION: Proteins and Nucleic Acids Encoding Same
; FILE REFERENCE: 21402-216
; CURRENT APPLICATION NUMBER: US/10/231,913
; CURRENT FILING DATE: 2002-08-30
; PRIOR APPLICATION NUMBER: 60/251,660
; PRIOR FILING DATE: 2000-12-06
; PRIOR APPLICATION NUMBER: 60/255,029
; PRIOR FILING DATE: 2000-12-12
; PRIOR APPLICATION NUMBER: 60/260,326
; PRIOR FILING DATE: 2001-01-08
; PRIOR APPLICATION NUMBER: 60/263,800
; PRIOR FILING DATE: 2001-01-24
; PRIOR APPLICATION NUMBER: 60/269,942
; PRIOR FILING DATE: 2001-02-20
; PRIOR APPLICATION NUMBER: 60/286,183
; PRIOR FILING DATE: 2001-04-24
; PRIOR APPLICATION NUMBER: 60/313,627
; PRIOR FILING DATE: 2001-08-20
; PRIOR APPLICATION NUMBER: 60/318,712
; PRIOR FILING DATE: 2001-09-12
; NUMBER OF SEQ ID NOS: 292
; SOFTWARE: Patent In Ver. 2.1
; SEQ ID NO 124
; LENGTH: 484
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-231-913-124
Query Match 99.7%; Score 2357; DB 15; Length 484;
Best Local Similarity 99.6%; Pred. No. 4.1e-217;
Matches 454; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 MKKINHGSLRVAKVAYPLGLCVGVFIYVAYIKWHRATATQAFSTTRAAPGARWQQA 60
Db 29 MRKISNHGSLRVAKVAYPLGLCVGVFIYVAYIKWHRATATQAFSTTRAAPGARWQQA 88
QY 61 SPLGTAADGHEVFGYIMFDAGSTGTRVHVVFQTRPREPTLTHTFFKAVKGLSAYAD 120
Db 89 SPLGTAADGHEVFGYIMFDAGSTGTRVHVVFQTRPREPTLTHTFFKAVKGLSAYAD 148
QY 121 VEKSAQGIREDLVAKQDIPDFWKATPLVLKATAGRLLLPGEKAQKLLQKVKEVKASP 180
|||||
Db 149 VEKSAQGIREDLVAKQDIPDFWKATPLVLKATAGRLLLPGEKAQKLLQKVKEVKASP 208
QY 181 FLVGDDCVSIMNGTDRGVSAWITINFLTGSLKTPGGSSVGMGLDLGGGSGTQIAFLPRVEGT 240
Db 209 FLVGDDCVSIMNGTDRGVSAWITINFLTGSLKTPGGSSVGMGLDLGGGSGTQIAFLPRVEGT 268
QY 241 LQASPPGYLTALRMFNRTYKLYSYVILGGLMSARLAILGGVGGOPAKDKGKELVSPCLSP 300
Db 269 LQASPPGYLTALRMFNRTYKLYSYVILGGLMSARLAILGGVGGOPAKDKGKELVSPCLSP 328
QY 301 SPFGWEHAEVTVYRVSQKAAASLHELCAARVSEVLQNRVHRTTEEVKXVDFYAFSYYIDL 360
Db 329 SPFGWEHAEVTVYRVSQKAAASLHELCAARVSEVLQNRVHRTTEEVKXVDFYAFSYYIDL 388
QY 361 AAGVGLIDAEKGGSLVVGDFEIAAKVYCRVLTETQPOSSPFCMDLTYVSLLLQEFPPRS 420
Db 389 AAGVGLIDAEKGGSLVVGDFEIAAKVYCRVLTETQPOSSPFCMDLTYVSLLLQEFPPRS 448
QY 421 KVLKLRKIDNVETSWALGAIFHYIDSLNRQKSPAS 456
Db 449 KVLKLRKIDNVETSWALGAIFHYIDSLNRQKSPAS 484
|||||
RESULT 6
US-10-231-913-38
; Sequence 38, Application US/10231913
; Publication No. US20040005576A1
; GENERAL INFORMATION:
; APPLICANT: Guo, Xiaojia S.
; APPLICANT: Li, Li
; APPLICANT: Patturajan, Meera
; APPLICANT: Shimkets, Richard A.
; APPLICANT: Casman, Stacie J.
; APPLICANT: Malyankar, Uriel M.
; APPLICANT: Tchernev, Velizar T.
; APPLICANT: Vernet, Corine A.
; APPLICANT: Spytek, Kimberly A.
; APPLICANT: Shenoy, Suresh G.
; APPLICANT: Alsobrook II, John P.
; APPLICANT: Edinger, Schlomit
; APPLICANT: Peyman, John A.
; APPLICANT: Stone, David J.
; APPLICANT: Ellerman, Karen
; APPLICANT: Gangolli, Esha A.
; APPLICANT: Boldog, Ference L.
; APPLICANT: Colman, Steven D.
; APPLICANT: Eisen, Andrew J.
; APPLICANT: Liu, Xiaohong
; APPLICANT: Padigaru, Muralidhara
; APPLICANT: Spaderna, Steven K.
; APPLICANT: Zerhusen, Bryan D.
; TITLE OF INVENTION: Proteins and Nucleic Acids Encoding Same
; FILE REFERENCE: 21402-216
; CURRENT APPLICATION NUMBER: US/10/231,913
; CURRENT FILING DATE: 2002-08-30
; PRIOR APPLICATION NUMBER: 60/251,660
; PRIOR FILING DATE: 2000-12-06
; PRIOR APPLICATION NUMBER: 60/255,029
; PRIOR FILING DATE: 2000-12-12
; PRIOR APPLICATION NUMBER: 60/260,326
; PRIOR FILING DATE: 2001-01-08
; PRIOR APPLICATION NUMBER: 60/263,800
; PRIOR FILING DATE: 2001-01-24
; PRIOR APPLICATION NUMBER: 60/269,942
; PRIOR FILING DATE: 2001-02-20
; PRIOR APPLICATION NUMBER: 60/286,183
; PRIOR FILING DATE: 2001-04-24
; PRIOR APPLICATION NUMBER: 60/313,627
; PRIOR FILING DATE: 2001-08-20
; PRIOR APPLICATION NUMBER: 60/318,712
; PRIOR FILING DATE: 2001-09-12
; NUMBER OF SEQ ID NOS: 292
```

```
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 38
; LENGTH: 446
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-231-913-38

Query Match      89.5%; Score 2116; DB 15; Length 446;
Best Local Similarity 91.0%; Pred. No. 5.1e-194;
Matches 415; Conservative 1; Mismatches 2; Indels 38; Gaps 1;

QY      1 MRKISNHGSLRVAKVAYPLGLCVGVFIYVAYIKWHRATATQAFSITRAAPGARWQQAAH 60
Db      29 MRKISNHGSLRVAV-----ARWQQAAH 50

QY      61 SPLGTAAADGHEVYFGIMFDAGSTGTRVHVFOFTRPPRETPTLTHETFKAVKPGLSAYADD 120
Db      51 SPLGTAAADGHEVYFGIMFDAGSTGTRVHVFOFTRPPRETPTLTHETFKALKPGLSAYADD 110

QY      121 VEKSAQGIREDLVAKQDIPDFWKATPLVLKATAGLRLPGEKAQKLLQKVKEVFKASP 180
Db      111 VEKSAQGIREDLVAKQDIPDFWKATPLVLKATAGLRLPGEKAQKLLQKVKEVFKASP 170

QY      181 FLVGDDCVSIMNGTDEGVSAMITINFLTGSILKTPGSSVGMIDLGGSTQIAFLPRVEGT 240
Db      171 FLVGDDCVSIMNGTDEGVSAMITINFLTGSILKTPGSSVGMIDLGGSTQIAFLPRVEGT 230

QY      241 LQASPPGYLTALRMFNRTYKLYSYSLGLGLMSARLAILGGVGGOPAKDGKELVSPCLSP 300
Db      231 LQASPPGYLTALRMFNRTYKLYSYSLGLGLMSARLAILGGVGGOPAKDGKELVSPCLSP 290

QY      301 SPFGWEHAETVRYVSGGQKAAASLHELCAARVSEVLQNRVHRTTEVKHVDVFAYFYDDL 360
Db      291 SPFGWEHAETVRYVSGGQKAAASLHELCAARVSEVLQNRVHRTTEVKHVDVFAYFYDDL 350

QY      361 AAGVGLIDAEGKSSLVGDFEIAAKYVCRTELTQPSPPSCMDLTYVSLLLQEFGFPRS 420
Db      351 AAGVGLIDAEGKSSLVGDFEIAAKYVCRTELTQPSPPSCMDLTYVSLLLQEFGFPRS 410

QY      421 KVLKTRKIDNVETSWALGAIFHYIDSLNRQKSPAS 456
Db      411 KVLKTRKIDNVETSWALGAIFHYIDSLNRQKSPAS 446

RESULT 7
US-10-231-913-125
; Sequence 125, Application US/10231913
; Publication No. US20040005576A1
; GENERAL INFORMATION:
; APPLICANT: Guo, Xiaojia S.
; APPLICANT: Li, Li
; APPLICANT: Patturajan, Meera
; APPLICANT: Shimkets, Richard A.
; APPLICANT: Casman, Stacie J.
; APPLICANT: Malyankar, Uriel M.
; APPLICANT: Tcheinev, Velizar T.
; APPLICANT: Vernet, Corine A.
; APPLICANT: Spytek, Kimberly A.
; APPLICANT: Shenoy, Suresh G.
; APPLICANT: Alsobrook II, John P.
; APPLICANT: Edinger, Schlomit
; APPLICANT: Peyman, John A.
; APPLICANT: Stone, David J.
; APPLICANT: Ellerman, Karen
; APPLICANT: Gangolli, Esha A.
; APPLICANT: Boldog, Ference L.
; APPLICANT: Colman, Steven D.
; APPLICANT: Eisen, Andrew J.
; APPLICANT: Liu, Xiaohong
; APPLICANT: Padigar, Muralidhara
; APPLICANT: Spaderna, Steven K.
; APPLICANT: Zernusen, Bryan D.
; TITLE OF INVENTION: Proteins and Nucleic Acids Encoding Same
```

```
; FILE REFERENCE: 21402-216
; CURRENT APPLICATION NUMBER: US/10/231,913
; CURRENT FILING DATE: 2002-08-30
; PRIOR APPLICATION NUMBER: 60/251,660
; PRIOR FILING DATE: 2000-12-06
; PRIOR APPLICATION NUMBER: 60/255,029
; PRIOR FILING DATE: 2000-12-12
; PRIOR APPLICATION NUMBER: 60/260,326
; PRIOR FILING DATE: 2001-01-08
; PRIOR APPLICATION NUMBER: 60/263,800
; PRIOR FILING DATE: 2001-01-24
; PRIOR APPLICATION NUMBER: 60/269,942
; PRIOR FILING DATE: 2001-02-20
; PRIOR APPLICATION NUMBER: 60/286,183
; PRIOR FILING DATE: 2001-04-24
; PRIOR APPLICATION NUMBER: 60/313,627
; PRIOR FILING DATE: 2001-08-20
; PRIOR APPLICATION NUMBER: 60/318,712
; PRIOR FILING DATE: 2001-09-12
; NUMBER OF SEQ ID NOS: 292
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 125
; LENGTH: 455
; TYPE: PRT
; ORGANISM: Rattus norvegicus
US-10-231-913-125

Query Match      87.3%; Score 2063.5; DB 15; Length 455;
Best Local Similarity 86.6%; Pred. No. 5.7e-189;
Matches 394; Conservative 27; Mismatches 33; Indels 1; Gaps 1;

QY      1 MRKISNHGSLRVAKVAYPLGLCVGVFIYVAYIKWHRATATQAFSITRAAPGARWQQAAH 60
Db      1 MRKIPNHGTLRMKTVAYPLGLCVGLFIYVAYIKWHRASAAQAFFIAGAAAGVVRWTQQAF 60

QY      61 SPLGTAAADGHEVYFGIMFDAGSTGTRVHVFOFTRPPRETPTLTHETFKAVKPGLSAYADD 120
Db      61 SSPDSATRGHEVYFGIMFDAGSTGTRVHVFOFTRPPRETPTLTHETFKALKPGLSAYADD 120

QY      121 VEKSAQGIREDLVAKQDIPDFWKATPLVLKATAGLRLPGEKAQKLLQKVKEVFKASP 180
Db      121 VEKSAQGIREDLVAKQDIPDFWKATPLVLKATAGLRLPGEKAQKLLQKVKEVFKASP 180

QY      181 FLVGDDCVSIMNGTDEGVSAMITINFLTGSILKTPGSSVGMIDLGGSTQIAFLPRVEGT 240
Db      181 FLVGDDCVSIMNGTDEGVSAMITINFLTGSILKTPGSSVGMIDLGGSTQIAFLPRVEGT 240

QY      241 LQASPPGYLTALRMFNRTYKLYSYSLGLGLMSARLAILGGVGGOPAKDGKELVSPCLSP 300
Db      241 LQASPPGYLTALRMFNRTYKLYSYSLGLGLMSARLAILGGVGGOPAKDGKELVSPCLSP 300

QY      301 SPFGWEHAETVRYVSGGQKAAASLHELCAARVSEVLQNRVHRTTEVKHVDVFAYFYDDL 360
Db      301 RFRGKWEHAETVRYISGQK-AVGLVELCASRVSEVLNRKVRHRTTEAHOHVDVFAYFYDDL 359

QY      361 AAGVGLIDAEGKSSLVGDFEIAAKYVCRTELTQPSPPSCMDLTYVSLLLQEFGFPRS 420
Db      360 AASFGLIDAEGKSSLVGDFEIAAKYVCRTELTQPSPPSCMDLTYVSLLLQEFGFPRS 419

QY      421 KVLKTRKIDNVETSWALGAIFHYIDSLNRQKSPA 455
Db      420 KVLKTRKIDNVETSWALGAIFHYIDSLNRQKSPA 454

RESULT 8
US-10-231-913-271
; Sequence 271, Application US/10231913
; Publication No. US20040005576A1
; GENERAL INFORMATION:
; APPLICANT: Guo, Xiaojia S.
; APPLICANT: Li, Li
; APPLICANT: Patturajan, Meera
; APPLICANT: Shimkets, Richard A.
```

APPLICANT: Casman, Stacie J.  
APPLICANT: Malyankar, Uriel M.  
APPLICANT: Tchernev, Velizar T.  
APPLICANT: Vernet, Corine A.  
APPLICANT: Spytek, Kimberly A.  
APPLICANT: Shenoy, Suresh G.  
APPLICANT: Alsobrook II, John P.  
APPLICANT: Edinger, Schlomit  
APPLICANT: Peyman, John A.  
APPLICANT: Stone, David J.  
APPLICANT: Ellerman, Karen  
APPLICANT: Gangolli, Esha A.  
APPLICANT: Boldog, Ference L.  
APPLICANT: Colman, Steven D.  
APPLICANT: Eisen, Andrew J.  
APPLICANT: Liu, Xiaohong  
APPLICANT: Padigaru, Muralidhara  
APPLICANT: Spaderna, Steven K.  
APPLICANT: Zerhusen, Bryan D.  
TITLE OF INVENTION: Proteins and Nucleic Acids Encoding Same  
FILE REFERENCE: 21402-216  
CURRENT APPLICATION NUMBER: US/10/231,913  
CURRENT FILING DATE: 2002-08-30  
PRIOR FILING DATE: 2000-12-06  
PRIOR FILING DATE: 2000-12-06  
PRIOR FILING DATE: 2000-12-12  
PRIOR APPLICATION NUMBER: 60/260,326  
PRIOR FILING DATE: 2001-01-08  
PRIOR APPLICATION NUMBER: 60/263,800  
PRIOR FILING DATE: 2001-01-24  
PRIOR APPLICATION NUMBER: 60/269,942  
PRIOR FILING DATE: 2001-02-20  
PRIOR FILING DATE: 2001-04-24  
PRIOR APPLICATION NUMBER: 60/313,627  
PRIOR FILING DATE: 2001-08-20  
PRIOR APPLICATION NUMBER: 60/318,712  
PRIOR FILING DATE: 2001-09-12  
NUMBER OF SEQ ID NOS: 292  
SOFTWARE: Patent In Ver. 2.1  
SEQ ID NO 271  
LENGTH: 379  
TYPE: PRT  
ORGANISM: Homo sapiens  
US-10-231-913-271

Query Match 82.7%; Score 1954; DB 15; Length 379;  
Best Local Similarity 99.7%; Pred. No. 1.4e-178;  
Matches 378; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 71 EVFYGIMFDAGSTGRVHVFOFTPRPTPTLTHTETKAVKPGLSAYADDVEKSAQGIRE 130  
DB 1 EVFYGIMFDAGSTGRVHVFOFTPRPTPTLTHTETKAVKPGLSAYADDVEKSAQGIRE 60

QY 131 LLDVAKQDIPDFWKATPLVLKATAGRLLPGEKAQKLLQKVEFKASPFVLVGDCVSI 190  
DB 61 LLDVAKQDIPDFWKATPLVLKATAGRLLPGEKAQKLLQKVEFKASPFVLVGDCVSI 120

QY 191 NNGTDEGVSAMTINFLGSLKTPGSSVGMJDLGGSGTQIAFLPRVEGTLOASPPGYLT 250  
DB 121 NNGTDEGVSAMTINFLGSLKTPGSSVGMJDLGGSGTQIAFLPRVEGTLOASPPGYLT 180

QY 251 ALRMENRTKLYSYVLGGLMSARIALILGGVEGQPAKDGKELVSPCLSPSPKGEWEHAE 310  
DB 181 ALRMENRTKLYSYVLGGLMSARIALILGGVEGQPAKDGKELVSPCLSPSPKGEWEHAE 240

QY 311 VTYRVSGQKAASLHCELCAARVSEVLQNRVHRTVEEVKHVDFYAFSYIIDLAAGVGLIDAE 370  
DB 241 VTYRVSGQKAASLHCELCAARVSEVLQNRVHRTVEEVKHVDFYAFSYIIDLAAGVGLIDAE 300

QY 371 KGSILVVGDFEIAAKVVCRTLETQPOSSPFSCMDLTIVSVLLLOEFGFPRSKVLKLTTRKID 430

Db 301 KGSILVVGDFEIAAKVVCRTLETQPOSSPFSCMDLTIVSVLLLOEFGFPRSKVLKLTTRKID 360

QY 431 NVETSWALGAIFHYIDSLN 449  
Db 361 NVETSWALGAIFHYIDSLN 379

RESULT 9  
US-10-231-913-126  
US-10-231-913-126  
Sequence 126, Application US/10231913  
Publication No. US20040005576A1  
GENERAL INFORMATION:  
APPLICANT: Guo, Xiaojia S.  
APPLICANT: Li, Li  
APPLICANT: Patturajan, Meera  
APPLICANT: Shimkets, Richard A.  
APPLICANT: Casman, Stacie J.  
APPLICANT: Malyankar, Uriel M.  
APPLICANT: Tchernev, Velizar T.  
APPLICANT: Vernet, Corine A.  
APPLICANT: Spytek, Kimberly A.  
APPLICANT: Shenoy, Suresh G.  
APPLICANT: Alsobrook II, John P.  
APPLICANT: Edinger, Schlomit  
APPLICANT: Peyman, John A.  
APPLICANT: Stone, David J.  
APPLICANT: Ellerman, Karen  
APPLICANT: Gangolli, Esha A.  
APPLICANT: Boldog, Ference L.  
APPLICANT: Colman, Steven D.  
APPLICANT: Eisen, Andrew J.  
APPLICANT: Liu, Xiaohong  
APPLICANT: Padigaru, Muralidhara  
APPLICANT: Spaderna, Steven K.  
APPLICANT: Zerhusen, Bryan D.  
TITLE OF INVENTION: Proteins and Nucleic Acids Encoding Same  
FILE REFERENCE: 21402-216  
CURRENT APPLICATION NUMBER: US/10/231,913  
CURRENT FILING DATE: 2002-08-30  
PRIOR FILING DATE: 2000-12-06  
PRIOR FILING DATE: 2000-12-06  
PRIOR FILING DATE: 2000-12-12  
PRIOR APPLICATION NUMBER: 60/255,029  
PRIOR FILING DATE: 2000-12-12  
PRIOR APPLICATION NUMBER: 60/260,326  
PRIOR FILING DATE: 2001-01-08  
PRIOR APPLICATION NUMBER: 60/263,800  
PRIOR FILING DATE: 2001-01-24  
PRIOR APPLICATION NUMBER: 60/269,942  
PRIOR FILING DATE: 2001-02-20  
PRIOR FILING DATE: 2001-04-24  
PRIOR APPLICATION NUMBER: 60/313,627  
PRIOR FILING DATE: 2001-08-20  
PRIOR APPLICATION NUMBER: 60/318,712  
PRIOR FILING DATE: 2001-09-12  
NUMBER OF SEQ ID NOS: 292  
SOFTWARE: Patent In Ver. 2.1  
SEQ ID NO 126  
LENGTH: 427  
TYPE: PRT  
ORGANISM: Mus musculus  
US-10-231-913-126

Query Match 42.6%; Score 1007; DB 15; Length 427;  
Best Local Similarity 50.0%; Pred. No. 1.5e-87;  
Matches 213; Conservative 62; Mismatches 133; Indels 18; Gaps 6;

QY 37 ATATQAQFSITPAAPGA-----RWGQ-----QAHSPGLGTAAAGHEVEFYGIMFDAGSTG 84  
DB 2 ATSWGAFVMLIIACVQSVTFVREQQTWPEGVFLSSMCPINVSAG---TFYGIMFDAGSTG 58

QY 85 TTVHVFOFT-RRPREPTPTLTHTETKAVKPGLSAYADDVEKSAQGIRELLDVAQDIPDFD 143

Db 59 TRIHVTFVQKTAGQLPFFLEGEIFDVSXPKLSAFVDPQKQAGTVOELLEVAKDSIPRSH 118  
QY 144 WKATPLVLKATAGRLLLPCKEKAQKLLQKVKEVFKASPELVGDDCVIMNGTDEGVSAWIT 203  
Db 119 WERTPVVLKATAGRLLLPCKEKAQKLLLEVEIFKNSFFLVPDGSVIMDGSYEGILAWVT 178  
QY 204 INFLTGSLKTPGSSVGMLLDLGGSTQIAPLPRVECTLOASPPGYLTALRMFNRTYKLYS 263  
Db 179 VNFLTQGLHGRGQETVGTLDLGGASTQITFLPQFEXTLEQTGRGYLTSPFEMFNSTFKLYT 238  
QY 264 YSYLGLGLMSARLAILGGYEGOPAKCKELVSPCLSPSPFKGEWHAETVRYVSGQKAAAS 323  
Db 239 HSYLGLGLKAARLAILGALAEK-GTGDGHTFRSACLPRWLEAEWIFGVVKYQYCGNGEGEM 297  
QY 324 LHELCAARVSEVLQNRVHRTTEEVKHVDYFAFSYXYDLAAGVGLIDAEGKGSVWGDPEFA 383  
Db 298 GFEPCEAEVLRVVQKGLHQPEEVRGSAFAYAFYVYDRAADTHLIDYEKGGLVKVEDFERK 357  
QY 384 AKYVCRTLETQPSQSPFSCMDLTYVSLLOE-FGPPRSKVLKTRKIDNVETSWALGAIF 442  
Db 358 AREVCNLSGFSGSPFLCMLDLYTALLKDGFGFADGTLTQTKVNNIETGVALGATF 417  
QY 443 HYIDSIL 448  
Db 418 HLLQSL 423

## RESULT 10

US-10-091-085-3  
; Sequence 3, Application US/10091085  
; Publication No. US20020146772A1  
; GENERAL INFORMATION:  
; APPLICANT: Ford, John  
; APPLICANT: Mulero, Julio  
; TITLE OF INVENTION: METHODS AND MATERIALS RELATING TO NOVEL CD39-LIKE  
; FILE REFERENCE: 28110/35761  
; CURRENT APPLICATION NUMBER: US/10/091,085  
; PRIOR FILING DATE: 2002-03-05  
; PRIOR APPLICATION NUMBER: 09/350,836  
; PRIOR FILING DATE: 1999-07-09  
; PRIOR APPLICATION NUMBER: 09/273,447  
; PRIOR FILING DATE: 1999-03-19  
; PRIOR APPLICATION NUMBER: 09/118,205  
; PRIOR FILING DATE: 1998-07-16  
; PRIOR APPLICATION NUMBER: 09/122,449  
; PRIOR FILING DATE: 1998-07-24  
; PRIOR APPLICATION NUMBER: 09/244,444  
; PRIOR FILING DATE: 1999-02-04  
; NUMBER OF SEQ ID NOS: 23  
; SOFTWARE: Patent In Ver. 2.0  
; SEQ ID NO 3  
; LENGTH: 428  
; TYPE: PRT  
; ORGANISM: Homo sapiens  
US-10-091-085-3

Query Match 42.3%; Score 999; DB 13; Length 428;  
Best Local Similarity 52.4%; Pred. No. 8.8e-87;  
Matches 204; Conservative 56; Mismatches 123; Indels 6; Gaps 4;  
QY 62 PLGTAADGHEVYFIMFDAGSTGTRVHVFOFT-RPPRETPTLTHTFKAVKPGLSAYADD 120  
Db 40 PINVSA---STLYGIMFDAGSTGTRIHVYTFVQKMPGQLPILEGVFDVSVKPGLSAFVDQ 96  
QY 121 VEKSAOGTRELILDVAKQDIPDFWKATPLVLKATAGRLLLPCKEKAQKLLQKVKEVFKASP 180  
Db 97 PKQAGTVOGLLEVAKDSIPRSHWKTTPVVLKATAGRLLLPEHKAALLFEVKEIFRKSPP 156  
QY 181 FLVGDGDCVSMNGTDEGVSAWITINFLTGSLKTPGSSVGMMLDLGGSTQIAPLPRVEGT 240  
Db 157 FLVFKGVSIMDGSDEGILAWVTNFLTQGLHGRQETVGTLDLGGASTQITFLPQFEXT 216  
QY 241 LOASPPGYLTALRMFNRTYKLYSYSLGLGLMSARLAILGGYEGOPAKCKELVSPCLSP 300  
Db 217 LEQTPRGYLTSPFEMFNSTFKLYTHSYLGFGLKAARLAILGALAEK-GTGDGHTFRSACLPR 275  
QY 301 SPKGEWHAETVRYVSGQKAAASLHELCAARVSEVLQNRVHRTTEEVKHVDYFAFSYXYDL 360  
Db 276 WLEAEWIFGVVKYQYCGNGEGEVGFECYAEVLRVVQKGLHQPEEVRGSAFAYAFYVYDRA 335  
QY 361 AAGVGLIDAEGKGSVWGDPEFAIYVCRTELETPQSSPFCMDLTYVSLLOE-FGPPR 419

QY 241 LOASPPGYLTALRMFNRTYKLYSYSLGLGLMSARLAILGGYEGOPAKCKELVSPCLSP 300  
Db 217 LEQTPRGYLTSPFEMFNSTFKLYTHSYLGFGLKAARLAILGALAEK-GTGDGHTFRSACLPR 275  
QY 301 SPKGEWHAETVRYVSGQKAAASLHELCAARVSEVLQNRVHRTTEEVKHVDYFAFSYXYDL 360  
Db 276 WLEAEWIFGVVKYQYCGNGEGEVGFECYAEVLRVVQKGLHQPEEVRGSAFAYAFYVYDRA 335  
QY 361 AAGVGLIDAEGKGSVWGDPEFAIYVCRTELETPQSSPFCMDLTYVSLLOE-FGPPR 419  
Db 336 AYDTMDIDYKGGILKVEDFERKAREVCNLENFTSGSPFLCMLDLYTALLKDGFGFAD 395  
QY 420 SKVLKTRKIDNVETSWALGAIFHYIDSIL 448  
Db 396 STVLQUTTKVNNIETGVALGATFHLQSL 424

## RESULT 11

US-10-091-085-5  
; Sequence 5, Application US/10091085  
; Publication No. US20020146772A1  
; GENERAL INFORMATION:  
; APPLICANT: Ford, John  
; APPLICANT: Mulero, Julio  
; TITLE OF INVENTION: METHODS AND MATERIALS RELATING TO NOVEL CD39-LIKE  
; FILE REFERENCE: 28110/35761  
; CURRENT APPLICATION NUMBER: US/10/091,085  
; PRIOR FILING DATE: 2002-03-05  
; PRIOR APPLICATION NUMBER: 09/350,836  
; PRIOR FILING DATE: 1999-07-09  
; PRIOR APPLICATION NUMBER: 09/273,447  
; PRIOR FILING DATE: 1999-03-19  
; PRIOR APPLICATION NUMBER: 09/118,205  
; PRIOR FILING DATE: 1998-07-16  
; PRIOR APPLICATION NUMBER: 09/122,449  
; PRIOR FILING DATE: 1998-07-24  
; PRIOR APPLICATION NUMBER: 09/244,444  
; PRIOR FILING DATE: 1999-02-04  
; NUMBER OF SEQ ID NOS: 23  
; SOFTWARE: Patent In Ver. 2.0  
; SEQ ID NO 5  
; LENGTH: 428  
; TYPE: PRT  
; ORGANISM: Homo sapiens  
US-10-091-085-5

Query Match 42.3%; Score 999; DB 13; Length 428;  
Best Local Similarity 52.4%; Pred. No. 8.8e-87;  
Matches 204; Conservative 56; Mismatches 123; Indels 6; Gaps 4;  
QY 62 PLGTAADGHEVYFIMFDAGSTGTRVHVFOFT-RPPRETPTLTHTFKAVKPGLSAYADD 120  
Db 40 PINVSA---STLYGIMFDAGSTGTRIHVYTFVQKMPGQLPILEGVFDVSVKPGLSAFVDQ 96  
QY 121 VEKSAOGTRELILDVAKQDIPDFWKATPLVLKATAGRLLLPCKEKAQKLLQKVKEVFKASP 180  
Db 97 PKQAGTVOGLLEVAKDSIPRSHWKTTPVVLKATAGRLLLPEHKAALLFEVKEIFRKSPP 156  
QY 181 FLVGDGDCVSMNGTDEGVSAWITINFLTGSLKTPGSSVGMMLDLGGSTQIAPLPRVEGT 240  
Db 157 FLVFKGVSIMDGSDEGILAWVTNFLTQGLHGRQETVGTLDLGGASTQITFLPQFEXT 216  
QY 241 LOASPPGYLTALRMFNRTYKLYSYSLGLGLMSARLAILGGYEGOPAKCKELVSPCLSP 300  
Db 217 LEQTPRGYLTSPFEMFNSTFKLYTHSYLGFGLKAARLAILGALAEK-GTGDGHTFRSACLPR 275  
QY 301 SPKGEWHAETVRYVSGQKAAASLHELCAARVSEVLQNRVHRTTEEVKHVDYFAFSYXYDL 360  
Db 276 WLEAEWIFGVVKYQYCGNGEGEVGFECYAEVLRVVQKGLHQPEEVRGSAFAYAFYVYDRA 335  
QY 361 AAGVGLIDAEGKGSVWGDPEFAIYVCRTELETPQSSPFCMDLTYVSLLOE-FGPPR 419





```

; TITLE OF INVENTION: Methods and Materials Relating to CD39-Like
;
; TITLE OF INVENTION: Polypeptides
;
; FILE REFERENCE: 28110/36457CON
;
; CURRENT APPLICATION NUMBER: US/10/286,926
;
; CURRENT FILING DATE: 2002-11-01
;
; PRIOR APPLICATION NUMBER: 09/557,800
;
; PRIOR FILING DATE: 2000-04-25
;
; PRIOR APPLICATION NUMBER: 09/481,238
;
; PRIOR FILING DATE: 2000-01-11
;
; PRIOR APPLICATION NUMBER: 09/370,265
;
; PRIOR FILING DATE: 1999-08-09
;
; PRIOR APPLICATION NUMBER: PCT/US99/16180
;
; PRIOR FILING DATE: 1999-07-16
;
; PRIOR APPLICATION NUMBER: 09/350836
;
; PRIOR FILING DATE: 1999-07-09
;
; PRIOR APPLICATION NUMBER: 09/273447
;
; PRIOR FILING DATE: 1999-03-19
;
; PRIOR APPLICATION NUMBER: 09/122449
;
; PRIOR FILING DATE: 1998-07-24
;
; PRIOR APPLICATION NUMBER: 09/244444
;
; PRIOR FILING DATE: 1999-02-04
;
; PRIOR APPLICATION NUMBER: 09/118,205
;
; PRIOR FILING DATE: 1998-07-16
;
; NUMBER OF SEQ ID NOS: 54
;
; SOFTWARE: PatentIn Ver. 2.0
;
; SEQ ID NO 5
;
; LENGTH: 428
;
; TYPE: PRT
;
; ORGANISM: Homo sapiens
;
; US-10-286-926-5

```

Query Match	42.3%	Score 999	DB 14	Length 428
Best Local Similarity	52.4%	Pred No. 8.8e-87		
Matches 204	Conservative 56	Mismatches 123	Indels 6	Gaps 4
QY 62	PLGTAADGHEVFYGYGIMFDAGSTGTRVHVFOFT-RPPRETPTLTHETKAVPGLSAVADD	120		
DB 40	PINVA---STLYGIMFDAGSTGTRIHHYTFVQKMPGQPLILEGEVSDSVKPGLSAFVQD	96		
QY 121	VEKSAQGIREFLLDVAKODIDPFDKWKATPIVLKATAGLRLLPGEKAKQLQKVKEVFRKASP	180		
DB 97	PKQGAETVQGLLEVAKDSIPRSHWKKTTPVLKATAGLRLLPEHKAKALLFEVKEIFRKSP	156		
QY 181	FLVGGDDCVSIMNGTDEGVSAWIIINFLTSLKTPGSSVGMGLDGGGSGTOIAFLPRVEGT	240		
DB 157	FLVPKGSVIMDSDEGILAWTVNFUTGOLHGRQRTVGTDLGGASTQITFLPQPEKT	216		
QY 241	LQASPPGYLTALAMFNRTYKLYSYSYLGILGIMSARLAILGVEGQPAKDGKELVSPCLSP	300		
DB 217	LEQTPRGYLTSPFMFNSTYKLYTHSYLGFGLKAARLATALTGALETE-GTDGHTFRSACLPR	275		
QY 301	SFKGEWEHAETVTVSGOKAASLHELCAARVSEVLQNRVHRTTEVKHVDYFAESYYDDL	360		
DB 276	WLEAEWIFGGVKYQYGGNOEGEVGFPECYAEVLVVRGKLHQPEEVQGRGFAESYYDYR	335		
QY 361	AAGVGLIDAEKGSVLVVGDFEIAAKVVCRTLETQPOSSPFSQMDLTVVSLLLQF-FGFPFR	419		
DB 336	AVDQDMIDYKEGKILKVEJFERKAREVCNDLENFTSGSPFLCMDLSYITALLKDGFGFAD	395		
QY 420	SKVLKTRKIDNVETSWALGAIFHYIDSL	448		
DB 396	STVLQLTKKVNNIETGWLCAFGPHLOSL	424		

Search completed: November 16, 2004, 17:12:01  
Job time : 144 secs



GenCore version 5.1.6  
Copyright (c) 1993 - 2004 Compugen Ltd.

OM protein - protein search, using sw model

Run on: November 16, 2004, 16:38:51 ; Search time 40 Seconds  
(without alignments)  
756.025 Million cell updates/sec

Title: US-09-905-589A-2

Perfect score: 2364

Sequence: 1 MRKISNHGSLRVAKVAYPLG.....ALGAIFHYDLSNRQKSPAS 456

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 478139 seqs, 66318000 residues

Total number of hits satisfying chosen parameters: 478139

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Listing first 45 summaries

Database :

Issued Patents AA:\*

1: /cgn2\_6/ptodata/1/iaa/5A\_COMB.pep.\*

2: /cgn2\_6/ptodata/1/iaa/5B\_COMB.pep.\*

3: /cgn2\_6/ptodata/1/iaa/6A\_COMB.pep.\*

4: /cgn2\_6/ptodata/1/iaa/6B\_COMB.pep.\*

5: /cgn2\_6/ptodata/1/iaa/PCTUS\_COMB.pep.\*

6: /cgn2\_6/ptodata/1/iaa/backfiles1.pep.\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	2364	100.0	456	US-09-240-639-2	Sequence 2, Appli
2	2364	100.0	456	US-09-908-510A-2	Sequence 2, Appli
3	2364	100.0	456	US-09-905-744-2	Sequence 2, Appli
4	2364	100.0	456	US-10-107-660-2	Sequence 2, Appli
5	2364	100.0	456	US-10-107-576-2	Sequence 2, Appli
6	2364	100.0	456	US-09-905-732-2	Sequence 2, Appli
7	2364	100.0	484	US-09-608-285A-27	Sequence 27, Appl
8	2364	100.0	484	US-09-370-265-27	Sequence 27, Appl
9	2364	100.0	484	US-09-557-800C-27	Sequence 27, Appl
10	2364	100.0	484	US-09-370-625A-27	Sequence 27, Appl
11	2003	84.7	471	US-09-608-285A-60	Sequence 60, Appl
12	999	42.3	428	US-09-608-285A-3	Sequence 3, Appli
13	999	42.3	428	US-09-608-285A-5	Sequence 5, Appli
14	999	42.3	428	US-09-240-639-6	Sequence 6, Appli
15	999	42.3	428	US-09-240-639-9	Sequence 9, Appli
16	999	42.3	428	US-09-350-836B-3	Sequence 3, Appli
17	999	42.3	428	US-09-350-836B-5	Sequence 5, Appli
18	999	42.3	428	US-09-370-265-3	Sequence 3, Appli
19	999	42.3	428	US-09-370-265-5	Sequence 5, Appli
20	999	42.3	428	US-09-557-800C-3	Sequence 3, Appli
21	999	42.3	428	US-09-557-800C-5	Sequence 5, Appli
22	999	42.3	428	US-09-370-625A-3	Sequence 3, Appli
23	999	42.3	428	US-09-370-625A-5	Sequence 5, Appli
24	999	42.3	428	US-09-908-510A-6	Sequence 6, Appli
25	999	42.3	428	US-09-908-510A-9	Sequence 9, Appli
26	999	42.3	428	US-09-905-744-6	Sequence 6, Appli
27	999	42.3	428	US-09-905-744-9	Sequence 9, Appli

28	999	42.3	428	4	US-10-107-660-6	Sequence 6, Appli
29	999	42.3	428	4	US-10-107-660-9	Sequence 9, Appli
30	999	42.3	428	4	US-10-107-576-6	Sequence 6, Appli
31	999	42.3	428	4	US-10-107-576-9	Sequence 9, Appli
32	999	42.3	428	4	US-09-905-732-6	Sequence 6, Appli
33	999	42.3	428	4	US-09-905-732-9	Sequence 9, Appli
34	996	42.1	428	3	US-09-608-285A-7	Sequence 7, Appli
35	996	42.1	428	3	US-09-350-836B-7	Sequence 7, Appli
36	996	42.1	428	4	US-09-370-265-7	Sequence 7, Appli
37	996	42.1	428	4	US-09-557-800C-7	Sequence 7, Appli
38	996	42.1	428	4	US-09-370-625A-7	Sequence 7, Appli
39	909	38.5	405	3	US-09-608-285A-25	Sequence 25, Appl
40	909	38.5	405	4	US-09-370-265-25	Sequence 25, Appl
41	909	38.5	405	4	US-09-557-800C-25	Sequence 25, Appl
42	909	38.5	405	4	US-09-370-625A-25	Sequence 25, Appl
43	909	38.5	465	4	US-09-557-800C-56	Sequence 56, Appl
44	909	38.5	465	4	US-09-370-625A-39	Sequence 39, Appl
45	904	38.2	465	3	US-09-240-639-8	Sequence 8, Appli

ALIGNMENTS

RESULT 1  
US-09-240-639-2  
; Sequence 2, Application US/09240639  
; Patent No. 6350447  
; GENERAL INFORMATION:  
; APPLICANT: Chadwick, Brian Paul  
; APPLICANT: Frischauf, Anna-Maria  
; TITLE OF INVENTION: METHODS AND COMPOSITIONS RELATING TO CD39-LIKE  
; TITLE OF INVENTION: POLYPEPTIDES AND NUCLEIC ACIDS  
; FILE REFERENCE: 9598-066  
; CURRENT APPLICATION NUMBER: US/09/240,639  
; CURRENT FILING DATE: 1998-01-29  
; NUMBER OF SEQ ID NOS: 29  
; SOFTWARE: Patent In Ver. 2.0  
; SEQ ID NO 2  
; LENGTH: 456  
; TYPE: PRT  
; ORGANISM: Homo sapiens  
US-09-240-639-2

Query Match	100.0%	Score 2364;	DB 3;	Length 456;
Best Local Similarity	100.0%	Pred. No. 1.1e-230;		
Matches	456;	Conservative 0;	Mismatches 0;	Indels 0; Gaps 0;
QY	1	MRKISNHGSLRVAKVAYPLG	CGVFIYVAIKWHRATATQAFFSITRAAPGARWQQA	60
DB	1	MRKISNHGSLRVAKVAYPLG	CGVFIYVAIKWHRATATQAFFSITRAAPGARWQQA	60
QY	61	SPLGTADGHEVFYGI	MPDAGSTGTRVHFQFTRPPRPTLTTHETFKAVKPGLSAYADD	120
DB	61	SPLGTADGHEVFYGI	MPDAGSTGTRVHFQFTRPPRPTLTTHETFKAVKPGLSAYADD	120
QY	121	VEKSAQGI	RELLDVAKQDIPDFWKATPLVLKATAGLRLPGEKAQKLLQKVEVFKASP	180
DB	121	VEKSAQGI	RELLDVAKQDIPDFWKATPLVLKATAGLRLPGEKAQKLLQKVEVFKASP	180
QY	181	FLVGDCCV	SIINMGDEGVSAMITINFLTGSUKTPGGSSVGMGLDGGGSGTQAFI	240
DB	181	FLVGDCCV	SIINMGDEGVSAMITINFLTGSUKTPGGSSVGMGLDGGGSGTQAFI	240
QY	241	LQASPPGY	LTAIRNFRTYKLYSYSLGLGMSARLAILGGVEGQPAKDGKELVSPCLSP	300
DB	241	LQASPPGY	LTAIRNFRTYKLYSYSLGLGMSARLAILGGVEGQPAKDGKELVSPCLSP	300
QY	301	SFKGEWEHAEV	TVYVSGKAAASLHEICAAVSVLQNRVHRTVEVKHVDYFAFYFYDL	360
DB	301	SFKGEWEHAEV	TVYVSGKAAASLHEICAAVSVLQNRVHRTVEVKHVDYFAFYFYDL	360
QY	361	AAGVGL	DAEKGSLVVGDFEIAAKYVCRTLETQOSSPSCMDLTIVVSLLLQEGFP	420
DB	361	AAGVGL	DAEKGSLVVGDFEIAAKYVCRTLETQOSSPSCMDLTIVVSLLLQEGFP	420

Db 361 AAGVGLIDAEGKSLVVGDFEIAAKYVCRTLETQPSPPSCMDLTYVSLLOEFGFPRS 420  
Qy 421 KVLKLRKIDNVETSWALGAIFHYIDSINROKSPAS 456  
Db 421 KVLKLRKIDNVETSWALGAIFHYIDSINROKSPAS 456  
RESULT 2  
US-09-908-510A-2  
; Sequence 2, Application US/09908510A  
; Patent No. 6759214  
; GENERAL INFORMATION:  
; APPLICANT: Chadwick, Brian Paul  
; APPLICANT: Frischauf, Anna Maria  
; TITLE OF INVENTION: METHODS AND COMPOSITIONS RELATING TO CD39-LIKE POLYPEPTIDES AND  
; FILE REFERENCE: 28110/36120E  
; CURRENT APPLICATION NUMBER: US/09/908,510A  
; PRIOR FILING DATE: 2001-07-13  
; PRIOR FILING DATE: 2001-07-13  
; PRIOR FILING DATE: 1999-01-29  
; NUMBER OF SEQ ID NOS: 32  
; SOFTWARE: PatentIn version 3.1  
; SEQ ID NO 2  
; LENGTH: 456  
; TYPE: PRT  
; ORGANISM: Homo Sapiens  
US-09-908-510A-2

Query Match 100.0%; Score 2364; DB 4; Length 456;  
Best Local Similarity 100.0%; Pred. No. 1.1e-230;  
Matches 456; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
Qy 1 MRKISNHGSLRVAKVAYPLGLCVGVFIYVAYIKWHRATATQAFPSITRAAPGARWGQOAH 60  
Db 1 MRKISNHGSLRVAKVAYPLGLCVGVFIYVAYIKWHRATATQAFPSITRAAPGARWGQOAH 60  
Qy 61 SPLGTAADGHEVFGIMFDAGSTGTRVHVFOFTPPRETPTLTHTETKAVKPGLSAYADD 120  
Db 61 SPLGTAADGHEVFGIMFDAGSTGTRVHVFOFTPPRETPTLTHTETKAVKPGLSAYADD 120  
Qy 121 VEKSAQGIREDLLDVAQDIPDFWKATPLVLKATAGLRLLPGEKAQKLLQKVEVFKASP 180  
Db 121 VEKSAQGIREDLLDVAQDIPDFWKATPLVLKATAGLRLLPGEKAQKLLQKVEVFKASP 180  
Qy 181 FLVGDDCVSINMGTDGVSAMITINFLTGSLKTPGSSVGMGLDGGSGTQIAFLPRVEGT 240  
Db 181 FLVGDDCVSINMGTDGVSAMITINFLTGSLKTPGSSVGMGLDGGSGTQIAFLPRVEGT 240  
Qy 241 LQASPPGYLTALRMFNRTYKLYSYLGLGMSARLAILGGVEGQPAKDGKELVSPCLSP 300  
Db 241 LQASPPGYLTALRMFNRTYKLYSYLGLGMSARLAILGGVEGQPAKDGKELVSPCLSP 300  
Qy 301 SFKGEWEHAEVTVRVSGKAAASLHELCAARVSEVLQNRVHRTBEVKHVDFAFYFYDYL 360  
Db 301 SFKGEWEHAEVTVRVSGKAAASLHELCAARVSEVLQNRVHRTBEVKHVDFAFYFYDYL 360  
Qy 361 AAGVGLIDAEGKSLVVGDFEIAAKYVCRTLETQPSPPSCMDLTYVSLLOEFGFPRS 420  
Db 361 AAGVGLIDAEGKSLVVGDFEIAAKYVCRTLETQPSPPSCMDLTYVSLLOEFGFPRS 420  
Qy 421 KVLKLRKIDNVETSWALGAIFHYIDSINROKSPAS 456  
Db 421 KVLKLRKIDNVETSWALGAIFHYIDSINROKSPAS 456

RESULT 3  
US-09-905-744-2  
; Sequence 2, Application US/09905744  
; Patent No. 6780410  
; GENERAL INFORMATION:  
; APPLICANT: Chadwick, Brian Paul  
; APPLICANT: Frischauf, Anna Maria

; TITLE OF INVENTION: METHODS AND COMPOSITIONS RELATING TO CD39-LIKE  
; FILE REFERENCE: 9598-066  
; CURRENT APPLICATION NUMBER: US/09/905,744  
; CURRENT FILING DATE: 2001-07-13  
; PRIOR APPLICATION NUMBER: 09/240,639  
; PRIOR FILING DATE: 1999-01-29  
; NUMBER OF SEQ ID NOS: 29  
; SOFTWARE: PatentIn Ver. 2.0  
; SEQ ID NO 2  
; LENGTH: 456  
; TYPE: PRT  
; ORGANISM: Homo sapiens  
US-09-905-744-2

Query Match 100.0%; Score 2364; DB 4; Length 456;  
Best Local Similarity 100.0%; Pred. No. 1.1e-230;  
Matches 456; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
Qy 1 MRKISNHGSLRVAKVAYPLGLCVGVFIYVAYIKWHRATATQAFPSITRAAPGARWGQOAH 60  
Db 1 MRKISNHGSLRVAKVAYPLGLCVGVFIYVAYIKWHRATATQAFPSITRAAPGARWGQOAH 60  
Qy 61 SPLGTAADGHEVFGIMFDAGSTGTRVHVFOFTPPRETPTLTHTETKAVKPGLSAYADD 120  
Db 61 SPLGTAADGHEVFGIMFDAGSTGTRVHVFOFTPPRETPTLTHTETKAVKPGLSAYADD 120  
Qy 121 VEKSAQGIREDLLDVAQDIPDFWKATPLVLKATAGLRLLPGEKAQKLLQKVEVFKASP 180  
Db 121 VEKSAQGIREDLLDVAQDIPDFWKATPLVLKATAGLRLLPGEKAQKLLQKVEVFKASP 180  
Qy 181 FLVGDDCVSINMGTDGVSAMITINFLTGSLKTPGSSVGMGLDGGSGTQIAFLPRVEGT 240  
Db 181 FLVGDDCVSINMGTDGVSAMITINFLTGSLKTPGSSVGMGLDGGSGTQIAFLPRVEGT 240  
Qy 241 LQASPPGYLTALRMFNRTYKLYSYLGLGMSARLAILGGVEGQPAKDGKELVSPCLSP 300  
Db 241 LQASPPGYLTALRMFNRTYKLYSYLGLGMSARLAILGGVEGQPAKDGKELVSPCLSP 300  
Qy 301 SFKGEWEHAEVTVRVSGKAAASLHELCAARVSEVLQNRVHRTBEVKHVDFAFYFYDYL 360  
Db 301 SFKGEWEHAEVTVRVSGKAAASLHELCAARVSEVLQNRVHRTBEVKHVDFAFYFYDYL 360  
Qy 361 AAGVGLIDAEGKSLVVGDFEIAAKYVCRTLETQPSPPSCMDLTYVSLLOEFGFPRS 420  
Db 361 AAGVGLIDAEGKSLVVGDFEIAAKYVCRTLETQPSPPSCMDLTYVSLLOEFGFPRS 420  
Qy 421 KVLKLRKIDNVETSWALGAIFHYIDSINROKSPAS 456  
Db 421 KVLKLRKIDNVETSWALGAIFHYIDSINROKSPAS 456

RESULT 4  
US-10-107-660-2  
; Sequence 2, Application US/10107660  
; Patent No. 6780977  
; GENERAL INFORMATION:  
; APPLICANT: Chadwick, Brian Paul  
; APPLICANT: Frischauf, Anna-Maria  
; TITLE OF INVENTION: METHODS AND COMPOSITIONS RELATING TO CD39-LIKE  
; FILE REFERENCE: 9598-066  
; CURRENT APPLICATION NUMBER: US/10/107,660  
; CURRENT FILING DATE: 2002-03-27  
; PRIOR APPLICATION NUMBER: US/09/240,639  
; PRIOR FILING DATE: 1998-01-29  
; NUMBER OF SEQ ID NOS: 29  
; SOFTWARE: PatentIn Ver. 2.0  
; SEQ ID NO 2  
; LENGTH: 456  
; TYPE: PRT  
; ORGANISM: Homo sapiens  
US-10-107-660-2

Query Match 100.0%; Score 2364; DB 4; Length 456;  
Best Local Similarity 100.0%; Pred. No. 1.1e-230;  
Matches 456; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MRKISNHGSLRVAKVAYPLGLCVGVFIYVAYIKWHRATATQAFFSITRAAPGARWQQAH 60  
DB 1 MRKISNHGSLRVAKVAYPLGLCVGVFIYVAYIKWHRATATQAFFSITRAAPGARWQQAH 60

QY 61 SPLGTAADGHEVFYGVIMFDAGSTGRVHVFOFTRPREPTTLTHETFKAVKPGLSAYADD 120  
DB 61 SPLGTAADGHEVFYGVIMFDAGSTGRVHVFOFTRPREPTTLTHETFKAVKPGLSAYADD 120

QY 121 VEKSAQGIREDLDVAKQDIPDFWKATPLVLKATAGLRLLPGEAKQLQKVEVFKASP 180  
DB 121 VEKSAQGIREDLDVAKQDIPDFWKATPLVLKATAGLRLLPGEAKQLQKVEVFKASP 180

QY 181 FLVGDDCVSINMGTDGVSAMITINFLTGLSLTPGSSVGMLDLGGGSTQIAFLPRVEGT 240  
DB 181 FLVGDDCVSINMGTDGVSAMITINFLTGLSLTPGSSVGMLDLGGGSTQIAFLPRVEGT 240

QY 241 LQASPPGYLTALRMFNRTYKLYSYLGLGMSARLAILGGVEGQPAKDGKELVSPCLSP 300  
DB 241 LQASPPGYLTALRMFNRTYKLYSYLGLGMSARLAILGGVEGQPAKDGKELVSPCLSP 300

QY 301 SFKGEWEHAEVTRYVSGOKAAASHELCAARVSEVLQNRVHRTTEVKHVDFAFSYYIDL 360  
DB 301 SFKGEWEHAEVTRYVSGOKAAASHELCAARVSEVLQNRVHRTTEVKHVDFAFSYYIDL 360

QY 361 AAGVGLIDAEKGGSLVVGDFEIAAAYVCRVLTETQPSPPSCMDLTYVSLLLQEGFPFRS 420  
DB 361 AAGVGLIDAEKGGSLVVGDFEIAAAYVCRVLTETQPSPPSCMDLTYVSLLLQEGFPFRS 420

QY 421 KVLKTRKIDNVETSWALGAIPHYSIDSLNRQKSPAS 456  
DB 421 KVLKTRKIDNVETSWALGAIPHYSIDSLNRQKSPAS 456

RESULT 5  
US-10-107-576-2  
; Sequence 2, Application US/10107576  
; Patent No. 6783959  
; GENERAL INFORMATION:  
; APPLICANT: Chadwick, Brian Paul  
; APPLICANT: Frischauf, Anna-Maria  
; TITLE OF INVENTION: METHODS AND COMPOSITIONS RELATING TO CD39-LIKE  
; FILE REFERENCE: 9539-066  
; CURRENT APPLICATION NUMBER: US/10/107,576  
; PRIOR FILING DATE: 2002-03-27  
; PRIOR APPLICATION NUMBER: US/09/240,639  
; NUMBER OF SEQ ID NOS: 29  
; SOFTWARE: Patent in Ver. 2.0  
; SEQ ID NO 2  
; LENGTH: 456  
; TYPE: PRT  
; ORGANISM: Homo sapiens  
US-10-107-576-2

Query Match 100.0%; Score 2364; DB 4; Length 456;  
Best Local Similarity 100.0%; Pred. No. 1.1e-230;  
Matches 456; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MRKISNHGSLRVAKVAYPLGLCVGVFIYVAYIKWHRATATQAFFSITRAAPGARWQQAH 60  
DB 1 MRKISNHGSLRVAKVAYPLGLCVGVFIYVAYIKWHRATATQAFFSITRAAPGARWQQAH 60

QY 61 SPLGTAADGHEVFYGVIMFDAGSTGRVHVFOFTRPREPTTLTHETFKAVKPGLSAYADD 120  
DB 61 SPLGTAADGHEVFYGVIMFDAGSTGRVHVFOFTRPREPTTLTHETFKAVKPGLSAYADD 120

QY 121 VEKSAQGIREDLDVAKQDIPDFWKATPLVLKATAGLRLLPGEAKQLQKVEVFKASP 180

DB 121 VEKSAQGIREDLDVAKQDIPDFWKATPLVLKATAGLRLLPGEAKQLQKVEVFKASP 180

QY 181 FLVGDDCVSINMGTDGVSAMITINFLTGLSLTPGSSVGMLDLGGGSTQIAFLPRVEGT 240  
DB 181 FLVGDDCVSINMGTDGVSAMITINFLTGLSLTPGSSVGMLDLGGGSTQIAFLPRVEGT 240

QY 241 LQASPPGYLTALRMFNRTYKLYSYLGLGMSARLAILGGVEGQPAKDGKELVSPCLSP 300  
DB 241 LQASPPGYLTALRMFNRTYKLYSYLGLGMSARLAILGGVEGQPAKDGKELVSPCLSP 300

QY 301 SFKGEWEHAEVTRYVSGOKAAASHELCAARVSEVLQNRVHRTTEVKHVDFAFSYYIDL 360  
DB 301 SFKGEWEHAEVTRYVSGOKAAASHELCAARVSEVLQNRVHRTTEVKHVDFAFSYYIDL 360

QY 361 AAGVGLIDAEKGGSLVVGDFEIAAAYVCRVLTETQPSPPSCMDLTYVSLLLQEGFPFRS 420  
DB 361 AAGVGLIDAEKGGSLVVGDFEIAAAYVCRVLTETQPSPPSCMDLTYVSLLLQEGFPFRS 420

QY 421 KVLKTRKIDNVETSWALGAIPHYSIDSLNRQKSPAS 456  
DB 421 KVLKTRKIDNVETSWALGAIPHYSIDSLNRQKSPAS 456

RESULT 6  
US-09-905-732-2  
; Sequence 2, Application US/09905732  
; Patent No. 6787328  
; GENERAL INFORMATION:  
; APPLICANT: Chadwick, Brian Paul  
; APPLICANT: Frischauf, Anna-Maria  
; TITLE OF INVENTION: METHODS AND COMPOSITIONS RELATING TO CD39-LIKE  
; FILE REFERENCE: 9539-066  
; CURRENT APPLICATION NUMBER: US/09/905,732  
; PRIOR FILING DATE: 2001-07-13  
; PRIOR APPLICATION NUMBER: US/09/240,639  
; NUMBER OF SEQ ID NOS: 29  
; SOFTWARE: Patent in Ver. 2.0  
; SEQ ID NO 2  
; LENGTH: 456  
; TYPE: PRT  
; ORGANISM: Homo sapiens  
US-09-905-732-2

Query Match 100.0%; Score 2364; DB 4; Length 456;  
Best Local Similarity 100.0%; Pred. No. 1.1e-230;  
Matches 456; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MRKISNHGSLRVAKVAYPLGLCVGVFIYVAYIKWHRATATQAFFSITRAAPGARWQQAH 60  
DB 1 MRKISNHGSLRVAKVAYPLGLCVGVFIYVAYIKWHRATATQAFFSITRAAPGARWQQAH 60

QY 61 SPLGTAADGHEVFYGVIMFDAGSTGRVHVFOFTRPREPTTLTHETFKAVKPGLSAYADD 120  
DB 61 SPLGTAADGHEVFYGVIMFDAGSTGRVHVFOFTRPREPTTLTHETFKAVKPGLSAYADD 120

QY 121 VEKSAQGIREDLDVAKQDIPDFWKATPLVLKATAGLRLLPGEAKQLQKVEVFKASP 180  
DB 121 VEKSAQGIREDLDVAKQDIPDFWKATPLVLKATAGLRLLPGEAKQLQKVEVFKASP 180

QY 181 FLVGDDCVSINMGTDGVSAMITINFLTGLSLTPGSSVGMLDLGGGSTQIAFLPRVEGT 240  
DB 181 FLVGDDCVSINMGTDGVSAMITINFLTGLSLTPGSSVGMLDLGGGSTQIAFLPRVEGT 240

QY 241 LQASPPGYLTALRMFNRTYKLYSYLGLGMSARLAILGGVEGQPAKDGKELVSPCLSP 300  
DB 241 LQASPPGYLTALRMFNRTYKLYSYLGLGMSARLAILGGVEGQPAKDGKELVSPCLSP 300

QY 301 SFKGEWEHAEVTRYVSGOKAAASHELCAARVSEVLQNRVHRTTEVKHVDFAFSYYIDL 360  
DB 301 SFKGEWEHAEVTRYVSGOKAAASHELCAARVSEVLQNRVHRTTEVKHVDFAFSYYIDL 360

```
QY 361 AAGVGLIDAEKGGSLVVGDFEIAAKYVCRTELETOQSSPFSCMDLTYSVLLQLQFPGPSP 420
Db 361 AAGVGLIDAEKGGSLVVGDFEIAAKYVCRTELETOQSSPFSCMDLTYSVLLQLQFPGPSP 420
QY 421 KVLKTRKIDNVETSWALGAIFHYIDSINRQKSPAS 456
Db 421 KVLKTRKIDNVETSWALGAIFHYIDSINRQKSPAS 456

RESULT 7
US-09-608-285A-27
; Sequence 27, Application US/09608285A
; Patent No. 6335013
; GENERAL INFORMATION:
; APPLICANT: Ford, John
; APPLICANT: Mulero, Julio
; APPLICANT: Yeung, George
; TITLE OF INVENTION: METHODS AND MATERIALS RELATING TO CD39-LIKE
; TITLE OF INVENTION: POLYPEPTIDES
; FILE REFERENCE: 28110/36570
; CURRENT APPLICATION NUMBER: US/09/608,285A
; CURRENT FILING DATE: 2000-06-30
; PRIOR APPLICATION NUMBER: 09/583,231
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: 09/557,800
; PRIOR FILING DATE: 2000-04-25
; PRIOR APPLICATION NUMBER: 09/481,238
; PRIOR FILING DATE: 2000-01-11
; PRIOR APPLICATION NUMBER: 09/370,265
; PRIOR FILING DATE: 1999-08-09
; PRIOR APPLICATION NUMBER: PCT/US99/16180
; PRIOR FILING DATE: 1999-07-16
; PRIOR APPLICATION NUMBER: 09/350,836
; PRIOR FILING DATE: 1999-07-09
; PRIOR APPLICATION NUMBER: 09/273,447
; PRIOR FILING DATE: 1999-03-19
; PRIOR APPLICATION NUMBER: 09/244,444
; PRIOR FILING DATE: 1999-02-04
; PRIOR APPLICATION NUMBER: 09/122,449
; PRIOR FILING DATE: 1998-07-24
; PRIOR APPLICATION NUMBER: 09/118,205
; PRIOR FILING DATE: 1998-07-16
; NUMBER OF SEQ ID NOS: 60
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 27
; LENGTH: 484
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-608-285A-27

Query Match 100.0%; Score 2364; DB 3; Length 484;
Best Local Similarity 100.0%; Pred. No. 1.2e-230; Indels 0; Gaps 0;
Matches 456; Conservative 0; Mismatches 0;

QY 1 MRKISNHGSLRVAKVAYPLGLCVGVFIYVAYIKWHRATATQAFSITRAAPGARWQQA 60
Db 29 MRKISNHGSLRVAKVAYPLGLCVGVFIYVAYIKWHRATATQAFSITRAAPGARWQQA 88
QY 61 SPLGTAADGHEVFGYIMFDAGSTGTRVHVQFTRPPRETPTLTHTFKAQKPLSAYADD 120
Db 89 SPLGTAADGHEVFGYIMFDAGSTGTRVHVQFTRPPRETPTLTHTFKAQKPLSAYADD 148
QY 121 VEKSAQGRRELLDVAQKODIPDFWKATPLVLKATAGLRLPGEKAQKLLQKVKEVFKASP 180
Db 149 VEKSAQGRRELLDVAQKODIPDFWKATPLVLKATAGLRLPGEKAQKLLQKVKEVFKASP 208
QY 181 FLVGGDCVSIIMGTDGVSAMITINFLTGLSKTPGSSVGMLDLGGSGTQIAFLPRVEGT 240
Db 209 FLVGGDCVSIIMGTDGVSAMITINFLTGLSKTPGSSVGMLDLGGSGTQIAFLPRVEGT 268
QY 241 LOASPPGYLTALRMNRTYKLSYSLGILGMSARLAILGGVEGQPAKDKELVSPCLSP 300
Db 269 FLVGGDCVSIIMGTDGVSAMITINFLTGLSKTPGSSVGMLDLGGSGTQIAFLPRVEGT 268
QY 301 SFKGEWHAETVYRVSGOKAAASLHELCAARVSEVLQNRVHRTVEVKHVDYFAFSYYIDL 360
Db 301 SFKGEWHAETVYRVSGOKAAASLHELCAARVSEVLQNRVHRTVEVKHVDYFAFSYYIDL 360

QY 269 LOASPPGYLTALRMNRTYKLSYSLGILGMSARLAILGGVEGQPAKDKELVSPCLSP 328
QY 301 SFKGEWHAETVYRVSGOKAAASLHELCAARVSEVLQNRVHRTVEVKHVDYFAFSYYIDL 360
Db 301 SFKGEWHAETVYRVSGOKAAASLHELCAARVSEVLQNRVHRTVEVKHVDYFAFSYYIDL 360

QY 301 SFKGEWHAETVYRVSGOKAAASLHELCAARVSEVLQNRVHRTVEVKHVDYFAFSYYIDL 360
Db 301 SFKGEWHAETVYRVSGOKAAASLHELCAARVSEVLQNRVHRTVEVKHVDYFAFSYYIDL 360
QY 329 SFKGEWHAETVYRVSGOKAAASLHELCAARVSEVLQNRVHRTVEVKHVDYFAFSYYIDL 388
QY 361 AAGVGLIDAEKGGSLVVGDFEIAAKYVCRTELETOQSSPFSCMDLTYSVLLQLQFPGPSP 420
Db 361 AAGVGLIDAEKGGSLVVGDFEIAAKYVCRTELETOQSSPFSCMDLTYSVLLQLQFPGPSP 420
QY 421 KVLKTRKIDNVETSWALGAIFHYIDSINRQKSPAS 456
Db 421 KVLKTRKIDNVETSWALGAIFHYIDSINRQKSPAS 456

RESULT 8
US-09-370-265-27
; Sequence 27, Application US/09370265
; Patent No. 6447771
; GENERAL INFORMATION:
; APPLICANT: Ford, John
; APPLICANT: Mulero, Julio
; TITLE OF INVENTION: METHODS AND MATERIALS RELATING TO NOVEL CD39-LIKE
; TITLE OF INVENTION: POLYPEPTIDES
; FILE REFERENCE: 28111/35908
; CURRENT APPLICATION NUMBER: US/09/370,265
; CURRENT FILING DATE: 1999-08-09
; PRIOR APPLICATION NUMBER: PCT/US99/16180
; PRIOR FILING DATE: 1999-07-16
; PRIOR APPLICATION NUMBER: 09/350,836
; PRIOR FILING DATE: 1999-07-09
; PRIOR APPLICATION NUMBER: 09/273,447
; PRIOR FILING DATE: 1999-03-19
; PRIOR APPLICATION NUMBER: 09/244,444
; PRIOR FILING DATE: 1999-02-04
; PRIOR APPLICATION NUMBER: 09/122,449
; PRIOR FILING DATE: 1998-07-24
; PRIOR APPLICATION NUMBER: 09/118,205
; PRIOR FILING DATE: 1998-07-16
; NUMBER OF SEQ ID NOS: 37
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 27
; LENGTH: 484
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-370-265-27

Query Match 100.0%; Score 2364; DB 4; Length 484;
Best Local Similarity 100.0%; Pred. No. 1.2e-230; Indels 0; Gaps 0;
Matches 456; Conservative 0; Mismatches 0;

QY 1 MRKISNHGSLRVAKVAYPLGLCVGVFIYVAYIKWHRATATQAFSITRAAPGARWQQA 60
Db 29 MRKISNHGSLRVAKVAYPLGLCVGVFIYVAYIKWHRATATQAFSITRAAPGARWQQA 88
QY 61 SPLGTAADGHEVFGYIMFDAGSTGTRVHVQFTRPPRETPTLTHTFKAQKPLSAYADD 120
Db 89 SPLGTAADGHEVFGYIMFDAGSTGTRVHVQFTRPPRETPTLTHTFKAQKPLSAYADD 148
QY 121 VEKSAQGRRELLDVAQKODIPDFWKATPLVLKATAGLRLPGEKAQKLLQKVKEVFKASP 180
Db 149 VEKSAQGRRELLDVAQKODIPDFWKATPLVLKATAGLRLPGEKAQKLLQKVKEVFKASP 208
QY 181 FLVGGDCVSIIMGTDGVSAMITINFLTGLSKTPGSSVGMLDLGGSGTQIAFLPRVEGT 240
Db 209 FLVGGDCVSIIMGTDGVSAMITINFLTGLSKTPGSSVGMLDLGGSGTQIAFLPRVEGT 268
QY 241 LOASPPGYLTALRMNRTYKLSYSLGILGMSARLAILGGVEGQPAKDKELVSPCLSP 300
Db 269 FLVGGDCVSIIMGTDGVSAMITINFLTGLSKTPGSSVGMLDLGGSGTQIAFLPRVEGT 268
QY 301 SFKGEWHAETVYRVSGOKAAASLHELCAARVSEVLQNRVHRTVEVKHVDYFAFSYYIDL 360
Db 301 SFKGEWHAETVYRVSGOKAAASLHELCAARVSEVLQNRVHRTVEVKHVDYFAFSYYIDL 360
```

Db 329 SFKGEWHAETVYRVSGOKAAASLHELCAARVSEVLQNRVHRTTEVKHVDYFAFSYYDL 388  
QY 361 AAGVGLIDAEGKSLVVGDFEIAAAYVCTLTETQSSPFCMDLTYVSLLLQEGFPPRS 420  
Db 389 AAGVGLIDAEGKSLVVGDFEIAAAYVCTLTETQSSPFCMDLTYVSLLLQEGFPPRS 448  
QY 421 KVLKTRKIDNVETSWALGAIFHYIDSINRQKSPAS 456  
Db 449 KVLKTRKIDNVETSWALGAIFHYIDSINRQKSPAS 484

RESULT 9

US-09-557-800C-27  
; Sequence 27, Application US/09557800C  
; Patent No. 6476211  
; GENERAL INFORMATION:  
; APPLICANT: Ford, John  
; APPLICANT: Mulero, Julio  
; APPLICANT: Yeung, George  
; TITLE OF INVENTION: Methods and Materials Relating to CD39-Like  
; FILE REFERENCE: 28110/36457  
; CURRENT APPLICATION NUMBER: US/09/557,800C  
; CURRENT FILING DATE: 2000-04-25  
; PRIOR APPLICATION NUMBER: 09/481,238  
; PRIOR FILING DATE: 2000-01-11  
; PRIOR APPLICATION NUMBER: 09/370,265  
; PRIOR FILING DATE: 1999-08-09  
; PRIOR APPLICATION NUMBER: PCT/US99/16180  
; PRIOR FILING DATE: 1999-07-16  
; PRIOR APPLICATION NUMBER: 09/350936  
; PRIOR FILING DATE: 1999-07-09  
; PRIOR APPLICATION NUMBER: 09/273447  
; PRIOR FILING DATE: 1999-03-19  
; PRIOR APPLICATION NUMBER: 09/122449  
; PRIOR FILING DATE: 1998-07-24  
; PRIOR APPLICATION NUMBER: 09/244444  
; PRIOR FILING DATE: 1999-02-04  
; PRIOR APPLICATION NUMBER: 09/118,205  
; PRIOR FILING DATE: 1998-07-16  
; NUMBER OF SEQ ID NOS: 56  
; SOFTWARE: PatentIn Ver. 2.0  
; SEQ ID NO 27  
; LENGTH: 484  
; TYPE: PRT  
; ORGANISM: Homo sapiens  
US-09-557-800C-27

Query Match 100.0%; Score 2364; DB 4; Length 484;  
Best Local Similarity 100.0%; Pred. No. 1.2e-230;  
Matches 456; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1 MRKISNHGSLRAKAVAYPLGLCVGVFIYVAIKWHRATATQAFSITRAAPCARWGQQA 60  
Db 29 MRKISNHGSLRAKAVAYPLGLCVGVFIYVAIKWHRATATQAFSITRAAPCARWGQQA 88  
QY 61 SPLGTAADGHEVYFGIMFDAGSTGRVHVFOFTPRPTTLTHETFKAVKPGLSAYADD 120  
Db 89 SPLGTAADGHEVYFGIMFDAGSTGRVHVFOFTPRPTTLTHETFKAVKPGLSAYADD 148  
QY 121 VEKSAQGIREDLLDVAQDIPDFWKATPLVLKATAGLLPGEKAQKLLQKVKEVFKASP 180  
Db 149 VEKSAQGIREDLLDVAQDIPDFWKATPLVLKATAGLLPGEKAQKLLQKVKEVFKASP 208  
QY 181 FLVGDDCVSINMGTDGVSAMITINFLTGSILKTPGSSVGMLDLGGSGTQIAFLPRVEGT 240  
Db 209 FLVGDDCVSINMGTDGVSAMITINFLTGSILKTPGSSVGMLDLGGSGTQIAFLPRVEGT 268  
QY 241 LQASPPGYLTALRMFNRTYKLYSYSLGLGMSARLAILGGVEGOPAKDGKELVSPCLSP 300  
Db 269 LQASPPGYLTALRMFNRTYKLYSYSLGLGMSARLAILGGVEGOPAKDGKELVSPCLSP 328  
QY 301 SFKGEWHAETVYRVSGOKAAASLHELCAARVSEVLQNRVHRTTEVKHVDYFAFSYYDL 360  
Db 329 SFKGEWHAETVYRVSGOKAAASLHELCAARVSEVLQNRVHRTTEVKHVDYFAFSYYDL 388  
QY 361 AAGVGLIDAEGKSLVVGDFEIAAAYVCTLTETQSSPFCMDLTYVSLLLQEGFPPRS 420  
Db 389 AAGVGLIDAEGKSLVVGDFEIAAAYVCTLTETQSSPFCMDLTYVSLLLQEGFPPRS 448  
QY 421 KVLKTRKIDNVETSWALGAIFHYIDSINRQKSPAS 456  
Db 449 KVLKTRKIDNVETSWALGAIFHYIDSINRQKSPAS 484

Db 329 SFKGEWHAETVYRVSGOKAAASLHELCAARVSEVLQNRVHRTTEVKHVDYFAFSYYDL 388  
QY 361 AAGVGLIDAEGKSLVVGDFEIAAAYVCTLTETQSSPFCMDLTYVSLLLQEGFPPRS 420  
Db 389 AAGVGLIDAEGKSLVVGDFEIAAAYVCTLTETQSSPFCMDLTYVSLLLQEGFPPRS 448  
QY 421 KVLKTRKIDNVETSWALGAIFHYIDSINRQKSPAS 456  
Db 449 KVLKTRKIDNVETSWALGAIFHYIDSINRQKSPAS 484

RESULT 10

US-09-370-625A-27  
; Sequence 27, Application US/09370625A  
; Patent No. 6600032  
; GENERAL INFORMATION:  
; APPLICANT: Ford, John  
; APPLICANT: Mulero, Julio  
; TITLE OF INVENTION: METHODS AND MATERIALS RELATING TO NOVEL CD39-LIKE POLYPEPTIDES  
; FILE REFERENCE: 28110/35908  
; CURRENT APPLICATION NUMBER: US/09/370,625A  
; CURRENT FILING DATE: 1999-08-09  
; PRIOR APPLICATION NUMBER: PCT/US99/16180  
; PRIOR FILING DATE: 1999-07-16  
; PRIOR APPLICATION NUMBER: 09/350,836  
; PRIOR FILING DATE: 1999-07-09  
; PRIOR APPLICATION NUMBER: 09/273,447  
; PRIOR FILING DATE: 1999-03-19  
; NUMBER OF SEQ ID NOS: 39  
; SOFTWARE: PatentIn Ver. 2.0  
; SEQ ID NO 27  
; LENGTH: 484  
; TYPE: PRT  
; ORGANISM: Homo sapiens  
US-09-370-625A-27

Query Match 100.0%; Score 2364; DB 4; Length 484;  
Best Local Similarity 100.0%; Pred. No. 1.2e-230;  
Matches 456; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1 MRKISNHGSLRAKAVAYPLGLCVGVFIYVAIKWHRATATQAFSITRAAPCARWGQQA 60  
Db 29 MRKISNHGSLRAKAVAYPLGLCVGVFIYVAIKWHRATATQAFSITRAAPCARWGQQA 88  
QY 61 SPLGTAADGHEVYFGIMFDAGSTGRVHVFOFTPRPTTLTHETFKAVKPGLSAYADD 120  
Db 89 SPLGTAADGHEVYFGIMFDAGSTGRVHVFOFTPRPTTLTHETFKAVKPGLSAYADD 148  
QY 121 VEKSAQGIREDLLDVAQDIPDFWKATPLVLKATAGLLPGEKAQKLLQKVKEVFKASP 180  
Db 149 VEKSAQGIREDLLDVAQDIPDFWKATPLVLKATAGLLPGEKAQKLLQKVKEVFKASP 208  
QY 181 FLVGDDCVSINMGTDGVSAMITINFLTGSILKTPGSSVGMLDLGGSGTQIAFLPRVEGT 240  
Db 209 FLVGDDCVSINMGTDGVSAMITINFLTGSILKTPGSSVGMLDLGGSGTQIAFLPRVEGT 268  
QY 241 LQASPPGYLTALRMFNRTYKLYSYSLGLGMSARLAILGGVEGOPAKDGKELVSPCLSP 300  
Db 269 LQASPPGYLTALRMFNRTYKLYSYSLGLGMSARLAILGGVEGOPAKDGKELVSPCLSP 328  
QY 301 SFKGEWHAETVYRVSGOKAAASLHELCAARVSEVLQNRVHRTTEVKHVDYFAFSYYDL 360  
Db 329 SFKGEWHAETVYRVSGOKAAASLHELCAARVSEVLQNRVHRTTEVKHVDYFAFSYYDL 388  
QY 361 AAGVGLIDAEGKSLVVGDFEIAAAYVCTLTETQSSPFCMDLTYVSLLLQEGFPPRS 420  
Db 389 AAGVGLIDAEGKSLVVGDFEIAAAYVCTLTETQSSPFCMDLTYVSLLLQEGFPPRS 448  
QY 421 KVLKTRKIDNVETSWALGAIFHYIDSINRQKSPAS 456  
Db 449 KVLKTRKIDNVETSWALGAIFHYIDSINRQKSPAS 484

## RESULT 11

US-09-608-285A-60  
; Sequence 60, Application US/09608285A  
; Patent No. 6335013  
; GENERAL INFORMATION:  
; APPLICANT: Ford, John  
; APPLICANT: Mulero, John  
; APPLICANT: Yeung, George  
; TITLE OF INVENTION: METHODS AND MATERIALS RELATING TO CD39-LIKE  
; TITLE OF INVENTION: POLYPEPTIDES  
; FILE REFERENCE: 28110/36570  
; CURRENT APPLICATION NUMBER: US/09/608,285A  
; CURRENT FILING DATE: 2000-06-30  
; PRIOR APPLICATION NUMBER: 09/583,231  
; PRIOR FILING DATE: 2000-05-26  
; PRIOR APPLICATION NUMBER: 09/557,800  
; PRIOR FILING DATE: 2000-04-25  
; PRIOR APPLICATION NUMBER: 09/481,238  
; PRIOR FILING DATE: 2000-01-11  
; PRIOR APPLICATION NUMBER: 09/370,265  
; PRIOR FILING DATE: 1999-08-09  
; PRIOR APPLICATION NUMBER: PCT/US99/16180  
; PRIOR FILING DATE: 1999-07-16  
; PRIOR APPLICATION NUMBER: 09/350,836  
; PRIOR FILING DATE: 1999-07-09  
; PRIOR APPLICATION NUMBER: 09/273,447  
; PRIOR FILING DATE: 1999-03-19  
; PRIOR APPLICATION NUMBER: 09/244,444  
; PRIOR FILING DATE: 1999-02-04  
; PRIOR APPLICATION NUMBER: 09/122,449  
; PRIOR FILING DATE: 1998-07-24  
; PRIOR APPLICATION NUMBER: 09/118,205  
; PRIOR FILING DATE: 1998-07-16  
; NUMBER OF SEQ ID NOS: 60  
; SOFTWARE: PatentIn Ver. 2.0  
; SEQ ID NO 60  
; LENGTH: 471  
; TYPE: PRT  
; ORGANISM: Homo sapiens  
US-09-608-285A-60

Query Match 84.7%; Score 2003; DB 3; Length 471;  
Best Local Similarity 98.5%; Pred. No. 4.6e-194;  
Matches 388; Conservative 1; Mismatches 5; Indels 0; Gaps 0;

Qy	1	MRKISNHGSLRVAKVAYPLGLCVGVFIYVAVIKWHRATATQAFSITRAAPGARWQQA	60
Db	29	MRKISNHGSLRVAKVAYPLGLCVGVFIYVAVIKWHRATATQAFSITRAAPGARWQQA	88
Qy	61	SPLGTAADGHEVFGIMFDAGSTGTRVHVFOFTRPPRETPTLTHTETKAVKPGLSAYADD	120
Db	89	SPLGTAADGHEVFGIMFDAGSTGTRVHVFOFTRPPRETPTLTHTETKAVKPGLSAYADD	148
Qy	121	VEKSAQGIREDLLVAKQDIPDFWKATPLVLKATAGLRLPGEKAQKLLQKVKEVFKASP	180
Db	149	VEKSAQGIREDLLVAKQDIPDFWKATPLVLKATAGLRLPGEKAQKLLQKVKEVFKASP	208
Qy	181	FLVGGDCVSIWNGTDEGVSAWITINFLTGSLSKTPGSSVGMGLDGGSGTQIAFLPRVGT	240
Db	209	FLVGGDCVSIWNGTDEGVSAWITINFLTGSLSKTPGSSVGMGLDGGSGTQIAFLPRVGT	268
Qy	241	LQASPPGYLTALRMENRTYKLYSYSLGGLMSARLAILGGVEGQPAKDGKELVSPCLSP	300
Db	269	LQASPPGYLTALRMENRTYKLYSYSLGGLMSARLAILGGVEGQPAKDGKELVSPCLSP	328
Qy	301	SFKGEWEHAEVTRYVSGQKAAASLHELCAARVSEVLQNRVHRTTEVKHVDVFAFSYYDL	360
Db	329	SFKGEWEHAEVTRYVSGQKAAASLHELCAARVSEVLQNRVHRTTEVKHVDVFAFSYYDL	388
Qy	361	AAGVGLIDAEKGGSLVVGDFEIAAAYVCHTLETO 394	
Db	389	AAGVGLIDAEKGGSLVVGDFEIAAAYVCHTLETO 422	

## RESULT 12

US-09-608-285A-3  
; Sequence 3, Application US/09608285A  
; Patent No. 6335013  
; GENERAL INFORMATION:  
; APPLICANT: Ford, John  
; APPLICANT: Mulero, John  
; APPLICANT: Yeung, George  
; TITLE OF INVENTION: METHODS AND MATERIALS RELATING TO CD39-LIKE  
; TITLE OF INVENTION: POLYPEPTIDES  
; FILE REFERENCE: 28110/36570  
; CURRENT APPLICATION NUMBER: US/09/608,285A  
; CURRENT FILING DATE: 2000-06-30  
; PRIOR APPLICATION NUMBER: 09/583,231  
; PRIOR FILING DATE: 2000-05-26  
; PRIOR APPLICATION NUMBER: 09/557,800  
; PRIOR FILING DATE: 2000-04-25  
; PRIOR APPLICATION NUMBER: 09/481,238  
; PRIOR FILING DATE: 2000-01-11  
; PRIOR APPLICATION NUMBER: 09/370,265  
; PRIOR FILING DATE: 1999-08-09  
; PRIOR APPLICATION NUMBER: PCT/US99/16180  
; PRIOR FILING DATE: 1999-07-16  
; PRIOR APPLICATION NUMBER: 09/350,836  
; PRIOR FILING DATE: 1999-07-09  
; PRIOR APPLICATION NUMBER: 09/273,447  
; PRIOR FILING DATE: 1999-03-19  
; PRIOR APPLICATION NUMBER: 09/244,444  
; PRIOR FILING DATE: 1999-02-04  
; PRIOR APPLICATION NUMBER: 09/122,449  
; PRIOR FILING DATE: 1998-07-24  
; PRIOR APPLICATION NUMBER: 09/118,205  
; PRIOR FILING DATE: 1998-07-16  
; NUMBER OF SEQ ID NOS: 60  
; SOFTWARE: PatentIn Ver. 2.0  
; SEQ ID NO 3  
; LENGTH: 428  
; TYPE: PRT  
; ORGANISM: Homo sapiens  
US-09-608-285A-3

Query Match 42.3%; Score 999; DB 3; Length 428;  
Best Local Similarity 52.4%; Pred. No. 2.2e-92;  
Matches 204; Conservative 56; Mismatches 123; Indels 6; Gaps 4;

Qy	62	PLGTAADGHEVFGIMFDAGSTGTRVHVFOFT-RPPRETPTLTHTETKAVKPGLSAYADD	120
Db	40	PINVSAAA-STLYGIMFDAGSTGTRVHVFOFTVQKMPGOLPILEGVEFDSVFKGLSAFVDQ	96
Qy	121	VEKSAQGIREDLLVAKQDIPDFWKATPLVLKATAGLRLPGEKAQKLLQKVKEVFKASP	180
Db	97	PKQGAETVQGLLEVAKQDSIPRSHWKTTPVLKATAGLRLPGEKAQKLLQKVKEVFKASP	156
Qy	181	FLVGGDCVSIWNGTDEGVSAWITINFLTGSLSKTPGSSVGMGLDGGSGTQIAFLPRVGT	240
Db	157	FLVFKGVSIMDGSDEGLAWVTNFLTQGLHGRQETVGTGLDGGASTQITFLPQFBKT	216
Qy	241	LQASPPGYLTALRMENRTYKLYSYSLGGLMSARLAILGGVEGQPAKDGKELVSPCLSP	300
Db	217	LEQTPRGVLTSEFMENSTYKLYTHSYLGLKARLALGALETE-GTDGHTFRSACLPR	275
Qy	301	SFKGEWEHAEVTRYVSGQKAAASLHELCAARVSEVLQNRVHRTTEVKHVDVFAFSYYDL	360
Db	276	WLEAEWIFGGVKYQYCGNOEGVEGPEPCYAEVLRVVRGK.HQPEEVQVQSGSFYAFSYYDR	335
Qy	361	AAGVGLIDAEKGGSLVVGDFEIAAAYVCHTLETOQSSPFCMDLTYVSLLOE-FGPR	419
Db	336	AVDTDMIDYEGGILKVEDFERKAREVCNLENFTSGSPFLCMLDLSYITALLKDGFGFAD	395
Qy	420	SKVLKLTAKIDNVETSWALGAIFHYIDSL 448	



Db 396 STVQLTKKVNNIETGALGATFHLLQSL 424

RESULT 13  
US-09-608-285A-5  
; Sequence 5, Application US/09608285A  
; Patent No. 635013  
; GENERAL INFORMATION:  
; APPLICANT: Ford, John  
; APPLICANT: Mulero, Julio  
; APPLICANT: Yeung, George  
; TITLE OF INVENTION: METHODS AND MATERIALS RELATING TO CD39-LIKE  
; FILE REFERENCE: 28110/36570  
; CURRENT APPLICATION NUMBER: US/09/608,285A  
; CURRENT FILING DATE: 2000-06-30  
; PRIOR APPLICATION NUMBER: 09/583,231  
; PRIOR FILING DATE: 2000-05-26  
; PRIOR APPLICATION NUMBER: 09/557,800  
; PRIOR FILING DATE: 2000-04-25  
; PRIOR APPLICATION NUMBER: 09/481,238  
; PRIOR FILING DATE: 2000-01-11  
; PRIOR APPLICATION NUMBER: 09/370,265  
; PRIOR FILING DATE: 1999-08-09  
; PRIOR APPLICATION NUMBER: PCT/US99/16180  
; PRIOR FILING DATE: 1999-07-16  
; PRIOR APPLICATION NUMBER: 09/350,836  
; PRIOR FILING DATE: 1999-07-09  
; PRIOR APPLICATION NUMBER: 09/273,447  
; PRIOR FILING DATE: 1999-03-19  
; PRIOR APPLICATION NUMBER: 09/244,444  
; PRIOR FILING DATE: 1999-02-04  
; PRIOR APPLICATION NUMBER: 09/122,449  
; PRIOR FILING DATE: 1998-07-24  
; PRIOR APPLICATION NUMBER: 09/118,205  
; PRIOR FILING DATE: 1998-07-16  
; NUMBER OF SEQ ID NOS: 60  
; SOFTWARE: PatentIn Ver. 2.0  
; SEQ ID NO 5  
; LENGTH: 428  
; TYPE: PRT  
; ORGANISM: Homo sapiens  
US-09-608-285A-5

Query Match 42.3%; Score 999; DB 3; Length 428;  
Best Local Similarity 52.4%; Pred. No. 2.2e-92;  
Matches 204; Conservative 56; Mismatches 123; Indels 6; Gaps 4;  
Qy 62 PLGTAADGHEVYFYGIMFDAGSTGTRVHVFT-PPRETPTLTHTFTKAVKPGLSAYADD 120  
Db 40 PINVSA---STLYGIMFDAGSTGTRIHVYTFVQKMPGQLPILGEVFDVSVKPGLSAFVDQ 96  
Qy 121 VEKSAQGIREDLDVAKQDIPDFWKATPLVLKATAGLRLLPGEKAKQLKQKVEVFKASP 180  
Db 97 PKQGAETVQGLEVAKQDIPRSHWKKTPWLKATAGLRLLPGEKAKQLKQKVEVFKASP 156  
Qy 181 FLVGDDCVSINMGTDGVSAMTTFNLTGSLKTPGSSVGMGLDGGSTQIAFLPRVSGT 240  
Db 157 FLVPGKGSVIMDGDEGILAWTVNFLTQGLHGRQETVGTLDLGGASTQTTFLPQFEXT 216  
Qy 241 LQASPPGYLTALRMFNRITYKLYSYLGLGMSARLAILGGVGGOPAKDGKELVSPCLSP 300  
Db 217 LEQTPRGYLTSEFENSTYKLYTHSYLGLGKARLALGALETE-GTDGHTFRSACLPR 275  
Qy 301 SFKEWEHAEVTVRVSGOKAAASLHELCAARVSEVLQNRVHRTBEVKHVDYAFSYYYDL 360  
Db 276 WLEAEWIFGGVKYQYGGNQEVEGPEPCYAEVLRVVRGKLHPQBEVQSGSFYAFSYYYDR 335  
Qy 361 AAGVGLIDAEKGGSLVVGDFEIAAKYVCRTLETQPSPPSCMDLTYYVSLLOE-FGPR 419  
Db 336 AVDTMDIDYEKGGLIKVEDFERKAREVCNLENFTSGSFFLCMDLSYITALLKOGFGPAD 395  
Qy 420 SKVLKLRKIDNVETSWALGAIFHYDLSL 448

RESULT 14  
US-09-240-639-6  
; Sequence 6, Application US/09240639  
; Patent No. 6350447  
; GENERAL INFORMATION:  
; APPLICANT: Chadwick, Brian Paul  
; APPLICANT: Frischauf, Anna-Maria  
; TITLE OF INVENTION: METHODS AND COMPOSITIONS RELATING TO CD39-LIKE  
; FILE REFERENCE: 9598-066  
; CURRENT APPLICATION NUMBER: US/09/240,639  
; CURRENT FILING DATE: 1998-01-29  
; NUMBER OF SEQ ID NOS: 29  
; SOFTWARE: PatentIn Ver. 2.0  
; SEQ ID NO 6  
; LENGTH: 428  
; TYPE: PRT  
; ORGANISM: Homo sapiens  
US-09-240-639-6

Db 396 STVQLTKKVNNIETGALGATFHLLQSL 424

RESULT 14  
US-09-240-639-6  
; Sequence 6, Application US/09240639  
; Patent No. 6350447  
; GENERAL INFORMATION:  
; APPLICANT: Chadwick, Brian Paul  
; APPLICANT: Frischauf, Anna-Maria  
; TITLE OF INVENTION: METHODS AND COMPOSITIONS RELATING TO CD39-LIKE  
; FILE REFERENCE: 9598-066  
; CURRENT APPLICATION NUMBER: US/09/240,639  
; CURRENT FILING DATE: 1998-01-29  
; NUMBER OF SEQ ID NOS: 29  
; SOFTWARE: PatentIn Ver. 2.0  
; SEQ ID NO 6  
; LENGTH: 428  
; TYPE: PRT  
; ORGANISM: Homo sapiens  
US-09-240-639-6

Query Match 42.3%; Score 999; DB 3; Length 428;  
Best Local Similarity 52.4%; Pred. No. 2.2e-92;  
Matches 204; Conservative 56; Mismatches 123; Indels 6; Gaps 4;  
Qy 62 PLGTAADGHEVYFYGIMFDAGSTGTRVHVFT-PPRETPTLTHTFTKAVKPGLSAYADD 120  
Db 40 PINVSA---STLYGIMFDAGSTGTRIHVYTFVQKMPGQLPILGEVFDVSVKPGLSAFVDQ 96  
Qy 121 VEKSAQGIREDLDVAKQDIPDFWKATPLVLKATAGLRLLPGEKAKQLKQKVEVFKASP 180  
Db 97 PKQGAETVQGLEVAKQDIPRSHWKKTPWLKATAGLRLLPGEKAKQLKQKVEVFKASP 156  
Qy 181 FLVGDDCVSINMGTDGVSAMTTFNLTGSLKTPGSSVGMGLDGGSTQIAFLPRVSGT 240  
Db 157 FLVPGKGSVIMDGDEGILAWTVNFLTQGLHGRQETVGTLDLGGASTQTTFLPQFEXT 216  
Qy 241 LQASPPGYLTALRMFNRITYKLYSYLGLGMSARLAILGGVGGOPAKDGKELVSPCLSP 300  
Db 217 LEQTPRGYLTSEFENSTYKLYTHSYLGLGKARLALGALETE-GTDGHTFRSACLPR 275  
Qy 301 SFKEWEHAEVTVRVSGOKAAASLHELCAARVSEVLQNRVHRTBEVKHVDYAFSYYYDL 360  
Db 276 WLEAEWIFGGVKYQYGGNQEVEGPEPCYAEVLRVVRGKLHPQBEVQSGSFYAFSYYYDR 335  
Qy 361 AAGVGLIDAEKGGSLVVGDFEIAAKYVCRTLETQPSPPSCMDLTYYVSLLOE-FGPR 419  
Db 336 AVDTMDIDYEKGGLIKVEDFERKAREVCNLENFTSGSFFLCMDLSYITALLKOGFGPAD 395  
Qy 420 SKVLKLRKIDNVETSWALGAIFHYDLSL 448  
Db 396 STVQLTKKVNNIETGALGATFHLLQSL 424

RESULT 15  
US-09-240-639-9  
; Sequence 9, Application US/09240639  
; Patent No. 6350447  
; GENERAL INFORMATION:  
; APPLICANT: Chadwick, Brian Paul  
; APPLICANT: Frischauf, Anna-Maria  
; TITLE OF INVENTION: METHODS AND COMPOSITIONS RELATING TO CD39-LIKE  
; FILE REFERENCE: 9598-066  
; CURRENT APPLICATION NUMBER: US/09/240,639  
; CURRENT FILING DATE: 1998-01-29  
; NUMBER OF SEQ ID NOS: 29  
; SOFTWARE: PatentIn Ver. 2.0  
; SEQ ID NO 9  
; LENGTH: 428  
; TYPE: PRT  
; ORGANISM: Homo sapiens  
US-09-240-639-9

